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Abstract 
Alternative splicing is an important mechanism of pre-mRNA processing, regulated by 
many splicing factors. Some splicing factors as T-STAR, are poorly characterised due to 
absence of RNA targets identified. The first main aim of this study was to identify the 
principles for splicing regulation by T-STAR, by characterising its first identified 
physiological targets Neurexin-2 and Tomosyn-2. The second important aim was to 
compare the T-STAR and Sam68 splicing regulation on example of Neurexin-2 being a 
T-STAR specific target, and Tomosyn-2 being regulated by both T-STAR and Sam68. By 
EMSA analyses, I identified that Neurexin-2 is a direct target of both T-STAR and Sam68. 
By minigene assays and mutagenesis, I found that T-STAR response element in 
Neurexin-2 is composite. Individually each AU-rich region is redundant for splicing 
regulation, but loss of two key groups of AU-rich sequence elements inhibits splicing 
control by T-STAR. Several splicing regulator proteins have been shown to follow a 
pattern where binding upstream of a regulated exon leads to splicing repression and 
binding downstream leads to splicing activation. The T-STAR response element starts 
just 13 nucleotides downstream of the regulated Neurexin-2 exon, suggesting T-STAR 
protein binding might physically occlude the 5´splice site. Instead, I found this T-STAR 
response element can still potently repress splicing even from more distant downstream 
locations, and surprisingly even when placed upstream of the regulated exon. To find out 
how general this form of position-independent splicing regulation is I identified AU-rich 
downstream sequence elements that control splicing patterns of Tomosyn-2 in response 
to both T-STAR and Sam68. These Tomosyn-2 splicing response sequences similarly 
repressed splicing when moved upstream of the regulated exon. The T-STAR response 
element in Neurexin-2 predominantly contained UUAA sequences, while the T-
STAR/Sam68 response element in Tomosyn-2 contained UAAA repeats. Conversion of 
the Neurexin response element to UAAA and UAAAA placed this exon under control of 
both Sam68 and T-STAR. Current data suggest that T-STAR and Sam68 proteins are 
unusual in that they repress splicing from either side of the exon. These proteins have 
subtly different target sequences that can enable them to control distinct patterns of target 
exons in the cell.   
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Chapter 1: Introduction 
1.1 Pre-mRNA splicing 
1.1.1 Single gene can give rise to multiple mRNA molecules 
For many years it has been an enigma why the biological complexity of different 
organisms does not overlap with the number of genes they code. The human genome is 
known to contain approximately 21 000 protein-coding genes, while the nematode 
Caenorhabditis elegans with much simpler physiology has a genome of 19 000 protein-
coding genes. Even the genome of a single-celled yeast Saccharomyces cerevisiae 
contains at least 6 000 protein-coding genes (Pennisi, 2005; Gerstein et al., 2007).  
This so-called gene number paradox was explained with discovery of how abundant post-
transcriptional gene modifications are. It was known, that once DNA is started being 
transcribed to messenger RNA (mRNA), the generated primary transcript (pre-mRNA) 
immediately undergoes a series of processing events, including 5' capping, splicing, 
transcription termination and 3' polyadenylation (Matlin et al., 2005). High frequencies 
of alternative splicing, alternative polyadenylation and RNA editing allow generating 
multiple RNAs from just one gene across the whole genome and thus highly expand the 
transcriptome (Figure 1.1). Generated mRNA variants encode functionally and 
structurally different proteins, causing an expansion of the proteome (Nilsen and 
Graveley, 2010). Alternative translation initiation and posttranslational modifications 
(such as phosphorylation, methylation, ubiquitylation, glycosylation, etc.) also help to 
increase the protein coding capacity of the genome (Wilhelm et al., 2014). 
Alternative splicing is proposed to be the major multiplication factor to expand the 
proteome. Around 95% of human genes are subjected to alternative splicing (Pan et al., 
2008). Majority of human genes generate two to three different mRNA isoforms (Djebali 
et al., 2012). However, some produce much more, e.g. the CD44, encoding human CD44 
glycoprotein, has 10 alternatively spliced exons, and might produce more than a 1000 
alternative transcripts (Screaton et al., 1992; Bell et al., 1998).  
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Figure 1.1 – Post-transcriptional mRNA processing result in multiple mRNAs from a single 
gene. A schematic, showing post-transcriptional RNA processing mechanisms A) alternative 
splicing, B) alternative polyadenylation, C) RNA editing. Image is adapted from (Siomi and 
Dreyfuss, 1997). 
 
1.1.2 Overview of pre-mRNA processing 
For DNA encoded information to be expressed, several important steps have to be 
completed. Initially, DNA is transcribed by RNA polymerase II to make a pre-mRNA 
(Hurwitz, 2005). This is followed by pre-mRNA maturation, by processing events 
including 5' capping, splicing, transcription termination and 3' polyadenylation. During 
5' capping, which takes place after the first 25 nucleotides of the transcript have been 
generated, a guanine base and a ribose sugar are attached to the 5' end of the transcript. 
The guanine base is subsequently methylated. The function of 5' cap is to protect 
transcript from degradation by exonuclease enzymes (Mandal et al., 2004). Following 
capping, splicing is initiated. Many proteins are involved in the splicing process, 
including small ribonucleoproteins (snRNPs), heterogenous nuclear ribonucleoproteins 
(hnRNPs) and other additional proteins (Matlin et al., 2005). To finalize the processing 
the 3' end of the pre-mRNA is defined by cleavage and a poly(A) tail is added. Poly(A) 
tail is protecting RNA from being degraded and to provide RNA transfer to cytoplasm 
for subsequent translation (Lutz, 2008).  
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Initially, mRNA processing was thought to happen post-transcriptionally. However, in 
reality transcription and processing are not consecutive, but simultaneous and 
interdependent (Neugebauer, 2002). It takes just several minutes to transcribe the gene of 
an average length. The RNA sequencing of human B lymphocytes has shown, that 
splicing was by 65% completed after 5 minutes since transcription start (Windhager et 
al., 2012). This, and many other evidence suggest, that mRNA processing is happening 
co-transcriptionally (Bentley, 2014). After RNA processing events, mature mRNA 
transcripts are transported from the nucleus to the cytoplasm, where they are translated 
into proteins. mRNA export is highly dependent on correct processing, i.e. transfer 
through nuclear pores requires recognition of a cap-binding complex (CBC), added 
during capping (Mandal et al., 2004). 
 
1.1.3 Splicing and splice sites 
During transcription, both coding exons and introns are transcribed together into pre-
mRNA. However, only exons are joined into mature mRNAs. Approximately 80% of 
human genome is transcribed. However, less than 1.5% are exons and as high as 26% 
correspond to introns (Gregory, 2005).  
Intron transcription is an energy consuming process for the cell. For instance, Dystrophin, 
which is the largest human gene is transcribed for 16 hours, however, around 99% of 
Dystrophin primary transcript is comprised of introns (Tennyson et al., 1995). 
Nevertheless, introns are crucial for the genome. Early experiments show that introns-
containing viral constructs increase the gene expression up to 400 times higher, than 
intron-lacking ones (Buchman and Berg, 1988). Similar results were obtained in yeast 
and mammals (Juneau et al., 2006; Shabalina et al., 2010). Introns are also important in 
transcription, genome organization, NMD, nuclear export, translation yield, etc. (Carmel 
and Chorev, 2012).  
The removal of non-coding introns and joining of exons into a final transcript is called 
splicing. Pre-mRNAs are cut at exon-intron junctions, termed 5' and 3' splice sites. In 
humans, the 5' splice site has a consensus sequence CAGGURAGU, where R is a purine 
(guanine or adenine) (Figure 1.2). Even though the consensus exists, splice site sequences 
are degenerate. In rare cases splice site sequence is represented by CAGGCRAGU, or by 
other nucleotide combinations. The 3' splice site is comprised of three elements, placed 
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within around 40 nucleotides upstream the intron/exon junction (Reed, 1996). The 3' 
splice site itself has a consensus YAGG , where Y is a pyrimidine (uracil or cytosine). 
Upstream of the 3' splice site there is a polypyrimidine tract (PPT). Commonly, the PPT 
is a string of uracil bases; rarely it is a run of cytosines. Further upstream there is a 
branchpoint sequence (BPS) YNYURAY, where adenine (A) is surrounded by a variable 
sequence (N can be any nucleotide) (Figure 1.2) (Valadkhan, 2007).  
 
Figure 1.2 – Conserved sequence elements recognized by the major spliceosome. Figure is 
showing four consensus elements required for intron recognition: the 5' splice site, branch point, 
polypyrimidine tract and the 3' splice site. R corresponds to purine, Y – to pyrimidine and N to 
any nucleotide. Image is adapted from (Wahl et al., 2009). 
 
1.1.4 Splice site recognition by the spliceosome  
Splicing is performed by a macromolecular complex, called the spliceosome. The 
spliceosome is a dynamic machinery that consists of small nuclear ribonucleoproteins 
(snRNPs), and a large number of additional splicing proteins and factors. SnRNPs are 
composed of Sm proteins (B/B’, D1, D2, D3, E, F, G) and one or two small nuclear RNAs 
(snRNAs). U1 and U2 SnRNPs recognize the splice sites, and initiate splicing. By being 
complementary to pre-mRNA and interacting with each other, snRNPs also provide a 
framework on the pre-mRNA, holding the other spliceosome components together. There 
are five snRNPs: U1, U2, U4, U5 and U6 (Will and Lührmann, 2011). U1 is partially 
complementary to the 5' splice site, while U2 recognizes the branchpoint sequence (Wahl 
et al., 2009). 
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1.1.5 Splicing reaction and spliceosome cycle 
Briefly, the splicing reaction starts with exon/intron recognition, followed by spliceosome 
assembly and two transesterification reactions, by which the intron is spliced out (Wahl 
et al., 2009) (Figure 1.3). 
 
Figure 1.3 – Two-step transesterification reactions, happening during splicing. Step 1: the 
2'OH of the branchpoint adenosine (blue rhombus) is attacking the phosphodiester bond of the 
5' splice site. As a result, lariat intron structure is formed. Step 2: the 3'OH group of the excised 
exon attacks the 3' splice site. Exons are joined together by splicing, while the intron lariat 
product is degraded. Figure is adapted from (Fabrizio and Lührmann, 2012). 
 
Within an assembled spliceosome, splicing occurs by two transesterification reactions. In 
the first reaction, the 2'OH group of an adenosine nucleotide in the branch point sequence 
(situated close to 3' splice site) attacks the phosphodiester bond of the 5' splice site, and 
forms a new phosphodiester bond between the 2'OH and 5' splice site. As a result, the 5' 
exon is released and the 3'exon forms a lariat intermediate with the intron. In the second 
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reaction, the free 3'OH group of the released 5'exon attacks the phosphodiester bond at 
the 3'splice site. Consequently, both free exons are ligated with a new phosphodiester 
bond and intron is released as a lariat. The spliceosome components dissociate and are 
recycled (Moore and Sharp, 1993; Sharp, 1994; Wahl et al., 2009). 
Splicing is a stepwise reaction. In different steps of the splicing reaction, different protein 
complexes form. These are the: H, E, A, B and C complexes, listed in order of their 
assembly (Figure 1.4). Straight after transcription, the H complex forms. It consists of  
pre-mRNA, bound by a group of RNA-binding proteins, called heterogeneous nuclear 
ribonucleoproteins (hnRNPs). Splicing starts when the E complex forms, when the 5' 
consensus splice site is recognized by the U1 snRNP. This is an ATP-dependent reaction. 
The 3' splice site is recognized by a set of proteins: SF1 (splicing factor 1) interacts with 
the branchpoint; U2AF65 (U2 auxiliary factor 65kDa subunit) recognizes polypyrimidine 
tract and U2AF35 (U2 auxiliary factor 35kDa subunit) recognizes the 3' splice site 
consensus sequence.  
 
Figure 1.4 – Spliceosome assembly cycle. This schematic shows how the major spliceosome 
assembles and disassembles in a series of steps. In addition to small ribonucleoproteins, specific 
enzymes are shown to be involved in the process. Figure is taken from Wahl et al, 2009. 
 
Further on, the A complex is generated. To make this A complex, SF1 is dissociated, and 
the branchpoint sequence in the 3' splice site is bound by the U2 snRNP. This is an ATP-
dependent reaction. U2 snRNP binding is stabilized by U2AF65 interactions with 
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polypyrimidine tract. An important consequence of complex A formation, is to make the 
branchpoint adenosine to jut out, ready to attack the 5' splice site. Following this, complex 
B forms. It is characterized by tri-snRNP U4/U6 and U5 binding the spliceosome. The 
role of U5 snRNP is to bring into the spliceosome the RNA helicases which activate the 
catalytic site of the spliceosome. The catalytic core of the spliceosome consists of many 
proteins, including U2 and U6 snRNPs. Immediately prior to this stage of cycle, U1 and 
U4 snRNPs dissociate from the spliceosome, triggering the first transesterification 
reaction. Prp2 RNA helicase remodels the spliceosome to catalytically activates the first 
transesterification reaction. During the first reaction, complex C is formed, creating the 
intron lariat intermediate. During the second transesterification reaction, when two exons 
are joined together, the lariat structure is released.  
U2, U5 and U6 snRNPs, as well as around 100 other splicing factors are important on the 
last stages of the spliceosome cycle (Black, 2003; Valadkhan, 2007; Wahl et al., 2009). 
Interactions within the spliceosome are weak. For this reason, about 170 supportive 
proteins perform supplementary stabilization : i.e. ATPases, helicases and DExD/H-box 
proteins function as molecular switches, catalysts, perform proofreading functions, etc. 
(Burgess and Guthrie, 1993). Once splicing is over, a mature transcript is released, while 
the intron lariat structure is degraded and snRNPs are recycled and used in the subsequent 
splicing reactions (Black, 2003; Valadkhan, 2007; Wahl et al., 2009). 
 
1.1.6 The minor spliceosome  
Most eukaryotic introns are removed by the spliceosome in a U2 snRNP-dependent way 
described in a previous section. This spliceosome is termed the major spliceosome. 
However, a small number of introns are excised by another machinery, called the minor 
spliceosome. The minor spliceosome has a set of specific snRNPs: U11, U12, U4atac and 
U6atac. These are functionally analogous to U1, U2, U4 and U6 snRNPs of the major 
spliceosome. Both spliceosome have U5 snRNP (Turunen et al., 2013). Introns, 
recognized by the major spliceosome usually start with GT nucleotide, and finish with 
AG bases. They are termed U2-dependent introns, while introns defined by the minor 
spliceosome typically start with AT sequence, finish with AC nucleotides, and are called 
U12-dependent. An interesting feature of U12-dependent introns is that they are spliced 
slower than U2-dependent introns (Burge et al., 1998; Patel and Steitz, 2003). Even 
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though the minor spliceosome is less abundant in cells, it is essential: Drosophila flies, 
missing U12 snRNA have severe defects during embryonic development (Patel and Steitz, 
2003). 
 
1.1.7 Alternative splicing 
Splicing can be constitutive – when all introns are spliced out and all exons are included 
into a final mRNA. However, splicing can also be regulated alternatively: introns might 
stay retained (intron retention), while exons might get completely or partially spliced out 
(alternative exon) (Figure 1.5) (Srebrow and Kornblihtt, 2006). 
Alternative splicing can add and remove coding information into mRNAs and  might give 
rise to different amino acids. This might bring changes to protein structure and function 
i.e. changes in enzyme activation domains, alterations in receptor ligand binding, 
differences in subcellular localization for signaling proteins, etc. (Black, 2000). An 
interesting example of the alteration of a protein’s role by alternative splicing is in the 
WT1 gene (WILMS TUMOUR1). WT1 protein can function as a splicing factor or 
transcription regulator depending on alternative 5' splice site selection in its encoding 
mRNA (Bor et al., 2006). 
Approximately 35% of alternative splicing events cause the alterations in the open 
reading frame (ORF). For that reason, generated transcripts might have premature stop 
codons (PTCs) and to prevent the production of shortened proteins are targets to 
degradation by nonsense - mediated decay (NMD) (Lewis et al., 2003; Soergel et al., 
2006). RNA is known to be an unstable molecule. Alternative splicing of 3'-unranslated 
regions (UTRs) was found to regulate transcript stability (Matlin et al., 2005).  
Alternative splicing is important in many cellular pathways, including cell death and 
differentiation, meiosis, cell signalling, etc. (Black, 2000). Alterations of mRNA splicing 
levels by mutations (i.e. exon skipping, production of aberrant transcripts, activation of 
cryptic splice sites, etc.) or mis-expression of splicing regulators can lead to medical 
conditions including cancer, neurodegeneration, infertility, premature ageing, muscular 
dystrophies, autoimmune diseases, etc. (Pajares et al., 2007; Wang and Cooper, 2007; 
Baralle et al., 2009).  
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Figure 1.5 – Different types of alternative splicing events. Constitutive exons are always 
included into the final mRNA. Cassette exons (also termed alternative exons) can be 
independently included or excluded from the final transcript. Alternative 3' and 5' splice sites are 
competitive with one being selected by the spliceosome. Alternative splice site selection can 
alter exon length. Retained introns are not excised from the pre-mRNA. Mutually exclusive 
exons are exons that are included or excluded in a coordinated manner. The use of alternative 
promoters and alternative polyadenylation can also alter the exons included and the length of the 
final transcript. Alternatively spliced exons are marked in orange, while constitutive exons are 
coloured in blue (Figure is adopted from (Matlin et al., 2005; Mills and Janitz, 2012). 
 
1.1.8 Sophisticated regulation of alternative splicing 
As seen from the sections above, splicing is a complex process, involving hundreds of 
regulatory factors and proteins. However, spliceosomes function with high fidelity and 
produce a great variety of transcripts depending on the cellular context. Splicing is tightly 
controlled on different stages of development and in different tissues, and its disruption 
can lead to severe disorders. In addition to spliceosome function in selecting splice sites, 
splicing is regulated through a “splicing codeˮ, which encompasses all binding sites for 
RNA-binding splicing repressors and activators within a pre-mRNA. The sequences for 
RNA-binding proteins in the pre-mRNA are called cis-acting elements, while the proteins 
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that bind these sequences are termed trans-acting factors. One current objective in the 
splicing field is to decipher this “codeˮ and to be able to foresee the splicing outcome of 
any pre-mRNA form its sequence (Wang and Burge, 2008).  
 
1.1.8.1 Cis-acting elements 
1.1.8.1.1 Splice site strength and position 
Splice site strength depends on complementarity between splice site sequences and U1 
and U2 snRNPs binding to them. Typically, when snRNPs are highly complementary to 
splice sites, splice sites as considered strong. When the extent of sequence 
complementarity is less, splice sites are termed weak. As a tendency, constitutive exons 
have stronger splice sites that are efficiently recognised by the spliceosome. Alternative 
exons have weak splice sites, that are thus recognized less efficiently (Hertel, 2008). 
Interestingly, recent studies show, that there are many variations of splice site sequences 
present, i.e. the human 5' splice site was found to have more than 9000 sequence variants 
(Roca et al., 2012). Furthermore, apart from U1 and U2 snRNPs, other snRNPs and 
splicing factors affect splice site choice (Roca et al., 2013). Relative positions of splice 
sites also affect the splicing outcome. Splice sites, which are closer to each other, tend to 
be favoured and paired quicker (Nogués et al., 2003). However, when being too close, 
splice sites prevent neighbouring exons from being spliced together, often leading to 
mutually exclusive exon splicing (Smith and Nadal-Ginard, 1989).  
 
1.1.8.1.2 Splicing regulatory elements 
Not all splice sites completely match the consensus. Additionally, competing or pseudo 
splice sites might confound the splicing machinery. For precise splicing regulation, 
additional short RNA sequences termed splicing regulatory elements (SREs) are present.  
SREs consist of intronic splicing enhancer/silencer elements (ISEs/ISSs) and exonic 
splicing enhancer/silencer elements (ESEs/ESSs) (Hertel, 2008). These elements are 
important for choosing between the real exon and pseudoexons, for splicing of 
constitutive exons and for choosing between competing splice sites. Splicing regulatory 
elements recruit many splicing factors for binding, and can positively or negatively 
influence exon inclusion (Figure 1.6) (Srebrow and Kornblihtt, 2006). The effect of SREs 
on splicing can be tissue-specific, and position-dependent (Dredge et al., 2005; Goers et 
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al., 2010; Llorian et al., 2010). Splicing regulatory elements are usually present in close 
vicinity of exon/intron junctions. Studies of splicing regulation by SR (serine/arginine-
rich) proteins show that with increasing distance between regulatory sequence elements 
and splice sites, the probability of exon inclusion decreases (Graveley et al., 1998). 
However, there are some examples of elements efficiently regulating the splicing on a 
distance from the exon, i.e. sequence motifs bound by NOVA protein (Ule et al., 2006).  
 
Figure 1.6 – Splicing regulatory elements can enhance and repress the splice site selection 
by the spliceosome. ESE/ISE (exonic splicing enhancers and intronic splicing enhancers) recruit 
the splicing activators, which in turn promote spliceosome assembly on splice sites. ESS/ISE 
(exonic splicing silences and intronic splicing silencers) attract splicing repressors and inhibit 
spliceosome assembly. Figure is adopted from (Srebrow and Kornblihtt, 2006). 
 
Finally, recognition of each exon depends on a specific interplay between splicing 
enhancers/silencers. Studies of SMN (survival of motor neuron) pre-mRNA splicing 
uncovered the multiple enhancer and silencer elements within SMN exon 7 and in the 
flanking introns. However, even a single base alteration in a regulatory element changed 
the balance between enhancers and silencers, leading to different levels of exon inclusion 
(Lorson and Androphy, 2000; Singh et al., 2004).  
 
1.1.8.2 Trans-acting elements 
Splicing regulatory elements are bound by trans-acting proteins which can either activate 
splicing or repress it. Proteins belonging to SR protein family are known to enhance 
splicing. SR proteins have one or two RRM (RNA recognition motif) protein domains 
and an RS (arginine-serine rich) domain. The RRM domain mediates SR protein binding 
with ESEs on the RNA, while RS domains promote spliceosome assembly and activate 
the splicing. In addition to the SR protein family, there are other SR-related proteins, that 
also activate splicing, e.g. these include Tra2α and Tra2β proteins (Tacke et al., 1998).  
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Witten and Ule et al 2011 described several possible mechanisms how splicing activation 
might happen. One mechanism is when splicing regulator proteins interact with and 
stabilize binding of U1 snRNP or other spliceosome components on pre-mRNA, that 
initiate spliceosome assembly. As another possibility, splicing activators can interact with 
other splicing factors (like TIA proteins), and indirectly stimulate their binding to U1 
snRNP and splicing. Splicing can also be activated when regulatory proteins interfere 
with intronic or exonic silencer elements (Witten and Ule, 2011). 
Proteins belonging to the hnRNP protein family often repress splicing. hnRNP proteins 
are characterized as having up to four RRM domains, or RGG (arginine-glycine-glycine) 
domain, or KH (hnRNP K homology) domain. In addition to hnRNP proteins, there are 
other known examples of splicing repressors, e.g. NOVA and MBNL proteins. Each of 
these repressor proteins recognizes a specific RNA binding sequence (Shen and Green, 
2006). A common mechanism of splicing repression happens through blocking the branch 
point sequence and inhibiting spliceosome assembly. This mechanism has been described 
for RBPs NOVA, Fox and PTB proteins (Ule et al., 2006; Zhang et al., 2008a; Xue et al., 
2009). Another mechanism explaining how splicing can be repressed is through 
influencing the kinetics of the splicing reaction. For instance, binding of some proteins 
(e.g. TIA proteins) to a preceding exon are thought to increase the speed of transition 
between the different stages of splicing reaction. This reduces the time for other splicing 
factors to bind and results in splicing repression (Witten and Ule, 2011). Splicing 
repression can also happen if a regulatory protein interferes with splicing enhancer 
sequences, as in the study by Wu et al on splicing repression of the MAG gene by Quaking 
protein (Wu et al., 2002). 
Even though SR proteins are classic splicing activators, and hnRNPs are classic 
repressors, exceptions exist. Some SR proteins can inhibit splicing when they bind to an 
intronic sequence in adenovirus IIIa pre-mRNA (Kanopka et al., 1996). Also, some 
hnRNP proteins activate splicing, including hnRNPL (Hui et al., 2005). The splicing 
effect of proteins on individual exons varies. The splicing outcome depends on the 
position of splicing regulatory elements relative to the target exon. For instance, MBLN 
and Nova proteins can activate splicing through binding downstream of a target exon and 
repress it when bound upstream (Goren et al., 2006). Some splicing factors are expressed 
in a tissue-specific manner, e.g. expression of the RNA-binding protein NOVA is brain-
specific. The study by Grosso et al 2008 has identified more than 100 cases of tissue-
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specific splicing regulation by splicing proteins (Grosso et al., 2008). Splicing outcomes 
can also be determined by splicing factors interacting with each other.  
 
1.1.8.3 Other factors that affect splicing 
1.1.8.3.1 Exon/Intron Architecture 
In addition to the splice site sequence, splice site recognition is dependent on exon size. 
For small exons, splice sites are recognized across the intron, in what is called intron 
definition. Intron definition is especially typical for eukaryotes with smaller introns, such 
as yeast (Berget, 1995). However, in higher eukaryotes, introns are large. In human the 
average exon length is 170 base pairs, while an average intron length reaches 5419 base 
pairs. 10% of introns stretch over more than 11 000 base pairs and around 5% of introns 
are longer than 200 000 base pairs (Sakharkar et al., 2004). For these long introns, splice 
sites are recognized across the exons, in what is called exon definition. During exon 
definition, U1 snRNP associates with the 5' splice site and stimulates the recognition of 
upstream 3' splice site across the exon (Robberson et al., 1990). This exon defined 
complex switches into an intron defined complex at the early stages of spliceosome 
assembly (Sharma et al., 2008). Splice site definition across the intron is much more 
efficient than splice site definition across the exon  
Splicing happens best when splice sites are separated by an optimal nucleotide length. 
Exons that are shorter than 50 nucleotides in length are not very efficiently spliced, as 
splicing factors assembling on their splice sites might suffer from “steric clashingˮ, and 
so do not function efficiently. However, exons exceeding 300 nucleotides are not easy to 
define and splice out. These longer exons might require additional splicing factors, thus 
are often skipped (Fox-Walsh et al., 2005). Intron size is also important for splicing 
efficiency. Splicing is more efficient when introns are short, as splice sites are more easily 
recognized. Computational analyses have shown that the length of the upstream intron is 
more important for splicing efficiency, than the length of the downstream intron (Hertel, 
2008). 
1.1.8.3.2 RNA secondary structure 
RNA is a single-stranded molecule, but it can fold back against itself to produce 
secondary and tertiary structures. Several genes show splicing changes due to RNA 
secondary structure formation. In TPM2 (tropomyosin 2 (beta)) secondary structure 
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formation leads to higher splicing efficiency (Sirand-Pugnet et al., 1995), while in GH1 
(growth hormone 1) (Estes et al., 1992) it results in higher expression of a minor 
transcript. RNA secondary structure can influence splice site selection and spliceosome 
assembly. When RNA structures mask splice sites and splicing enhancer elements, they 
can interfere with spliceosome assembly and repress splicing. In other cases, local RNA 
structures can hide the splicing silencer elements, and promote spliceosome assembly 
(Hertel, 2008). For long introns, secondary structures might serve to bring distal splice 
sites closer to each other (Shepard and Hertel, 2009). It was estimated that increased GC 
content of RNA sequence (usually associated with more stable structures) around the 
splice sites stimulates the formation of secondary structures (Zhang et al., 2011).  
1.1.8.3.3 Co-transcriptional splicing regulation 
Splicing is known to often happen co-transcriptionally (Neugebauer, 2002). Thus, 
transcription is another factor influencing splicing. To begin with, the transcription speed 
is important. If transcription elongation is rapid, alternative exons with weak splice sites 
might be not recognised by spliceosome machinery because of the synthesis of stronger 
downstream exons, and hence, will be skipped. When transcription elongation is slow, it 
favours weak exon inclusion into mature transcripts (Kornblihtt et al., 2004). Secondly, 
the structure of the promoters that recruit Polymerase II for transcription is important. 
Differences in promoter structure can lead to different splicing factors recruited (de la 
Mata et al., 2003). Thirdly, the aberrations in transcription termination can affect the 
splicing of the last intron in the transcript (Niwa and Berget, 1991).  
1.1.8.3.4 Effect of chromatin structure and modifications 
Splicing is also known to be facilitated by the chromatin state. Two models exist to 
explain the effect of chromatin on splicing. The “Kinetic modelˮ suggests that chromatin 
affects the rate of transcription elongation, and thus, affects the splicing. As evidence for 
this model, exons of more highly expressed genes are associated with increased number 
of nucleosomes. Nucleosomes are thought to produce a barrier for RNA polymerase II 
and to slow down the transcription, promoting exon inclusion. The “Recruitment modelˮ 
states that histone modifications can regulate the splicing through attracting the splicing 
factors. Some histone H3 methyltransferases (as Kmt2a, Kmt3a and Kmt4) are linked 
with splicing factors, including hnRNPM and hnRNPL. Inhibition of splicing leads to a 
decrease in histone methyltransferase recruitment (Brown et al., 2012).  
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1.2 Alternative splicing in the brain 
My thesis research is specifically focused on splicing regulation by several RNA-binding 
proteins in the brain. In this section, I will review the recent findings about the splicing 
in the brain.  
1.2.1 The brain has a high frequency and a unique pattern of alternative splicing 
events 
Brain is the tissue with the highest amount of alternative splicing in human body. 
According to EST (expressed sequence tag) analyses, more than 40% of genes in brain 
are alternatively spliced. Some of them have more than one splicing event (Yeo et al., 
2004). There are several explanations for the high pattern of alternative splicing in the 
brain. First, some splicing factors in the brain need to be synthesized, to form memories. 
Second, some mRNAs in the brain, after being transcribed in the nucleus need to be 
spatially localized along the axons to synapses. Thirdly, to increase the complexity of the 
brain, some pre-mRNAs have a different processing pattern in the brain, compared to 
other tissues (i.e. PMCA and AChE). Fourthly, some RNA-binding proteins in the brain 
are neuron-specific and absent in other tissues (i.e. NOVA, PTB2, etc.) (Darnell, 2013). 
Alternative splicing is associated with many important processes in the brain, including 
brain development. For instance, neuron migration across the neocortex requires exon 7 
b and 7c skipping in the Dab1 transcript controlled by the NOVA2 splicing factor. 
NOVA2 knockout mice have shown defects in neuronal migration (Grabowski, 2011). 
Nova proteins also regulate RNA targets involved in synaptogenesis (Ule et al., 2005). 
Alternative splicing also modifies synaptic transmission. For example, the SAP-97 
(synapse associated protein-97) splicing adjusts SAP-97 capacity to bind AMPA 
receptors and, hence, controls activity of glutamatergic synapses. Similarly, splicing of 
the NMDA receptor C2-C2’ domain allows constant neuronal activity and supports 
synaptic plasticity (Lipscombe, 2005). Splicing in the brain is also linked to ageing and 
age-related diseases. Microarray studies identified exon 11 skipping in lamin A gene that 
leads to premature ageing syndrome (Hutchinson-Gilford progeria); PSEN1 mutations in 
the 5' splice site of intron 4 were detected in Alzheimer’s disease; mutations in splice sites 
of Park2 introns cause Parkinson’s disease, etc. (Tollervey et al., 2011; Mills and Janitz, 
2012).  
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The most frequent alternative splicing event in brain is exon skipping. Skipping of exons 
15 and 16 in FXR1 gene results in fragile X mental retardation (Yeo et al., 2004). 
Interestingly, total RNA sequencing of human brain has shown up to 40% of reads to 
localize within introns, especially in fetal brain. These intronic RNAs mainly represent 
unprocessed pre-mRNA transcripts. Several genes with the highest intronic RNA scores 
(e.g. Nrxn1 and Auts2) are involved in autism and schizophrenia. Thus, it can be 
suggested, that intronic RNAs correlate with alternative splicing changes in developing 
fetal brain (Ameur et al., 2011). 
1.2.2 Splicing changes in neurological diseases 
Neurological diseases occur when a certain number of neurons lose their functional ability 
and connections, do not respond to external and internal signals and degenerate (Courtney 
et al., 2010). A review by Anthony and Gallo 2010 provides a list of neurological 
conditions linked with defects in alternative splicing. These conditions include spinal 
muscular atrophy, amyotrophic lateral sclerosis, myotonic dystrophy, Rett syndrome, 
ataxias, Schizophrenia and sporadic Alzheimer’s disease (Anthony and Gallo, 2010). 
Alternative splicing can become aberrant due to malfunction of either cis-splicing 
elements or trans-acting factors. Cis-mutations in splicing enhancer or silencer sequences 
can affect splicing by weakening or strengthening the regulatory elements, as well as 
creating or destroying splice sites (Licatalosi and Darnell, 2006). A point mutation in 
SMN2 gene results in SMN2 exon 7 skipping. (Zhang et al., 2008b). Mutations in the exon 
10 and intron 10 of the MAPT gene that codes for tau protein impair the MAPT splicing. 
Consequently, tau aggregates form and impair the axonal function of tau (Hong et al., 
1998).  
Splicing can be abnormally regulated due to the defects in the RNA-binding proteins. For 
instance, mutations in the gene coding for the RNA-binding protein TDP-43 lead to 
production of TPD-43 with an abnormal C-terminal domain that fails to interact with 
hnRNP proteins. Aberrant TDP-43 is associated with amyotrophic lateral sclerosis (ALS) 
(Lagier-Tourenne and Cleveland, 2009; Anthony and Gallo, 2010). Other aberrations of 
splicing proteins in the nervous system include abnormal posttranslational modifications, 
mislocalization, aggregation, degradation, sequestration, etc. (Ule, 2008). 
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1.2.3 RNA-binding proteins in the brain 
Many splicing factors are expressed in the brain. These include Sam68, T-STAR and 
QUAKING (QKI) proteins that are the subject of my research. These belong to the STAR 
(signal transduction and activation of RNA) protein family. Thus, in the following 
sections I will review in detail the features of these RNA binding proteins.  
1.2.3.1 The STAR protein family 
The STAR protein family is characterised by the presence of the STAR (signal 
transduction and activation of RNA) protein domain and gained their name due to being 
linked with signal transduction pathways and RNA metabolism. STAR proteins use the 
KH (heterogeneous nuclear ribonucleoproteins K homology) domain for RNA binding, 
however compared to other KH proteins they have several specific features. STAR 
proteins have only one KH domain, which is flanked QUA1 and QUA2 domains on either 
side (Artzt and Wu, 2010). The KH domain is involved in RNA binding. The QUA1 
domain is involved in protein dimerization (Chen and Richard, 1998), while the QUA2 
domain participates in RNA binding (Liu et al., 2001). The KH, QUA1 and QUA2 
domains together comprise the STAR domain of the proteins.  
STAR proteins are widely expressed and are involved in a variety of developmental 
events including neurogenesis, spermatogenesis, cardiovascular development and bone 
metabolism. STAR proteins have been shown to regulate pre-mRNA splicing, RNA 
localization, mRNA stability and efficiency of translation. They are also involved in cell 
signaling and post-translational modifications. STAR proteins show high conservation 
among eukaryotes. There are eight STAR proteins known: Sam68 (Src-associated in 
mitosis, 68Kda), T-STAR (testis – signal transduction and activation of RNA) (also called 
SLM2 – Sam68-like mammalian protein 2), SLM1 (Sam68-like mammalian protein 1), 
QKI (quaking) and SF (splicing factor 1) are mammalian proteins (QKI is mouse-
specific); How (held out of wings) protein is found in Drosophila; Asd-2 (alternative 
splicing defective 2) and GLD-1 (defective in germline development 1) are both found in 
C. elegans (Artzt and Wu, 2010). My PhD was mainly focused on Sam68, T-STAR and 
QKI proteins.   
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Figure 1.7 – Domain structure of STAR proteins. All STAR proteins have a STAR domain 
that consists of KH domain, flanked by QUA1 and QUA2 domains and required for RNA 
binding. In addition, other motifs are present. SF1 does not have QUA1 domain. Instead, U2AF 
domain (shaded light blue) is required for RNA binding. Proline rich sequences (labelled as Pro) 
for protein-protein interactions. The RG regions (in grey) are required for methylation. The 
tyrosine-rich domain is subject to phosphorylation. There is also a nuclear localization domain 
is present in the C terminus of all proteins (not shown on the figure). This figure is adapted from 
(Stoss et al., 2004). 
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1.2.3.2 Sam68 
Sam68 (Src-associated in mitosis, 68Kda) is a ubiquitously expressed protein, with high 
expression levels in the testis and brain (Fumagalli et al., 1994). The STAR (also called 
GSG) domain of Sam68 is represented by a KH (K homology domain), flanked by QUA1 
and QUA2 domains (Figure 1.7). The 100 amino-acid KH domain is required for RNA 
binding, while the flanking domains provide RNA-binding affinity and enable proteins to 
homodimerize. Six proline-rich sequences (P0-P5), surrounding the STAR domain, allow 
Sam68 to interact with SH3 (SRC Homology 3) and WW (tryptophan rich) domains of 
other proteins. Two RG (arginine-glycine) regions that flank the proline-rich domains are 
targets for methylation by PRMT1 (protein methytransferase 1) (Fumagalli et al., 1994; 
Taylor and Shalloway, 1994).  
Sam68 methylation alters its RNA binding capacity and localization (Bedford et al., 2000; 
Côté et al., 2003). The tyrosine rich domain of Sam68 is subject to phosphorylation by 
tyrosine kinases (e.g. Src and Brk kinases) and binds proteins with SH2 (Src homology 
2) domains (Wang et al., 1995; Derry et al., 2000). Phosphorylation usually affects 
Sam68 RNA-binding abilities (Sánchez-Jiménez and Sánchez-Margalet, 2013). Sam68 is 
also a target for SUMOylation, acetylation and serine/threonine phosphorylation (Sette et 
al., 2002; Babic et al., 2004; Babic et al., 2006). Sam68 was shown to be involved in 
transcription, alternative splicing, translation, signal transduction and RNA export, cell 
cycle progression, etc. (Rajan et al., 2008; Sette et al., 2010). By SELEX (systematic 
evolution of ligands by exponential enrichment) and microarray experiments, Sam68 was 
shown to bind A/U rich RNA sequences. Out of them, 5'-UAAA-3' and 5'-UUUA-3' 
motifs bound Sam68 with highest affinity (Lin et al., 1997; Chawla et al., 2009; Pedrotti 
et al., 2010; Feracci et al., 2014). 
Many studies were performed to uncover the RNA targets and to study the tissue-specific 
mechanism of splicing by Sam68. In muscle Sam68 was found to bind intronic 
Tropomyosin-β sequence and affect alternative splicing of SMN2 exon 7. These events 
link Sam68 to muscle contraction and spinal muscular atrophy, respectively; (Pedrotti et 
al., 2010). By means of splicing-sensitive microarrays Sam68 was found to regulate the 
neurogenic splicing targets Numa1, Sorbs1 and Kifap3/Kap3 RNAs. Sam68 knockout 
inhibited cellular differentiation in the mouse neocortex. Sam68 knockout mice also 
developed bone and motor coordination abnormalities (Chawla et al., 2009). Recent 
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studies by Iijima et al 2011 and Ehrmann et al 2013 revealed Sam68 to repress Neurexin-
1 and Neurexin-3 splicing in neurons (Iijima et al., 2011; Ehrmann et al., 2013).   
Sam68 levels are elevated in breast, prostate and kidney cancers. Sam68 was also found 
to be associated with the lung and colorectal cancers, as well as with neuroblastoma. 
Because of its increased expression, Sam68 could be used as prognostic marker in cancer 
diagnosis (Liao et al., 2013; Zhang et al., 2014; Zhao et al., 2014). Sam68 affects 
alternative splicing of exon v5 in CD44, intron retention in the proto-oncogenic cyclin 
D1b and alternative splicing of the apoptotic regulator Bcl-x (making antiapoptotic Bcl-x 
isoform) (Cheng and Sharp, 2006; Paronetto et al., 2007; Paronetto et al., 2010). Hence, 
Sam68 is linked to migration, adhesion and proliferation of cancer cells (Bielli et al., 
2011).  
Sam68 is also linked to adipogenesis. A study by Huot et al showed Sam68 to regulate 
alternative splicing of mTOR through binding its’ intron 5. Sam68 depletion caused 
reduced mTOR levels and caused defects in adipogenesis (Huot et al., 2012).  
Sam68 is also abundant in the testis. Recently, Sam68 was found to regulate alternative 
splicing of the Sgce gene exon 8 in the testis (Chawla et al., 2009). Sam68 was also shown 
to interact with other RNA-binding proteins. In germ cells, Sam68 mainly follows a 
nuclear mode of expression, with some cytoplasmic expression during meiosis II. As a 
result of this cytoplasmic expression, Sam68 regulates translation during germ cell 
development and spermatogenesis. Sam68 knockout mice are sterile. Hence, Sam68 is 
linked to male fertility (Paronetto et al., 2011).  
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1.2.3.3 T-STAR 
T-STAR (testis – signal transduction and activation of RNA) also called SLM2 (Sam68-
like mammalian protein 2) is another STAR family protein, closely related to Sam68 by 
structure and function. T-STAR is less ubiquitously expressed than Sam68, with highest 
expression in the testis, and weaker expression in the brain (Venables et al., 1999). T-
STAR and Sam68 have similar protein domains. T-STAR is shorter than Sam68, as it is 
lacking the first hundred amino acids of the N-terminal region of Sam68. Furthermore, 
T-STAR contains just a single proline-rich domain and has a larger RG domain (Figure 
1.7) (Venables et al., 1999). T-STAR is also known to be phosphorylated and methylated, 
to suppress its binding efficiency (Artzt and Wu, 2010). T-STAR is subjected for 
degradation by the proteasome via the E3 ubiquitin ligase (Venables et al., 1999). T-
STAR interacts with testis-specific RBMY and hnRNPG-T proteins, suggesting a role in 
germ cell development. T-STAR also interacts with Sam68 (Venables et al., 1999). 
SELEX studies has identified a 5'-U(U/A)AA-3' motif as RNA target for T-STAR 
(Galarneau and Richard, 2009a).  
The role of T-STAR in splicing regulation is not yet extensively studied. However, recent 
studies uncover some T-STAR functions in splicing. A recent study by Ehrmann et al 
2013 found that T-STAR represses the splicing of exons in the Neurexin 1, 2 and 3 and 
Tomosyn-2 gene in the mouse brain (Ehrmann et al., 2013). A study by Zhang et al, 2009 
has identified Fabp9, Crisp2 and Tssk2 genes as potential targets for T-STAR binding in 
mouse testis. These targets were shown to be alternatively spliced and involved in 
spermatogenesis.  However, they have not yet been physiologically validated (Zhang et 
al., 2009). T-STAR was also shown to affect alternative splicing of exon v5 in CD44 
minigene, and hence, it might have a role in cancer (Matter et al., 2002). 
1.2.3.4 QKI 
The Quaking gene was first discovered in mice. Mice expressing aberrant QKI had an 
inability to form a compact myelin sheath in their Schwann cells and oligodendrocytes, 
and developed tremors when moving. QKI is highly expressed in glial cells (including 
astrocytes and oligodendrocytes) as well as in many other cell-types and tissues (Hardy, 
1998).  
There are three QKI isoforms: QKI5 which is nuclear, as well as QKI6 and QKI7 which 
are cytoplasmic (Wu et al., 1999). These QKI protein isoforms only differ in their C-
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terminal region and 3'-UTRs. All have the same STAR domain, consisting of KH, QUA1 
and QUA2 domains, a tyrosine domain for phosphorylation and, possibly, several 
putative SRC-homology (SH3)-binding domains for mediating protein-protein 
interactions. QKI was found to be phosphorylated in their C-terminal tyrosines in the 
early mouse brain development: this was suggested to repress QKI affinity to RNAs and 
to be associated with its role in myelinogenesis. QKI5 was also shown to be weakly 
methylated in arginine residues. 
The RNA binding motif of QKI was determined by mutagenesis experiments as 5'-
NA(A/C)UAA-3' (where N is any nucleotide) (Ryder and Williamson, 2004). Similar 
motifs were identified by SELEX: 5'-NACUAAY-3' and 5'-YAAY-3' (where Y is any 
pyrimidine) (Galarneau and Richard, 2005). QKI is known to be involved in alternative 
splicing, translation and mRNA stability. In addition to myelin formation, it has a role in 
embryogenesis, where it participates in the blood vessel formation and cardiovascular 
development (Noveroske et al., 2002). Furthermore, QKI was recently identified as a 
tumour suppressor in prostate, gastric and other cancers (Bian et al., 2012; Zhao et al., 
2014).  
There are many splicing targets of QKI identified. QKI5 was shown to regulate the 
splicing of exon 12 of the MAG gene (myelin-associated glycoprotein) (Wu et al., 2002). 
QKI5 was recently shown to regulate a NUMB gene in lung cancer (Zong et al., 2014). 
QKI has also been found to regulate SOX2 gene expression through binding to its 3'-UTR 
region in oral cancers (Lu et al., 2014). QKI was also shown to interact with the 3'-UTR 
region of β-catenin in colon cancers (Yang et al., 2010). Furthermore, QKI promotes exon 
9 inclusion of the Capzb gene in muscle cells (Hall et al., 2013). Finally, QKI was shown 
to regulate the splicing of exon a2 of Myocardin pre-mRNA in vascular smooth muscle 
(van der Veer et al., 2013).  
1.2.3.5 RNA splicing targets: Neurexin-2 and Tomosyn-2 
My PhD has specifically focused on neurological splicing targets for T-STAR and Sam68 
proteins. In this section I am introducing my studied targets in more detail. Four genes 
have been recently identified as physiological splicing targets of T-STAR in mouse brain. 
These are: Tomosyn-2, Neurexin-1, Neurexin-2 and Neurexin-3 (one alternative cassette 
exon in each) (Ehrmann et al., 2013).  
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Neurexins are cell adhesion proteins highly distributed in synapses. Neurexins are located 
presynaptically. Forming complexes with Neuroligin proteins, Neurexins are involved in 
synapse formation, maturation and maintenance. Mutations in Neurexins are associated 
with several neurological conditions, including Alzheimer’s disease and autism (Sindi et 
al., 2014). There are two isoforms of Neurexin proteins, the longer α-Neurexins and the 
shorter β-Neurexins. Neurexin function and distribution to excitatory and inhibitory 
synapses is regulated by a complicated pattern of alternative splicing in Neurexin genes. 
α-Neurexin genes contain alternative splice sites (SS1-5), two of which are also present 
in the β-Neurexin genes (SS4 and SS5). Differences in splicing result in differences in the 
Neurexin ectodomain, altering Neurexin-Neuroligin interactions. Current study has 
focused on Neurexin-2 splicing regulation by T-STAR. As visible from the Figure 1.8, 
Neurexin-2 has different alternative splicing events, including four cassette exons. T-
STAR specifically regulates AS4 (alternatively spliced segment 4, generated through 
alternative splicing of SS4) (Figure 1.8) altering the edge of the Neuroligin binding 
domain in the Neurexin protein. As a consequence, an α-helix is generated that might 
result in a steric clash or interfere with the salt bridge, crucial for Neurexin-Neuroligin 
interactions (Araç et al., 2007);(Krueger et al., 2012). 
 
Figure 1.8 – Neurexin-2 splicing pattern. Neurexin-2 is alternatively spliced into 6 splice 
variants generated by 13 splicing events. Cassette exon (AS4) regulated by T-STAR is labelled 
by the red rectangle. The figure is adapted from UCSC genome browser.  
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Tomosyn-2 encodes a SNARE protein (soluble n-ethylmaleimide-sensitive-factor 
attachment receptor) protein expressed all over the brain, but mainly in the hippocampus 
and cerebellum. Tomosyn-2 is involved in neuronal exocytosis and is thought to direct 
and inhibit vesicle fusion in the synapse. Tomosyn-2 is important in postnatal stages of 
mouse brain development (Groffen et al., 2005). Recently, a Tomosyn-2 knockout mouse 
was generated. This mouse had a phenotype of impaired motor performance, with 
synaptic defects in the neuromuscular junction. Based on this study, Tomosyn-2 was 
shown to inhibit the release of neurotransmitter acetylcholine from axon terminals. This 
normally helps to avoid synaptic fatigue and maintain a normal motor function (Geerts et 
al., 2014).  
The splicing of Tomosyn-2 gene results in production of twelve splice variants (Figure 
1.9). However, four of them (called s, m, b and xb) are better described in the literature 
and are linked to differences in protein structure. Each isoform encodes the Tomosyn-2 
protein with its hypervariable domain of a different length. The hypervariable domain 
separates the WD40 repeat domain from the coiled coil domain of Tomosyn-2. The 
hypervariable domain is important for Tomosyn-2 pairing with other SNARE complexes. 
That defines the fusogenic capacity of the synapse. Repressing Tomosyn-2 exon 23 
splicing (Figure 1.9), T-STAR promotes the production of m-Tomosyn-2 isoform 
(McNew et al., 1999; Hatsuzawa et al., 2003). The study by Williams et al 2011 showed 
that expression of m-Tomosyn-2 isoform results in a higher concentration of Tomosyn-2 
protein (Williams et al., 2011). Thus, it is highly possible that the role of T-STAR splicing 
repression of Tomosyn-2 is to change the size of hypervariable domain, to promote the 
higher expression of Tomosyn-2 and to regulate the vesicle fusion in the synapse. 
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Figure 1.9 – Tomosyn-2 splicing pattern. Tomosyn-2 is alternatively spliced into 12 splice 
variants created by 11 splicing events. Cassette exon regulated by T-STAR is labelled by the red 
rectangle. The figure is adapted from UCSC genome browser. 
 
1.3 Techniques to study protein-RNA interactions 
1.3.1 An overview 
Due to the biological and biomedical importance of alternative splicing, a set of 
experimental techniques has been developed to study the alternative splicing on a genome 
wide scale. They can be subdivided into the in vivo, in vitro and the in silico splicing 
assays. In vivo methods are used to model the mechanism of splicing regulation by 
different cis- and trans-acting factors in living cells and tissues. An example of in vivo 
methods are minigene assays. Recently, powerful high-throughput techniques as CLIP 
(UV cross-linking and Immunoprecipitation) and RNA-sequencing have been developed. 
In vitro methods aim to recapitulate the RNA-protein interactions happening in vivo. One 
of them is SELEX, which helps to identify the RNA-binding sequences for a specific 
trans-acting factor. In silico methods allow us to answer many questions on splicing 
through computational techniques. In silico methods are helpful in predicting splice site 
selection, the frequency of alternative events in a specific tissue, the consequences of 
mutations on splicing, or in modeling the structures of RNA-protein complexes, etc. To 
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conclude, the most efficient way to study alternative splicing is by combining the different 
in vivo, in vitro and in silico approaches (Garcia-Blanco, 2005; Witten and Ule, 2011).  
 
1.3.2 Minigene assays 
It is very common to study the splicing in vivo by using minigene splicing assays. To 
generate a minigene, a genomic region of interest (that usually encompasses the 
alternatively spliced exon with the flanking intronic sequence) is cloned into a plasmid 
vector. In my PhD, selected DNA fragments were cloned into the pXJ41 exon trap vector, 
in between the constitutively spliced β-globin exons of the vector. Subsequently, plasmids, 
containing the cloned fragments are transfected into the cells. Transcription in the vector 
was driven by the eukaryotic human cytomegalovirus promoter. Splicing patterns form 
the minigene are assessed by RT-PCR. The minigene assay is the most common technique 
nowadays to test the effect of a mutation on the splicing outcome. Splicing factor binding 
motifs, splice sites, or auxiliary regions are often mutagenized to replace, move, delete or 
insert the regulatory sequence elements and to study their effect on the splicing.  
 
1.3.3 In-vitro splicing assays 
In-vitro splicing assays are often used to characterize cis-acting elements and trans-acting 
splicing factors. During the assay, minigenes containing the constructs of interests are 
cloned. Consequently, they are digested. DNA is reverse-transcribed, radiolabelled and 
incubated with the whole nuclear extract from the cell or a specific protein of interest. 
The splicing products, resulting in the reaction are analyzed on the denaturing gel. EMSA 
(electrophoretic mobility shift assay) used in the current study is based on electrophoretic 
separation of protein-RNA complexes from the unbound RNA. EMSA do not require 
transfection and long maintenance of the cell lines. One EMSA limitation is that isotope 
decay time is limiting the experiment time. Furthermore, EMSA restricts the size of the 
tested fragment up maximum 250 nucleotides (Hicks et al., 2005).  
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1.3.4 SELEX 
SELEX (systematic evolution of ligands by exponential enrichment) is an in vitro 
screening assay that allows potential RNA sites bound by a specific protein to be selected. 
SELEX starts with a DNA library - up to 1016 oligonucleotides with fixed ends (Wang 
and Burge, 2008). This is transcribed into an RNA library, and incubated with a protein 
of interest. Unbound targets are removed by affinity chromatography, while bound ones 
are reverse-transcribed to DNA and amplified. Through a series of experimental cycles, 
only strongly bound targets are selected. Genomic SELEX technique was developed 
(Glisovic et al., 2008). Through addition of adaptor sequences to DNA fragments in the 
library, Genomic SELEX uses genome as a starting point, rather than being randomized. 
One of the disadvantages of SELEX are non-specific bindings which result in 
identification of some non-functional RNA targets as reviewed by (Ule et al., 2005; Elliott 
and Rajan, 2010). Furthermore, the data generated by SELEX always requires verification 
by in vivo techniques. 
1.3.5 Yeast three-hybrid 
The yeast three-hybrid system is based on two non-interacting proteins that are expected 
to bind a target RNA molecule, which will connect them as a linker. Once RNA is bound 
to one protein, the second protein activates transcription of a reporter gene and a visible 
output is produced. Yeast-three hybrid is inappropriate for proteins that are involved in 
transcription activation themselves (Hook et al., 2005).  
 
1.3.6 RNA-binding protein immunoprecipitation and Affinity tag assay 
RBP immunoprecipitation (RIP) creates protein-target RNA cross-links in live cells by 
means of formaldehyde. Cells are then lysed and proteins of interest in complex with 
target RNAs are immunoprecepitated. However, the RIP technique is highly dependent 
on antibody specificity. Affinity tag assay is similar to RIP, but applies a designed tag, 
specific to a certain antibody, to attach and link a precipitated protein to antibody. Thus, 
no antibody specificity is required. However, the tag on itself might interfere with protein-
RNA binding (Glisovic et al., 2008).  
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1.3.7 Alternative splicing microarrays 
The development of splice-sensitive microarrays allowed identification of a variety of 
splicing events in one experiment. Microarrays use multiple oligonucleotide probes 
(designed to recognize the exons, introns or exon-intron junctions) to hybridize with the 
labelled target RNA (Matlin et al., 2005). The development of isoform-specific 
microarrays allowed different splice isoforms generated from one gene to be 
distinguished (Johnson et al., 2003). Microarrays have some limitations, including cross-
hybridization of probes and a high percentage of unspecific binding. Furthermore, as 
microarrays require pre-designed probes, they can only be applied for the organisms with 
the sequenced genomes (Mills and Janitz, 2012). 
 
1.3.8 UV cross-linking and Immunoprecipitation (CLIP) 
High throughput sequencing of RNA isolated by UV cross-linking and 
Immunoprecipitation (CLIP) can detect real physiological RNA targets. CLIP applies UV 
radiation to introduce irreversible RNA-protein cross-links in live cells/tissue 
homogenate. RNA-protein complexes are immunoprecipitated, cleaved by Proteinase K 
and separated by SDS-PAGE gel electrophoresis. RNAs then are reverse-transcribed and 
a cDNA library is generated. As a result, short CLIP tags are produced, which correspond 
to regions of original protein binding. CLIP tags are subsequently amplified and subjected 
to high-throughput sequencing. Thus, RNA targets from the whole transcriptome are 
identified. However, they still have to be functionally validated by subject protein 
depletion (e.g. by mouse knockout or by small interfering RNA (siRNA).  
HITS-CLIP was successfully used to identify the splicing targets of FOX2 (Yeo et al., 
2004), NOVA (Ule et al., 2006) and Tra2β (Grellscheid et al., 2011). Recently, new types 
of CLIP, called iCLIP (individual nucleotide resolution CLIP) and PAR-CLIP 
(Photoactivatable-Ribonucleoside-Enhanced Crosslinking and Immunoprecipitation) 
were developed. In contrast to older CLIP version, by means of RNA circularization 
iCLIP allows the detection of exact nucleotides cross-linked to protein. iCLIP also 
prevents the loss of prematurely truncated RNAs, thus providing more data (Konig et al., 
2011). As for PAR-CLIP, by applying photoactivatable nucleoside analogs that require a 
longer-wavelenght UV for the crosslinking, it has higher crosslinking efficiency 
compared to the other CLIP versions. One of the limitations of CLIP techniques are that 
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they do not distinguish between stable as and transient RNA-protein interactions. Also, 
the RNA binding sequences identified by CLIP are often degenerate, and differ from the 
natural motifs bound by the protein (Foot et al., 2014). Furthermore, CLIP data requires 
extensive bioinformatics analyses, including ranking the targets by the number of CLIP 
tags, by the type of a regulated alternative even, or by their physiological functions 
(Ascano et al., 2012). 
 
1.4 Research aims and objectives 
The study by Ehrmann et al 2013 has identified the first physiological splicing targets for 
T-STAR proteins, in the Neurexin-1, Neurexin-2 and Neurexin-3 and Tomosyn-2 genes 
(Ehrmann et al., 2013). The splicing of Neurexin-1 and Neurexin-3 genes was also shown 
to be regulated by Sam68 protein.  
The key aim of my project was to identify the mechanism of splicing regulation of 
Neurexin-2 and Tomosyn-2 by T-STAR and Sam68 and to compare the T-STAR and 
Sam68 functions in splicing regulation.  
The third Chapter of my thesis is focused on Neurexin-2. To uncover the mechanism of 
splicing by T-STAR and Sam68 I firstly aimed to test if T-STAR and Sam68 proteins 
bind to Neurexin target sequences directly. To complete this aim, I applied the EMSA 
technique. Subsequently, I aimed to identify the RNA binding sites for T-STAR and 
Sam68 in the Neurexin RNA. Also, my aim was to uncover the positional effect of T-
STAR and Sam68 RNA binding motifs on the splicing outcome. To complete these aims, 
I performed multiple cloning experiments, applied the site-directed mutagenesis 
technique and assessed splicing patterns by the minigene splicing assays. 
The fourth Chapter is focused on studying Tomosyn-2 splicing regulation by T-STAR and 
Sam68. By site-directed mutagenesis experiments I was aiming to dissect T-STAR and 
Sam68 binding sites and to uncover the positional effect of T-STAR and Sam68 RNA 
binding motifs on the splicing outcome. I also aimed to identify if Tomosyn-2 splicing is 
regionally regulated by T-STAR in mouse brain using RT-PCR experiments.  
In the fifth Chapter, I aimed to compare the binding sequence specificity between T-
STAR and Sam6 applying the site-directed mutagenesis technique and assessed splicing 
patterns by the minigene splicing assays.  
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In addition to my study on T-STAR and Sam68 proteins, as described in Chapter five, by 
using a series of mutagenesis and minigene splicing assays I aimed to uncover the 
mechanism of splicing regulation of Neurexin-2 more generally, and whether it involved 
other STAR proteins. 
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Chapter 2: Materials and Methods 
 
2.1 Electromobility Shift Assay (EMSA)  
2.1.1    Construct cloning and protein preparation 
GST-tagged T-STAR and Sam68 fusion proteins, required for EMSAs, were produced 
and purified by Mrs. Caroline Dalgliesh (Newcastle University). One region from the 
Nrxn1 gene (92bp subject sequence) (Figure 2.1 A) and two short regions from Nrxn2 
(95bp subject sequence and 113bp negative control sequence) (Figure 2.1 B) were cloned 
in front of a T7 promoter in pBSK- (Bluescript) vector. Cloning was also performed by 
Mrs. Caroline Dalgliesh (Newcastle University). 
 
Figure 2.1 – The distribution of Neurexin sequences used for gel shift constructs to make. 
A – Neurexin-1 cassette exon is highlighted in black, Region 1 used in gel shift experiment is 
highlighted in grey. B - Neurexin-2 cassette exon is highlighted in black, Region 2 and a Control 
region used in gel shift experiment are highlighted in grey. Region 2 partially covers the exon.   
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2.1.2    Bradford assay to quantify protein concentrations 
Bradford assay is a spectroscopy-based method for quantification protein concentrations. 
BSA was used as a protein standard. A set of eight standard protein concentrations was 
prepared: 0.625 ug/ml; 1.25 ug/ml; 2.5 ug/ml; 5 ug/ml; 10 ug/ml; 15 ug/ml; 20 ug/ml and 
25 ug/ml. Buffer D was used to dilute BSA samples. Coomassie Blue stain was added to 
standard samples, 1:1. Absorbance of each standard was read on a spectrophotometer to 
a wavelength of 595 nm. A standard curve was produced from standard concentrations 
(absorbance versus the concentration). Absorbance for T-STAR-GST and Sam68-GST 
proteins was also measured. A standard curve was used to calculate the concentrations 
for T-STAR-GST and Sam68-GST. 
 
Table 2.1: Components of Buffer D 
Reagent Volume 
0.5M EDTA 0.2 ml 
2.5M KCl 20 ml 
Glycerol 25 ml 
DEPC-treated H2O 198.75 ml 
1M DTT 0.25 ml 
1M HEPES pH 7.9 20 ml 
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2.1.3    Verifying protein concentrations on the gel 
To verify concentrations calculated in Bradford assay, equal concentrations of proteins 
were loaded on 10% SDS-PAGE gel. The gel was washed in Coomassie Blue satin. By 
visual analysis of stained bands the accuracy of protein concentrations was assessed.  
 
2.1.4    Restriction digest 
Cloned gel shift constructs were subjected to restriction digest in order to linearize them. 
Constructs were digested by EcoRI (following the instructions in Table 2.2). To look for 
digest quality, all constructs were run on 1% agarose gel. Non-digested samples were run 
nearby as controls. Digested samples were column purified using QIAGEN PCR 
Purification kit by manufacturer’s protocol.  
Table 2.2: Conditions for restriction digest of Neurexin constructs for EMSA 
Constituent Volume (μl) / Concentration 
pBSK vector or PCR product  5.0 in 10x reaction buffer (2 µg of DNA) 
EcoRI buffer  1.0 (1x) 
EcoRI 3.0 (30 units) 
BSA (100x) 6.0 (10x) 
 
2.1.5    Transcription and labelling  
To transcribe linearized DNA into RNA, 500ng of each sample was added into reaction 
mix described in Table 2.3. 
Table 2.3: Transcription mix for EMSA 
Reagent Volume (μl) 
T7 RNA polymerase buffer 3.5 
AUC 10 mM 1.5 
BSA 2 μg/μl 0.75 
DTT 500mM 0.3 
Cold GTP 0.5 mM 1.0 
32P-GTP 0.5 mM 1.0 
RNAsin 40U/μl 1.0 
T7 RNA polymerase 20 U/μl 1.0 
DEPC-treated H2O 3.45 
+ 500ng target DNA 1.0 to 2.0 
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Mixtures were vortexed and incubated at 37C for 1.5 hours. To prevent vapour spreading 
after incubation, samples were briefly centrifuged. Following that, each sample was 
combined with DNase mix (see contents in Table 2.4; contents for DNAse buffer (1x):  
2ml of 1M Tris; 1ml of 1M MgCl2; DEPC-treated water up to 100ml), vortexed, incubated 
at 37C for 25 minutes and briefly centrifuged.  
 
Table 2.4: DNase mixture contents for EMSA 
Reagent Volume (μl) 
DNase 10 U/μl 2.0 
RNAsin 40 U/μl 2.0 
DNase buffer (1x) 250.0 
 
2.1.6    RNA Precipitation 
Radiolabelled samples were mixed with 200μl of tRNA buffer (see contents in Table 2.5; 
components of 2xPK buffer see in table 2.6). Precipitation was performed in Manual 
Phase Lock gel column (PLGs) (purchased from ‘5 PRIME’ company). Prior to 
experiment start, columns were centrifuged for 50 seconds at 13500rcf to move the gel to 
the tube bottom. 200μl Phenol-Chloroform and target samples were added to the columns 
and mixed by pipetting. Columns were centrifuged at 4C, 12000rcf for 5 minutes. 250μl 
Chloroform was added, followed by another centrifugation step at 4C, 12000rcf for 5 
minutes. An upper aqueous phase (corresponding to RNA) was transferred to new 
eppendorfs. RNA was washed by 12.5μl 5M Ammonium Acetate for 45 minutes. 
Subsequently, RNA pellet was washed by 1) 750μl 100% DEPC Ethanol and 2) by 500μl 
80% DEPC ethanol by centrifugation at 4C, each time at 12000rcf for 5 minutes. All 
solution was removed from the tubes, and RNA pellets were left open to dry for 10 
minutes. Afterwards, they were re-dissolved in 50μl DEPC-treated water, and RNA was 
denatured by incubating tubes at 80C for 3 minutes.  
 
Table 2.5: Components of tRNA mixture 
Reagent Volume (μl) 
2xPK buffer 123.0 
E.coli tRNA carrier 1.0 
DEPC-treated water 72.0 
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Table 2.6: Components of 2x PK buffer 
Reagent Volume 
1M Tris-HCl pH 7.4 20 ml 
0.2M EDTA 5 ml 
10% SDS 5 ml 
5M NaCl 2 ml 
DEPC-treated water 68 ml 
 
2.1.7    Checking RNA quality 
1μl from each RNA sample was diluted in 2μl of DEPC-treated water and 2μl of blue 
loading dye. Resulting mixes were electrophoresed on 6% Urea polyacrylamide gel (see 
gel constituents in Table 2.7; contents of 10x TBE in Table 2.8) at 650V for 15 minutes. 
Following electrophoresis, gel was dried on a vacuum gel drier for 1 hour and exposed to 
a storage phosphor screen overnight. The screen was scanned with a Typhoon Imager. 
After image analysis, the RNA dilution factor was decided. RNAs were diluted in DEPC-
treated water aiming to have equal RNA concentrations in each tube.  
Table 2.7: Polyacrylamide gel components for EMSA 
Constituent 
For 6% UREA 
polyacrylamide gel (6%, 
10X TBE, Urea, 20ml 
volume) 
For 6% polyacrylamide 
gel (6%, 10X TBE, 30ml 
volume) 
Reagent Amount Reagent 
Urea 8.4 g - 
Acrylamide 40% 3 ml 4.5 ml 
10x TBE 2 ml 1.5 ml 
dH2O Up to 20 ml Up to 30ml 
APS 200 μl 160 μl 
TEMED 7.5 μl 30 μl 
 
 
Table 2.8: Constituents of 10x TBE buffer 
Reagent Volume / Amount 
Tris-NaOH 108g 
Boric Acid 55g 
0.5M EDTA pH 8.0 40 l 
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2.1.8    Electromobility Shift Assay 
50, 100, 200 and 400ng of proteins (Sam68-GST and T-STAR-GST) were mixed with 
each RNA sample to check the RNA binding. Mentioned protein amounts were mixed 
with buffer D, adjusting buffer volume to a final volume of 12.5μl. A binding mix was 
also prepared (see Table 2.9 for constituents). 
Table 2.9: Constituents of Binding mix for EMSA 
Reagent Volume (μl) 
KCl 2.5M 1.5 
NaCl 1M 0.5 
NP-40 1% 2.5 
BSA 2μg/μl 0.375 
Glycerol 87% 0.375 
DTT 100mM 0.25 
RNAsin 40U/μl 1.0 
DEPC-treated H20 4.0 
tRNA E.coli 200ng/μl 1.0 
  
11.5μl of Binding mix was combined with 12.5 μl of protein mix and 1 μl of diluted and 
denatured RNA. Resulting mixtures were vortexed, briefly centrifuged and incubated for 
20 minutes at room temperature. Following that, mixes were run on a 6% Polyacrylamide 
gel (See Table 2.7 for constituents) for 2 hours at 3W. Gels were dried for 2 hours and 
exposed to the storage phosphor screen overnight. The screen was scanned with a 
Typhoon Imager. Images were analysed and suggestions about protein effect were made.  
 
2.2   Cell culture 
2.2.1    HEK-293 cells 
The HEK-293 cell line was used for all transfections in this thesis. HEK293 is a human 
embryonic kidney cell line (Graham et al., 1977). It has a high transfection efficiency and 
thus is often used in splicing assays. HEK293 cells were initially purchased from the 
American Type Culture collection and LGC Standards, Europe. Catalogue number is: 
ATCC-CRL-1573.  
  
Chapter 2  Materials and Methods 
 
37 
 
2.2.2    Cell culture conditions and maintenance  
Culture was performed in a Class II laminar flow microbiological safety cabinet. Cells 
were grown in 25cm2/75cm2 flasks in 37°C incubator with 5% CO2. DMEM (Dulbecco’s 
Modified Eagle’s Media) with phenol red (purchased from PAA) with 10% FBS added 
(purchased from Sigma-Aldrich) was used as a culture medium. Cells were passaged once 
70-80% confluency was reached in the flask. To passage, DMEM was removed and cells 
were washed with 1xPBS (phosphate buffered Saline). This was followed by incubation 
with 2ml of 2mM trypsin-EDTA (Sigma-Aldrich) for 5 minutes at 37°C. To stop the 
effect of trypsin, the culture media was added. Cells were centrifuged at 180xg for 5 
minutes. The supernatant was discarded, while cell pellets were dissolved in DMEM with 
10% FBS and placed into new flasks for culture with a ratio 1:5 (diluted cells to new 
culture media). 
2.2.3    Cryopreservation 
Cells were regularly frozen to maintain a cell stock. After reaching a high confluency in 
the flask, cells were passaged as normally and aliquoted in 1 ml of cryoprotective media 
(95% FBS, 5% DMSO (dimethyl sulphoxide; purchased from Sigma-Aldrich)). Frozen 
stocks were kept at -80°C in cryovials (Sigma-Aldrich). To thaw the cells, cryovials were 
incubated in 37°C water bath for 5 minutes. To replace the cryoprotective media by 
DMEM cells were centrifuged at 180xg for 5 minutes. Freezing media was discarded. 
Cells were resuspended in DMEM with 10% FBS and placed for culturing into new 
flasks.  
 
2.3   Tomosyn-2 minigene cloning 
2.3.1    Primer design  
The Tomosyn-2 alternative exon and approximately 300 nucleotides of flanking upstream 
and downstream intronic sequences were selected for cloning into the exon trap pXJ41 
vector. Primers were designed in the Primer3 program available at: 
http://bioinfo.ut.ee/primer3-0.4.0/primer3/. An EcoRI restriction site and a string of six 
adenine bases was added to the 5' end of each primer. Primers are listed in Table 2.10. 
The sequence used for Tomosyn-2 cloning is shown on Figure 2.2. 
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Table 2.10: Primers used for Tomosyn-2 cloning 
Primer Sequence 
Tomosyn-2 cloning 
primer  F 
AAAAAACAATTGGCATATTTCATATTG CCATCCA 
 
Tomosyn-2 cloning 
primer  R 
AAAAAACAATTGCAGTAGAGGAAATTAAGGTTGCAG 
 
 
 
Figure 2.2 - Tomosyn-2 sequence used for minigene cloning. Figure shows the Tomosyn-2 
region that was predicted to respond to T-STAR and was cloned into pXJ41 vector. Cassette 
exon is highlighted in black. Sequences for cloning primers are underlined.  
 
2.3.2    PCR amplification 
50μl reactions were performed by the protocol shown in Table 2.11. PCR Phusion Kit 
from Thermo Scientific was used. Amplification was carried out in SensoQuest thermo 
cyclers by the program shown in  
 
Table 2.12. All PCR products were column purified using the QIAquick PCR Purification 
Kit following a standard manufacturer’s protocol. 
Table 2.11: PCR protocol 
Reagent Volume (μl) / Concentration 
5xHF buffer 10.0 (1x) 
dNPs (10mM) 1.0 (200uM) 
10µM Forward Primer 2.5 (0.5 uM) 
10µM Reverse Primer 2.5 (0.5 uM) 
DMSO  1.0 (3%) 
Template (mouse genomic DNA)  1.0 (< 250 ng) 
Phusion DNA Polymerase 0.5 (1.0 units/50 µl PCR) 
dH2O 31.5 
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Table 2.12: Thermocycler PCR program  
Step  Temperature C Time Cycle Number 
Heat activation 98C 30 seconds 1 
Denaturation 98C 10 seconds 32 
Annealing 60C 20 seconds 32 
Extension 72C 45 seconds 32 
End Stage 
Extension 
72C 4 minutes 1 
Cooling  15C ∞ 1 
 
2.3.3    Gel electrophoresis 
PCR products were run on 1.2% agarose gels for product size estimation. Lanes 
corresponding to amplified products were cut out. Constructs were purified from the gel 
(using QIAquick Gel Extraction Kit by manufacturer’s instruction). 
 
2.3.4    Restriction digests  
To create a single cut in the vector, the pXJ41 vector stock was digested by MfeI 
restriction enzyme (New England Biolabs). Samples were digested by EcoRI enzyme 
(New England Biolabs) (Table 2.13). Digestion mixes were incubated for 3 hours at 37C 
followed by a 15 minute heat inactivation at 65C. Afterwards, digestion mixes were 
column purified using QIAquick PCR Purification Kits (by standard manufacturer’s 
protocol). Following digestion, to prevent the vector re-circularization, the vector was 
also treated by Antarctic Phosphatase (New England Biolabs) (Table 2.14). Vector digest 
was incubated at 37C for 45 minutes. 
Table 2.13: Components of restriction digestion reaction 
Constituent Volume (μl) / Concentration 
pXJ41 vector or PCR 50.0 in 1x reaction buffer (2-3 ug of DNA) 
MfeI/EcoRI buffer (10x) 1.0 (1x) 
MfeI/EcoRI 3.0 (30 units) 
BSA (100x) 6.0 (10x) 
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Table 2.14: Components of vector digest by Antarctic Phosphatase 
Constituent Volume (μl) / Concentration 
pXJ41 vector 60.0 (2-3 ug of DNA)  
Antarctic Phosphatase buffer 7.0 (1x) 
Antarctic Phosphatase 3.0 (30 units) 
2.3.5    Ligation and Re-cleavage 
Ligation reactions were performed in steps described in Table 2.15, at 16C overnight. 
To remove the non-digested/re-circularized vector background, ligation mixes were re-
cleaved with MfeI restriction enzyme (Table 2.16). Re-cleavage mixes were incubated at 
37C for 2 hours, followed by 15-minute heat inactivation at 65C. 
Table 2.15: Standard ligation protocol 
Component Volume (μl) / Concentration 
Insert 8.0 (0.5 ug of DNA) 
Vector  3.0 (0.2 ug of DNA) 
T4 Buffer (10x) 2.0 (1x) 
T4 DNA Ligase (Promega) 2.0 (20 units) 
dH2O 5.0 
 
Table 2.16: Components of re-cleavage reaction 
Component Volume (μl) 
Ligation mix 20.0 (0.7 ug of DNA) 
MfeI buffer (10x) 5.0 (1x) 
MfeI 2.0 (20 units) 
dH2O 23.0 
 
2.3.6    Cloning and Sequencing 
4μl of inserts were transformed into 25μl of commercial competent cells (α-Select 
Chemically Competent Cells from BIOLINE) using the BIOLINE heat shock protocol. 
Transformants were allowed to settle on LB + Ampicillin (1μl ampicillin per 1ml LB) 
plates overnight. Subsequently, 8 to 15 colonies were picked from each plate and grown 
overnight (in separate tubes) in LB + Ampicillin, in the incubated shaker at 37C. Bacteria 
from each colony were subjected to colony screening by PCR, when one primer of vector 
(see vector primers in Table 2.17) and one cloning primer specific to the insert was used 
to make sure that bacteria contained a correct plasmid (Table 2.18 for PCR conditions). 
Bacteria, amplified overnight in a shaker, were centrifuged for 1.5minute at 11 000rcf. 
Plasmids were extracted from a resulting pellet by means of QIAprep Miniprep Kit, 
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following QIAGEN instructions. Plasmid DNA was sent for sequencing with vector 
primers (pXJB1 and pXJRTF, Table 2.17) to Source Bioscience, Oxford. Sequences were 
verified by aligning the expected and received sequence versions using the CLUSTALW2 
program.  
Table 2.17: pXJ41 vector primers used for colony screening and for sequencing 
Primer Sequence 
pXJB1 GCTCCGGATCGATCCTGAGAACT 
pXJRTF GCTGCAATAAACAAGTTCTGCT 
 
Table 2.18: Thermocycler PCR program for colony screening 
Step  Temperature Time Cycle Number 
Heat activation 95C 2 minutes 1 
Denaturation 95C 1 minute 35 
Annealing 58C 1 minute 35 
Extension 72C 1 minute 35 
End Stage 
Extension 
72C 5 minutes 1 
Cooling  4C ∞ 1 
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2.4    Site-directed mutagenesis 
2.4.1    Primer design 
Site-directed mutagenesis by overlap extension PCR was performed to introduce 
mutations into potential T-STAR and Sam68 binding regions of the Nrxn2 and Tomosyn-
2 sequence. All primers and templates used to make mutants are listed in Appendix I. 
Figure 2.3 shows the regions of Neurexin-2 (Figure 2.3 A) and Tomosyn-2 (Figure 2.3 B) 
mutagenized in deferent experiments. The method of mutagenesis is described in Figure 
2.4.  
 
 
Figure 2.3  - Sequence regions altered through site-directed mutagenesis. A – Neurexin-2 
sequence region that was cloned into the pXJ41 vector and subsequently subjected for 
mutagenesis. Exon is highlighted in black. T-STAR target region is highlighted in blue. Numbers 
highlighted in blue show the downstream (163 and 241 nucleotides downstream the target exon) 
and upstream (42 and 100 nucleotides upstream the target exon) positions for the target region 
insertion. B – Tomosyn-2 sequence region that was cloned into the pXJ41 vector and 
subsequently subjected for mutagenesis. Exon is highlighted in black. Potential T-STAR target 
regions are highlighted in blue and purple. Number highlighted in blue show an upstream 
position for the first (blue) target region insertion (54 bases upstream the exon).  
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Figure 2.4  - Site-directed mutagenesis. A schematic showing site-directed mutagenesis by overlap-
extension using PCR. Mutagenic primers with a number of single base changes were designed to 
create specific mutations. These primers were used in PCR 1 and PCR 2 reactions, which produced 
two overlapping DNA fragments with complementary mutations in opposite DNA strands. Both 
products were then combined and then re-amplified by PCR3. The final product was then cloned into 
pXJ41 vector. 
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2.4.2    PCR amplification 
50μl reactions were performed using the protocol stated in Table 2.19 (PCR 1 and 2) and 
Table 2.20 (PCR 3). PCR Phusion Kit from Thermo Scientific was used. Amplification 
was carried out in SensoQuest thermo cyclers by the program stated in Table 2.12. All 
PCR products were column purified applying QIAquick PCR Purification Kit (following 
the standard manufacturer’s protocol). 
Table 2.19: PCR 1 and PCR 2 protocol 
Reagent Volume (μl) / 
Concentration 
5xHF buffer 10.0 (1x) 
dNPs 1.0 (200 uM) 
Mutant Reverse (PCR 1) / Mutant Forward primer (PCR 2) 2.5 (0.5 uM) 
pXJRTF (PCR 1) /pXJB1 (PCR 2) 2.5 (0.5 uM) 
DMSO  1.0 (2%) 
Template (see table 2.16)  1.0 (< 250 ng) 
Phusion DNA Polymerase 0.5 (1.0 unit) 
dH2O 31.5 
 
Table 2.20: PCR 3 protocol 
Reagent Volume (μl) / 
Concentration 
5xHF buffer 10.0 (1x) 
dNPs 1.0 (200 uM) 
pXJB1 2.5 (0.5 uM) 
pXJRTF  2.5 (0.5 uM) 
DMSO  1.0 (2%) 
Template 1 – (PCR 1) 1.0 (< 250 ng) 
Template 2 – (PCR 2) 1.0 (< 250 ng) 
Phusion DNA Polymerase 0.5 (1.0 unit) 
dH2O 30.5 
 
2.4.3 Gel Electrophoresis 
PCR 1 and 2 products were run on a 1.2% agarose gels for product size estimation only. 
PCR 3 products were run on 2% agarose gel. Lanes corresponding to amplified products 
were cut out. Constructs were purified from the gel (using QIAquick Gel Extraction Kits 
according to manufacturer’s instructions). 
All the rest of the steps for site-directed mutagenesis were performed exactly the same as 
described in parts 2.3.4, 2.3.5 and 2.3.6. 
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2.5    Minigene splicing assays 
2.5.1 Transfection 
Verified plasmids and plasmids encoding GFP fusion proteins (e.g. T-STAR-GFP and 
Sam68-GFP; cloned and provided to me by Mrs. Caroline Dalgliesh, Newcastle 
University) were co-transfected into HEK-293 cells. Transfections were performed using 
GeneJammer by a protocol in Table 2.21. In every transfection experiment in addition to 
the samples of interest, Neurexin-2 (or Tomosyn-2) minigene was co-transfected together 
with: 1) GFP plasmid, 2) T-STAR-GFP, 3) Sam68-GFP, as control samples. 
Table 2.21: Transfection protocol 
Reaction Mix Constituents Volumes Incubation time 
Mix 1 GeneJammer + DMEM 3μl of GeneJammer, 
97μl DMEM 
13 minutes 
Mix 2 Mix 1 + Plasmids + 
expression vectors 
200ng plasmids + 
500ng expression 
vectors + 100μl 
Mix1 
30 minutes 
Short  Centrifugation 
Mix 3 Mix 2 + HEK-293 (pre-
plated for 24 hours in 6-
well plates) 
 37C, overnight 
  
Following overnight incubation, the transfection efficiency was checked using a 
fluorescent microscope – cells that had accepted GFP-linked constructs were fluorescent. 
T-STAR and Sam68 proteins are normally localized in the nucleus. Efficiency was 
assessed by eye. When 60-70% of cells (or more) had fluorescent nuclei, experiment was 
continued. Cells were equally divided into 2 tubes and centrifuged at for 5min at 7000rcf. 
Resulting pellet aliquots were subjected to RNA extraction and Western blotting. 
 
2.5.2    RNA extraction  
Each pellet was completely dissolved in 100μl Trizol (by vortexing). 20μl of chloroform 
reagent was added. Samples were then vortexed and centrifuged at 13000rcf at 4C for 
15 minutes. The upper aqueous phase corresponding to RNA was moved to separate 
tubes, and 50μl Isopropanol was added. Samples were vortexed, followed by a 10 minute 
incubation on the bench. Samples were subsequently centrifuged at 13000rcf at 4C for 
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10 minutes. All supernatant was removed. Pellets were washed using 75% ethanol in 
DEPC-treated water, and centrifuged at 6700rcf at 4C for 5 minutes. As previously, all 
solution was removed and pellets were left to air-dry in open tubes for 10 minutes. 
Samples were then diluted in 50μl DEPC-treated water, warmed in a hot block at 65C 
and vortexed. 50ng/μl RNA concentrations were prepared for reverse transcription PCR 
(RT-RCR). 
 
2.5.3    RT-PCR 
RT-PCR was performed using QIAGEN 1-step RT-PCR kit using the recommended 
QIAGEN protocol. Reaction components and amplification steps are shown in Table 2.22 
and Table 2.23, respectively.  
Table 2.22: RT-PCR reaction constituents 
Reaction component Volume (μl) / Concentration 
Q solution 1.0 (1x) 
5X buffer 1.0 (1x) 
dNTPs 0.2 (200 uM) 
pXJRTF (10μM) 0.3 (0.3 uM) 
pXJB1 (10μM) 0.3 (0.3 uM) 
RNA (50ng/μl) 2.0 (0.1 ug) 
Enzyme mix 0.2 
 
Table 2.23: RT-PCR reaction steps 
Reaction Step Temperature Time Cycle № 
Reverse 
transcription 
50C 30 minutes 1 
Heating 95C 15 minutes 1 
Denaturation 94C 30 seconds 32 
Annealing 56C 30 seconds 32 
Primer extension 72C 1 minute 32 
Final extension 72C 10 minutes 1 
Incubation 4C ∞ 1 
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2.5.4    DNA size verification and product quantification 
DNA was electrophoresed on a QIAxcel multi-capillary gel electrophoresis (Qiagen) 
device. The QIAxcel Bio calculator software (Qiagen) was used to measure DNA size 
(bp) and concentration (ng/µl). The percentage of splicing exclusion (PSE) was calculated 
by the formula: 
 
2.5.5    Western Immunoblotting 
Half of each transfected sample was tested for protein expression levels using Western 
blotting, applying a primary mouse polyclonal α-GFP antibody (Abcam, ab1218) and a 
secondary sheep α-mouse HRP-linked secondary antibody (Amersham, NA931VS). 
Loading and transfection efficiency was verified by actin immunoblotting using a primary 
rabbit α-actin rabbit polyclonal antibody (Sigma) and a secondary α-rabbit antibody 
(Jacson Lab). All antibodies used were diluted 1:2000. Briefly, cell samples were lysed 
in 2x SDS loading buffer and boiled at 100C for 5 minutes. Proteins were separated on 
10% SDS-PAGE gels, followed by transfer to PVDF membrane (Hybond-P, GE). The 
membranes were blocked in blocking solution (TBST (Tris-Buffered Saline with Tween 
20) with 5% non-fat dry milk) for one hour and incubated with a primary antibody for 
one hour. Membranes were subsequently washed with TBST (three times, 5 minutes each 
time). Membranes were further probed with a secondary antibody for 1 hour, followed by 
washing with TBST (three times, 5 minutes each time). Prior to exposing membranes to 
a film, ECL (enhanced chemiluminescent) Prime Western Blotting Detection Kit 
(Amersham) was applied.  
 
2.6    Tomosyn-2 splicing analysis in brain tissues by RT-PCR 
The splicing pattern of the T-STAR regulated Tomosyn-2 exon was analysed in 11 brain 
regions of three adult wild type and T-STAR knockout mice. The regions tested were: 
olfactory bulb, cortex, hippocampus, basal ganglia, thalamus, hypothalamus, midbrain, 
cerebellum, pons, medulla and spinal cord. Brain dissection and tissue preparation, as 
well as RNA extraction was performed by Dr Ingrid Ehrmann (Newcastle University). 
For some samples, RNA was converted by me to cDNA and amplified by PCR using a 2-
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step RT-PCR reaction (Superscript III Reverse Transcriptase kit, Invitrogen) (Table 2.24) 
shows the first cDNA strand synthesis reaction protocol. Primers used for reaction were 
designed in Primer 3 program (http://bioinfo.ut.ee/primer3-0.4.0/primer3/) and are listed 
in a Table 2.25. However, majority of brain cDNA samples were kindly provided to me 
ready made by Dr Ingrid Ehrmann (Newcastle University). 
 
Table 2.24: RT-PCR reaction steps and constituents 
Reaction component  Volume (μl) / Concentration 
Primers (random 6-mers)  1.0 (0.5 uM) 
RNA template 1.0 (0.1-0.3 ug) 
10x dNTPs  1.0 (200 uM) 
DEPC-treated H20 10.0  
Incubate at 65C for 5 minutes. Incubate on ice for 1 minute. Centrifuge. 
5x First Strand Buffer 4.0  
0.1 M DTT 1.0  
RNAse OUT 1.0 (40 units) 
Superscript III RT 1.0 (200 units) 
Incubate at 25C for 5 minutes. Incubate at 50C for 1 hour. Inactivate at 70C for 15 
minutes. Store at -20C. 
 
Table 2.25: Tomosyn-2 primers used for RT-PCRs in different mouse brain regions 
Primer Sequence 
Tomosyn-2 in brain F TATCACCGAAGGGACTGTCG 
Tomosyn-2 in brain R TGGCAAGCTTAATTTCCTTGA 
 
The quality of the produced cDNA was first amplified by PCR and assessed on agarose 
gel for a house keeping gene Hprt, which is known to be equally expressed in all brain 
regions. Following that, cDNA from different brain regions was tested with primers for 
the Tomosyn-2 target exon. Reaction components and PCR conditions for the Hprt and 
Tomosyn-2 cDNA amplification are shown in Table 2.26 and Table 2.27, respectively. 
Table 2.26: PCR reaction constituents 
Reaction component  Volume (μl) 
5x GoTaq buffer (Promega) 5.0 (1x) 
10mM dNTPs 0.5 (0.5 uM) 
Forward primer 0.5 (0.2 uM) 
Reverse primer 0.5 (0.2 uM) 
cDNA 1.0 (<0.5µg) 
GoTaq (Promega) 0.15 (0.75 units) 
dH2O 17.35 
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Table 2.27: Thermo cycler PCR program  
Step  Temperature C Time Cycle Number 
Heat activation 94C 2 minutes 1 
Denaturation 94C 1 minute 30 
Annealing 60C 1 minute 30 
Extension 72C 1 minute 30 
End Stage 
Extension 
72C 10 minutes 1 
Cooling  15C ∞ 1 
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Chapter 3: Dissecting the mechanism of splicing of Nrxn2 cassette 
exon by T-STAR 
3.1 Introduction 
T-STAR (testis – signal transduction and activation of RNA) and Sam68 (Src-associated 
in mitosis, 68Kda) are two splicing factors with an important role in alternative splicing.  
They both belong to the same STAR protein family and have a similar domain structure. 
Sam68 is ubiquitously expressed, while T-STAR expression is specific to brain, testis and 
kidney. Both proteins have been predicted to bind AU-rich motifs on pre-mRNA (Lin et 
al., 1997; Chawla et al., 2009; Pedrotti et al., 2010; Feracci et al., 2014; Galarneau and 
Richard, 2009a) . Sam68 was shown to regulate alternative exons in a number of targets: 
CD44 (in cancer), SMN2 (in muscle), Numa1 and Sorbs1 (in neurogenesis) (Bielli et al., 
2011; Iijima et al., 2011). However, this response to Sam68 was only detected in 
minigene assays, and has not been physiologically validated. For a long time, there were 
no T-STAR targets known. 
As a mentioned in Introduction sections, four genes have been recently identified as 
physiological splicing targets of T-STAR in mouse brain. These are: Tomosyn-2, 
Neurexin-1, Neurexin-2 and Neurexin-3 (one alternative cassette exon in each) (Ehrmann 
et al., 2013). These targets opened a possibility to study the mechanism of splicing 
regulation by T-STAR and to compare it to that of Sam68.  
Before I started this project, some work had already been performed to uncover the 
mechanism of T-STAR and Sam68 splicing regulation of Neurexin genes. Neurexins 
showed region-specific splicing repression in mouse brain, with highest repression in 
forebrain-derived regions. This correlated with the T-STAR expression pattern in the 
brain. Also, minigene assays confirmed that T-STAR and Sam68 both repress the splicing 
of a target cassette exon 20 of Neurexin-1 and Neurexin-3 (equivalent to AS4). Neurexin-
2 AS4 was only repressed by T-STAR, and did not respond to Sam68 (Figure 3.1). Thus, 
Sam68 and T-STAR, even being similar proteins, have some shared and some different 
splicing targets (Ehrmann et al., 2013). In this Chapter by means of EMSA assay, I 
investigated whether T-STAR and Sam68 bind Neurexin-1 and Neurexin-2 in vivo.  
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Figure 3.1 – Neurexin-2 splicing is specifically repressed by T-STAR but not by Sam68. 
Different versions of Neurexin-2 minigene exon were co-transfected with GFP-only, T-STAR, 
Sam68, T-STAR and Sam68 mutants, as well as T-STAR and Sam68 together. Transfection 
efficiency was assessed by the presence of fluorescence in HEK293 cell nuclei, using the 
fluorescent microscope. Transfected cells were harvested and subjected to RNA extraction. RNA 
was reverse-transcribed into cDNA. Transfected Neurexin-2 cDNA were amplified applying 
pXJ41 vector primers. The PCRs were loaded on QIAxcel, as a result, the gel pictures and 
concentrations for included/excluded bands were observed. Figure shows the gel picture and the 
graphs for the percentage of splicing exclusion (PSE%) of AS4 in Neurexin-2 transfected with 
different constructs. Statistical significance was calculated applying the independent two-sample 
t-test. Error bars show standard errors of the mean. Figure is adopted from (Ehrmann et al., 2013). 
 
Previously, by means of SELEX, and recently by NMR studies, potential binding sites 
for T-STAR have been identified. Based on SELEX, T-STAR tends to bind 
UAAA/UUAA motifs (Lin et al., 1997; Galarneau and Richard, 2009b) Based on NMR, 
T-STAR was shown to bind UAA motif, specifically followed by A and preceded by U 
(as UUAAA) (Foot et al., 2014). However, these are the predicted sequences from in vitro 
experiments only, not confirmed by any real targets. Here I examine what are the 
sequences needed for T-STAR regulation of a real physiological target Nrxn2 (Neurexin-
2). In the study by Ehrmann et al, to uncover the T-STAR regulatory sequence in Nrxn2, 
five U(U/A)AA motifs downstream from the AS4 were altered by mutagenesis (in this 
thesis I refer to the mentioned mutant as to the “Neurexin-2 mutant with a big mutation”). 
Mutation of U(U/A)AA repeats completely blocked exon exclusion by T-STAR 
(Ehrmann et al., 2013). In this Chapter I dissected this ISS to find the important and less 
important sites for T-STAR splicing regulation of Nrxn2. 
There are many examples in the literature when binding of RNA binding proteins (RBPs) 
share common positional principles. For instance, for RBPs including Nova, PTB, Fox 
Chapter 3                    Dissecting the mechanism of Splicing of Nrxn2 cassette exon by T-STAR 
 
52 
 
and muscleblind, binding near the branch point upstream of the exon, near splice sites or 
within the exon leads to exon exclusion (splicing repression) (Dredge et al., 2005; Zhang 
et al., 2008b; Goers et al., 2010; Llorian et al., 2010). Repression is thought to happen 
because of protein competition with core spliceosome components. As one example, SR 
proteins were shown to bind an intronic sequence close to the branch point in adenovirus. 
This blocks 3' splice site usage and represses the splicing (Kanopka et al., 1996; Kanopka 
et al., 1998). RBPs binding downstream of exons, like TIA and hnRNP L, often activate 
splicing. There are several mechanisms how splicing activation might happen. One of the 
common ones is when an RBP interacts with and stabilizes U1 snRNP, which is a splicing 
initiator (Witten and Ule, 2011). This is a general rule, but the precise mechanism for 
each splicing event is more sophisticated. Different from the general tendency, Nrxn2 
AS4 splicing is repressed by T-STAR with binding sites downstream of the regulated 
cassette exon. Here I investigate if Nrxn2 splicing repression by T-STAR is position 
dependant and test the hypothesis that T-STAR represses the splicing of Nrxn2 by 
blocking the 5' splice site. 
 
 
 
3.2  The aims of this Chapter were: 
1. To investigate whether T-STAR and Sam68 directly interact with Nrxn2 response 
element 
2. To dissect the target response element into smaller elements and investigate their 
importance for Nrxn2 splicing exclusion and splicing repression by T-STAR 
3. To investigate the importance of the upstream and downstream position of 
response element for splicing regulation 
4. To study whether T-STAR is blocking splicing exclusion by means of blocking 
the 5' splice site 
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3.3 Results 
3.3.1 Both T-STAR and Sam68 bind Nrxn2 target sequence directly 
 
 
Figure 3.2 – EMSA assay is performed in a series of steps. A – In the EMSA assay a 
radiolabelled RNA probe is mixed with purified protein. Then, the naked RNA (as a control) or 
RNA-protein mixture is subjected to gel electrophoresis. Unbound RNA is expected to migrate 
further down in the gel, while RNA bound by the protein will generate a heavier complex that 
will stop earlier, producing a higher size band on a gel. B – The sequences of the RNA probes 
used for EMSA. Sequences coding for Neurexin-1 and Neurexin-2 response elements each 
containing potential sites for protein binding (highlighted in green). A negative control probe is 
taken from a further downstream sequence of Neurexin-2 that does not contain any potential 
STAR protein binding sites.  
 
Minigene studies have shown Nrxn1 and Nrxn3 to be regulated by both Sam68 and T-
STAR. Nrxn2 was shown to be regulated by T-STAR only (Ehrmann et al., 2013). As 
long as T-STAR and Sam68 were both predicted to bind similar sequences, I aimed to 
see whether both proteins could bind Nrxn2 and Nrxn1 directly. Alternatively, T-STAR 
might bind to Nrxn2 better than Sam68. For this, EMSA assays were performed. 
GST-tagged T-STAR and Sam68 fusion proteins, required for EMSAs, were produced 
by Mrs. Caroline Dalgliesh (Newcastle University). RNA probes comprised of regions of 
Nrxn1 and Nrxn2 genes were cloned into pBluescript vector. Two probes contained 
predicted sequences for T-STAR and Sam68 binding. A third probe was cloned from 
Nrxn2 sequence localized further downstream from the target region, known to be 
important for splicing regulation, to serve as a negative control for the binding assays 
(Figure 3.2 B). Prior to EMSAs, I adjusted the concentrations of Sam68-GST and T-
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STAR-GST fusion proteins to be equal, by running them on a Coomassie stained gel 
(Figure 3.3 A). 
The full experimental details are given in section 2.1 of the Materials and Methods 
Chapter. Briefly, before the EMSA assays, pBluescript plasmids were transcribed into P32 
radiolabelled RNA probes. RNAs were diluted, and incubated with purified full length 
Sam68-GST and T-STAR-GST fusion proteins and analysed by gel electrophoresis. In 
case of RNA-protein binding, a shift was expected on a gel (Figure 3.2 A for a general 
EMSA method). 
EMSAs were used to test the binding of T-STAR and Sam68 to the labelled RNA probes. 
Lane 0 of each gel shows how the probe migrates in the absence of T-STAR or Sam68 
protein (Figure 3.3 B). Addition of either T-STAR or Sam68 protein prevented the Nrxn2 
RNA probe from moving outside the well into the gel, suggesting the formation of large 
molecular complexes on this probe. T-STAR protein bound to and shifted the Nrxn2 
probe, with a complete shift observed with 100 ng of added T-STAR protein. Sam68 
protein also shifted the Nrxn2 RNA probe, but with a maximal shift observed at 200 ng 
of added protein (a higher concentration than for T-STAR, Figure 3.3 B). Similar results 
were observed for the Nrxn1 gene (Figure 3.3 C). No binding was observed to a control 
RNA probe (Figure 3.3 D). 
Even though Sam68 did not regulate the splicing of Nrxn2 in a minigene, these EMSA 
results suggest that Nrxn1 and Nrxn2 are both bound by both T-STAR and Sam68. 
However, a higher concentration of Sam68 compared to that of T-STAR is required for 
binding.  
The described EMSA results were included in the publication on T-STAR and Neurexin 
by Ehrmann et al 2013, making me a co-author of this paper (Ehrmann et al., 2013).  
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Figure 3.3. T-STAR and Sam68 bind the Neurexin-1 and Neurexin-2 RNAs directly. A- A 
Coomassie-stained SDS-PAGE gel, confirming the equal amounts of T-STAR and Sam68 were 
used in for the gel shift assay. B – A radiograph for Neurexin-2 shift gel shift experiment. Lane 
0 corresponds to the naked RNA, lanes 1 to 3 to different concentrations of Sam68 and lanes 4 
to 6 to different T-STAR concentrations. Naked RNA does not produce any shift, forming a band 
at the gel bottom, corresponding to migration of unbound probe. Sam68 shifts Neurexin-2 even 
at 50 ng of the protein added, with a complete shift at 200 ng of the protein, when the complex 
is too heavy to move and gets stuck in the well. T-STAR detectably shifts the probe with 50 ng 
of the protein, while a complete shift occurs with 100 ng. C - A radiograph for Neurexin-1 shift 
gel shift experiment; the results are similar as for Neurexin-2. D – EMSA experiments were 
carried out with the negative control probe. 
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3.3.2 Splicing repression of the Nrxn2 cassette exon depends on multiple redundant 
binding sites, as well as a general repressor element 
The previously described EMSA experiment and mutagenesis of an extended region, with 
T-STAR binding sites identified a 51 base pair region 12 bases downstream of the Nrxn2 
target exon, within which T-STAR and Sam68 binding occurs (Figure 3.4). There are 7 
potential T-STAR binding sites in this region: 6 single UUAA sequences (Sites 1-4 and 
5-6) (these were predicted as potential T-STAR binding sequences from SELEX data) 
and a sequence of 3 CUAA repeats (Site 7) (Figure 3.4).  
To test the importance of these binding sites, using site directed mutagenesis, seven 
mutant minigenes were cloned, where UA was replaced by CC (a base combination that 
T-STAR is expected not to bind).   
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Figure 3.4 – A diagram of Nrxn2 cassette exon and flanking intron sequence, taken from 
the UCSC genome browser. The region highlighted in black and limited with red lines 
corresponds to the downstream sequence element that contains multiple sites for T-STAR 
binding. Mutated nucleotides are shown in red. The Mutant called “Big Mutation” was created 
by (Ehrmann et al., 2013) and showed to completely abolish T-STAR-mediated exon exclusion. 
Seven different mutant minigenes 1-7 have been produced from this region. 
 
Each minigene was co-expressed in HEK293 cells with expression constructs encoding 
T-STAR and Sam68 proteins. The cells were harvested, RNA was extracted and reverse 
transcribed. Following capillary gel electrophoresis, splicing patterns were analysed. Two 
bands were always observed on a gel, one for exon inclusion and one for exon exclusion. 
Concentration for each band was calculated by a multi-capillary QIAxcel gel 
electrophoresis device. Based on the concentration ratio between exon exclusion and exon 
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inclusion, percentages were calculated and plotted on the graphs (Figure 3.5). The full 
details of how the calculation was performed are given in section 2.5.4 of the Materials 
and Methods Chapter. The level of splicing exclusion (splicing repression) caused by 
overexpressed T-STAR and Sam68 was compared with the level of splicing exclusion 
without co-transfection of STAR proteins (GFP co-transfection) for the same constructs. 
The level of splicing exclusion in each mutant Nrxn2 construct was also compared with 
the level of splicing exclusion in the wild type Nrxn2. 
The co-expression experiments show that mutations made in T-STAR binding sites of 
mutants 1, 2, 3, 4 and 6 did not significantly reduce exon exclusion, compared to the wild 
type minigene (Figure 3.5). 
The constructs were analysed after co-expression of STAR proteins. Mutants 1 and 2 did 
not show any change in splicing repression by T-STAR, compared to wild type. There 
was a small reduction in splicing repression by T-STAR in mutants 3, 4 and 6. This was 
significantly different from the GFP-only co-transfection for each mutant. Thus, even 
when individual sites were mutated, splicing repression still happened. No effect on 
Nrxn2 splicing of Sam68 overexpression was detected in any of the mentioned mutants. 
In contrast with the other mutations, Mutant 5 showed a substantial reduction in exon 
exclusion when compared to the wildtype minigene. Furthermore, Mutant 5 transfected 
with T-STAR and Sam68 was no longer significantly different from the GFP-only 
control. This suggests that UUUAAAAA is the most important site for T-STAR splicing 
repression in the whole ISS.   
Mutant 7 was still highly repressed by T-STAR, compared to wild type. However, 
splicing repression has decreased even with endogenous T-STAR levels (GFP-only). This 
might mean that Mutant 7, which is comprised of a triple CUAA sequence repeat, might 
represent a general splicing silencer element in Nrxn2 sequence that is needed to gel full 
levels of repression of Nrxn2 AS4. 
None of the mutants above had such a strong effect as mutating the whole binding region 
(Nrxn2 mutant with big mutation), where: a) exon inclusion is no longer repressed by co-
transfected T-STAR; b) exon inclusion is much less repressed even without co-
transfection of STAR proteins (i.e. at endogenous protein levels) (Figure 3.5). 
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Figure 3.5 – Individual mutations downstream of the Nrxn2 AS4 indicate the redundancy 
between single sites for Nrxn2 splicing repression by T-STAR. Graphs show the percentage 
of splicing exclusion (PSE%) in different versions of Nrxn2 minigene exon co-transfected with 
GFP-only, T-STAR and Sam68. Data represents the mean of minimum three biological 
replicates. In each case, statistical significance was compared between HEK293 cells expressing 
GFP and HEK293 cells expressing the GFP fusion proteins by means of independent two-sample 
t-test, where *p<0.05, **p<0.01, ***p<0.001.  
 
Together this data indicated that UUAA sites in Mutants 3, 4, 6 and mainly the 
UUUAAAAA site in Mutant 5 are important for T-STAR splicing repression. The CUAA 
triple sequence repeat (Mutant 7) might represent a Nrxn2 splicing repressor element, 
important for repression of the exon, but not responsible for the response to T-STAR. 
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Figure 3.6 – Without co-transfection of STAR proteins levels of splicing repression of most 
mutants are not significantly different from the wild type control. Graphs show the 
percentage of splicing exclusion for different versions of the Nrxn2 minigene exon co-
transfected with GFP-only. The data represents the mean of minimum three biological replicates. 
Statistical significance was compared between HEK293 cells expressing GFP in wild type Nrxn2 
and HEK293 cells expressing GFP in mutant Nrxn2 by means of independent two-sample t-test, 
where *p<0.05, **p<0.01, ***p<0.001.  
 
 
Figure 3.7 – The Western blot confirms that GFP, T-STAR and Sam68 showed similar 
levels of expression after transfection. Figure shows Western blot analysis of HEK293 cells 
co-transfected with GFP-coupled fusion proteins and wild type Nrxn2 minigene. Probing was 
performed for GFP and actin. 
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Figure 3.7 is a Western blot for HEK293 cells co-transfected with GFP-coupled fusion 
proteins and wild type Nrxn2 minigene. Western blot shows that the expression levels of 
T-STAR and Sam68 were similar.  
From Figure 3.5 it is visible that for some of the mutants the percentage of exon exclusion 
is changing even for the GFP-only co-transfection. On Figure 3.6 
 I have plotted the graph for the GFP-only controls in those mutants tested. Neither of the 
mutants 1 to 6 appeared to be significantly different from the wild type GFP co-
transfection. For the Nrxn2 mutant with the big mutation and Nrxn2 Mutant 7, percentage 
of splicing exclusions are both significantly different from the wild type GFP.  
 
3.3.3 Loss of two key groups of AU-rich sequence elements inhibits splicing control 
by T-STAR. 
Even though mutation of individual UUAA sites 1 - 4 in the Nrxn2 response element were 
not strong determinants for T-STAR splicing regulation, these sites are predicted as 
binding sites for T-STAR by SELEX. To test if they are redundantly required for splicing 
control by a minigene assay, I combined them into a single large mutation 1-4, to check 
if these sites have an additive or redundant effect. Figure 3.8 shows the effect of these 
mutations on splicing, after transfection into HEK293. Even the combined mutant 1-4 did 
not have any effect of splicing repression by T-STAR. T-STAR was still able to repress 
the exon exclusion of Mutant 1-4 up to a significant level, compared to the GFP-only 
control. 
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Figure 3.8 – A combined Mutant 1-4 is still efficiently repressed by T-STAR. Graphs show 
the percentage of splicing exclusion in a combined Mutant 1-4 of Nrxn2 exon. The data 
represents the mean of minimum three biological replicates. Statistical significance was 
compared between HEK293 cells expressing GFP and HEK293 cells expressing the GFP fusion 
proteins by means of independent two-sample t-test,where *p<0.05, **p<0.01, ***p<0.001.  
 
To further look for redundancy between the sites, mutations 1-4 were combined with 
Mutation 5 to create a Mutant 145. Interestingly, even at endogenous protein levels in 
HEK293 cells splicing repression was very high (Figure 3.9). This could have happened 
if with the sequence deletion a splicing enhancer was removed, thus leading to the high 
splicing repression with endogenous T-STAR and Sam68 levels. Comparing to GFP 
control, T-STAR appeared not to repress the splicing of this Nrxn2 mutant anymore 
(Figure 3.9), with the percentage of splicing exclusion nearly equal among GFP-only 
control, T-STAR and Sam68 co-transfections. The additive effect of Mutation 5 together 
with Mutations 1-4 is stronger, than Mutation 5 on its own. These results suggest that 
even though sites 1-4 are not necessary for T-STAR repressive function on their own, 
they still have an important role in the complete T-STAR splicing element. The equal 
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expression levels of fusion proteins for Mutant 145 co-transfection was confirmed by 
Western Blot (Figure 3.10). 
To further investigate the role of the sequence affected by Mutant 7 for T-STAR splicing 
repression, a combined Mutant 57 was created. In contrast to Mutant 5 alone, Mutant 57 
was highly repressed by T-STAR (Figure 3.9). As the site covered by Mutant 5 is gone, 
the splicing of the Mutant 57 is repressed by T-STAR through sites 1-4.  
 
 
Figure 3.9 – The loss of sites 1-4 and 5 inhibits the Nrxn2 splicing repression by T-STAR. 
Graphs show the percentage of splicing exclusion in wild type, as well as combined mutants 
M57 and M145 of Nrxn2 minigene exon transfected with T-STAR, Sam68 and GFP-only 
control. The data represents the mean of minimum three biological replicates. In each case, 
statistical significance was compared between HEK293 cells expressing GFP and HEK293 cells 
expressing the GFP fusion proteins by means of independent two-sample t-test, where *p<0.05, 
**p<0.01, ***p<0.001.  
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Figure 3.10 – Fusion-protein constructs co-transfected with Nrxn2 Mutant 145 into 
HEK293 cells were equally expressed. Western blot analysis of HEK293 cells co-transfected 
with GFP-coupled fusion proteins and Nrxn2 M145 minigene. The Western blot was probed for 
GFP and actin, and shows equal expression levels of each fusion protein. 
 
Thus, CUAACUAACUAA appeared not to be a T-STAR regulatory site, but to some 
extent prevent T-STAR from regulation. I further aimed to study how 
CUAACUAACUAA affects T-STAR. In wild type Nrxn2 CUAACUAACUAA is 
separating two groups of binding sites: UUAA repeats and UAAAAA sequence. Even 
when CUAACUAACUAA was mutated, it still creates a ‘gap’ between the mentioned 
target motifs. Thus, it was decided to delete CUAACUAACUAA from the sequence 
completely.  
A mutant with deleted CUAACUAACUAA sequence was created (Figure 3.11). 
Interestingly, after co-transfection with T-STAR, strong repression by T-STAR was 
observed (25% significant difference comparing to GFP-only control). This repression 
pattern is significantly higher (by 12%) than repression in wild type Nrxn2 co-transfection 
with T-STAR. Sam68 did not show to regulate splicing repression. Thus, a complete 
deletion of repetitive repressor sequence has increased T-STAR effect on Nrxn2 splicing 
repression, compared to the wild type minigene. 
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Figure 3.11 – The deletion of CUAA repeat region results in a stronger Nrxn2 splicing 
repression by T-STAR. Graphs show the percentage of splicing exclusion in wild type, as well 
as mutant with repetitive repressor site deleted, transfected with T-STAR, Sam68 and GFP-only 
control. The data represents the mean of minimum three biological replicates. In each case, 
statistical significance was compared between HEK293 cells expressing GFP and HEK293 cells 
expressing the GFP fusion proteins by means of independent two-sample t-test, where *p<0.05, 
**p<0.01, ***p<0.001. 
 
3.3.4 Splicing repression of Nrxn2 can occur from upstream and downstream 
intronic locations 
Splicing factors are known to function differently depending on their binding position 
regarding to the target exon. The currently accepted rules are that when a splicing factor 
binds upstream, it represses splicing through blocking the branch point site, while when 
it binds downstream, splicing is activated through stabilising the U1 snRNP binding 
(Witten and Ule, 2011). T-STAR response sequences in Nrxn2 are situated 12 bases 
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downstream of the target exon. Binding downstream, T-STAR represses the splicing, 
which is more an exception to the general rules. 
Knowing the sequence elements through which T-STAR represses Nrxn2 splicing, we 
further addressed the mechanism through which T-STAR causes splicing repression. I 
hypothesised that T-STAR might be blocking the U1 spliceosome access to the 5' splice 
site, and hence prevent the spliceosome assembly. I aimed to test if splicing is position 
dependent and if T-STAR exerts the same effect both upstream and downstream of the 
target exon. If T-STAR is restricting U1 snRNP access to the 5' splice site, I predict 
moving the binding site upstream of the exon, or far downstream, might prevent splicing 
regulation.  
Thus, Nrxn2 mutants were cloned, where the whole T-STAR response sequence was 
moved 100, 150 and 250 bases further downstream in the intron sequence. The 250 base 
interval was chosen as the most distant one, as the downstream intron length in the 
minigene did not allow to move the sites even further downstream. As a template for this 
cloning the Nrxn2 mutant with a big mutation was used, in which all T-STAR response 
elements have been mutated, making it unresponsive to T-STAR overexpression.  
After co-transfection with T-STAR, all of the mutants still showed significant repression 
of exon splicing, compared to a GFP-only control. Even though splicing repression has 
reduced with endogenous T-STAR levels within HEK293 cells, T-STAR still repressed 
Nrxn2 splicing of each of the mutants to a similar level as in the wild type control (Figure 
3.12). Hence, even with binding sites being a distance of 100, 150 or 250 bases 
downstream the Nrxn2 exon, T-STAR still efficiently repressed Nrxn2 splicing. Sam68 
co-transfection did not have any effect on splicing of any of the mutants - in all three 
mutants the percentage of splicing exclusion for Sam68 co-transfection is nearly equal to 
the GFP-only control (Figure 3.12). 
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Figure 3.12 – T-STAR response element can still potently repress splicing even from more 
distant downstream locations. Graphs show the percentage of splicing exclusion in transcripts 
made from three mutants where the Nrxn2 binding site is moved: A) 100 bases, B) 150 bases, C) 
250 base downstream the target Nrxn2 exon, compared to the wild type minigene control. The 
data represents the mean of minimum three biological replicates. In each case, statistical 
significance was compared between HEK293 cells expressing GFP and HEK293 cells 
expressing the GFP fusion proteins by means of independent two-sample t-test, where *p<0.05, 
**p<0.01, ***p<0.001.  
 
The experiments above show that Nrxn2 splicing repression by T-STAR can still be 
repressed even with the binding sites being further in a downstream intron. To investigate 
whether splicing is similarly repressed when the binding sites are moved into the upstream 
intron, two mutants were cloned with the whole T-STAR response sequence moved 42 
and 100 bases upstream of the exon. The program called Sroogle (Splicing Regulation 
Online Graphical Engine) (http://sroogle.tau.ac.il/) was used to identify the Branch Site 
sequence and Polypyrimidine tract in the sequence upstream. A 42-base distance was 
chosen as an earliest point upstream to prevent any interference with these important 
sequence elements (Figure 3.13 A). 
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Figure 3.13 – Output of a wild type Nrxn2 sequence in the Sroogle program. A - for the exon 
start and an upstream intron; B - for the exon end and the downstream intron). Splice sites, 
Branch site and Polypyrimidine tract are marked with coloured dash lines, that match by colour 
with the names in a table below. The T-STAR binding region is marked by a continuous blue 
line on a picture B. 
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Figure 3.14 – T-STAR response element can still potently repress splicing even when placed 
upstream of the regulated Nrxn2 exon. Graphs show the percentage of splicing exclusion for 
moving mutant: when the binding site is moved A) 42 bases, B) 100 bases upstream of the target 
Nrxn2 exon, compared with the wild type minigene control. The data represents the mean of 
minimum three biological replicates. In each case, statistical significance was compared between 
HEK293 cells expressing GFP and HEK293 cells expressing the GFP fusion proteins by means 
of independent two-sample t-test, where *p<0.05, **p<0.01, ***p<0.001.  
 
When co-transfected with T-STAR and Sam68, both mutants where the T-STAR binding 
site was moved upstream were still highly repressed by T-STAR co-expression (Figure 
3.14 A and B). There was also some reduction in splicing repression on endogenous 
protein levels. As previously, Sam68 did not induce splicing repression of these. 
 
3.4  Discussion 
3.4.1 Do T-STAR and Sam68 bind Nrxn2 directly? 
The first aim of this Chapter was to investigate whether T-STAR and Sam68 directly 
interact with the Nrxn2 response element. T-STAR and Sam68 are both very similar 
proteins, both belonging to the same protein family, having a similar domain composition 
and UA-rich sequences predicted as target regions for RNA-binding. It thus would be 
expected that they regulate the same set of targets. However, the study by Ehrmann et al 
2013 showed that T-STAR is a specific splicing regulator of Nrxn2 gene. In this study it 
was found, that three Neurexin genes (Nrxn1, Nrxn2 and Nrxn3) are all regulated by T-
STAR, but only two of them (Nrxn1 and Nrxn3) were regulated by Sam68. Hence, Nrxn2 
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appeared to be T-STAR specific (Ehrmann et al., 2013). The preliminary target region 
identified for T-STAR was highly rich in UA elements, but also highly resembled a 
Sam68 binding site. Thus, it was of interest, whether T-STAR and Sam68 can both bind 
the target region, even though only T-STAR induces a splicing response. To find this out 
an EMSA was performed. Both T-STAR and Sam68 proteins appeared to bind the target 
region of Nrxn2; however, T-STAR binding was more efficient, as 100ng was enough for 
complete shift (comparing to 200ng of Sam68). That might mean that the Nrxn2 binding 
site is more T-STAR specific than Sam68 specific. Interestingly, the study by Ehrmann 
et al also showed that when co-transfecting T-STAR and Sam68 together with Nrxn2 
minigene, the effect of T-STAR is completely abolished by Sam68. This might suggest, 
that even though Sam68 binding is less efficient than T-STAR, it might be competing 
with T-STAR for the same binding sites, and blocking the latter from binding. It was 
previously shown by Venables et al that T-STAR interacts with Sam68 in the yeast two-
hybrid system (Venables et al., 1999). Thus, when overexpressed, Sam68 could be 
interacting with T-STAR, and blocking it from splicing regulation.  
As it was shown on Figure 1.7 of the Introduction Chapter, T-STAR is having a shorter 
N-terminus, comparing to Sam68. Thus, it might be that N-terminus of Sam68 prevents 
it from regulating Neurexin-2 splicing. To test that, a mutant Sam68 should be made, with 
its N-terminus being equal by length and composition to the one of T-STAR. It then 
should be transfected with Neurexin-2 minigene. Furthermore, Neurexin-2 splicing might 
be specific to T-STAR due to Neurexin-2 sequence composition. As visible from the 
Figure, T-STAR sites in Neurexin-2 are clustered, while the potential Sam68 and T-STAR 
sites in Neurexin-1 and Neurexin-3 are more dispersed across the downstream intron.  
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Figure 3.15 – Neurexin-2 has a cluster of T-STAR binding sites, while in Neurexin-1 and 
Neurexin-3 target sites are more dispersed. Figure shows the sequences of the target exons 
regulated by T-STAR (and by Sam68 for Neurexin-1 and Neurexin-3) and the flanking introns. 
Exons are highlighted in black, while the potential T-STAR and Sam68 target sites in the 
downstream introns are highlighted in yellow. 
 
3.4.2 Splicing repression of the Nrxn2 cassette exon depends on multiple redundant 
binding sites, as well as a general repressor element 
The second aim of this Chapter was to dissect the target response element into smaller 
elements and investigate their importance for Nrxn2 splicing repression by T-STAR 
In the study by Ehrmann et al 2013, an overall T-STAR target region in Nrxn2 was 
identified. This sequence contained several UA-rich sequence repeats that might 
independently bind T-STAR protein. This region was dissected by me to try to identify 
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smaller T-STAR binding sequence motifs. Minigene assays were performed to monitor 
functional response. Even though minigene creation is laborious and does not allow a 
global analysis, when working on a few targets minigenes provide an ideal mechanism to 
manipulate the sequence, mutating and rearranging it in required ways. There are many 
others studies which used minigene assays for splicing e.g. a study by (Steffensen et al., 
2014) for the BRCA1 gene; the study by (Ulzi et al., 2014) for the CLCN1 gene; the study 
by (Xiao et al., 2012) on the Bcl-x gene; the study by (Grellscheid et al., 2011) on the 
Tra2β target HIPK3; etc. Minigene assays have shown that T-STAR target region in 
Nrxn2 is having an interesting structure.  
Being a UA-rich sequence, the CUAACUAACUAA region (covered by Mutant 7), 
consisting of three CUAA repeats was predicted to be a T-STAR binding site. However, 
when the CUAACUAACUAA region was mutagenized, T-STAR still regulated Nrxn2 
splicing up to similar level as in wild type; but overall levels of splicing exclusion were 
significantly reduced. This suggested that CUAACUAACUAA is functioning as a 
general splicing repressor sequence. Previous studies show that there are certain 
sequences that function as exonic or intronic splicing repressor elements. For instance, 
CUCUCU functions as an intronic splicing silencer element, while UGCAUG – as a 
splicing enhancer sequence (Chan and Black, 1997; Modafferi and Black, 1997). 
The UUUAAAAA site (covered by Mutant 5) appeared to be the strongest site for T-
STAR regulation. When mutated, no significant difference in splicing repression was any 
more noticeable between GFP-only control and T-STAR co-transfection. However, by 
mutating site 5 splicing repression by T-STAR was not blocked completely (splicing was 
still repressed by T-STAR 6%, compared to 14% repression in a wild type control).  
The UUAA sites (1-4) were predicted by SELEX as potential T-STAR binding sites (Lin 
et al., 1997; Galarneau and Richard, 2009a). However, mutagenesis of separate UUAA 
sites did not show any large effect on T-STAR splicing regulation. Even when combined 
together into one mutation 1-4, loss of the UUAA sites did not impact T-STAR function 
in splicing. However, sites 1-4 were important for regulation by T-STAR. When sites 5 
and 1-4 were blocked together into a mutant 145, no splicing regulation by T-STAR was 
visible any more. This fits with the recent unpublished findings by Dr Cyril Dominguez 
lab (Leicester University) that T-STAR binds the RNA sequence as a dimer with at least 
15 nucleotides spacing between the binding sites for each monomer. Sites 1-4 and 5 have 
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15 nucleotides of CUAA sequence between them, thus might be ideal sites of T-STAR 
monomers to bind. Hence, with both 1-4 and 5 being blocked, T-STAR fails to function.  
A combined together Mutant 5 with Mutant 7 (Mutant 57), still responded to T-STAR, as 
Mutant 7 does alone. That means, when we block mutant 5 and 7 together, T-STAR is 
able to function and regulate Nrxn2 splicing, presumably through sites 1-4.  
Thus, to summarize, CUAACUAACUAA functions to repress splicing, but does not 
mediate a response to transfected T-STAR.  
Experiments show, that when CUAACUAACUAA is wild type, site 5 (UAAAAA) 
serves as a main site to respond to transfected T-STAR, and sites 1-4 (UUAA) recruit T-
STAR as secondary sites, having just a small effect on T-STAR regulation.  
Removal of CUAACUAACUAA sequence reduces the baseline level of splicing 
repression, but response to transfected T-STAR keeps still being strong. Splicing 
repression could be performed through site 5 (UAAAAA). However, when site 5 is 
mutated with site 7 together into a Mutant 57, T-STAR still highly represses Nrxn2 
splicing. That means, when site 7 is mutated, sites 1-4 still function as T-STAR target 
motifs.  
 The above mechanism is a good example of a complex and tight splicing control by the 
cell, where many factors participate and many compensatory mechanisms function, in 
case one of the pathways fails to work. Such tight control may be important for regulating 
the amounts of alternative transcript produced, and eventually, the amounts of the protein. 
Interestingly, when repetitive sequence covered by Mutant 7 was deleted completely, the 
T-STAR repression pattern has significantly raised. CUAACUAACUAA is separating 
two groups of binding sites: UUAA repeats and UAAAAA sequence. Once it was deleted, 
the gap has disappeared and separate sequences created a single motif. Thus, a longer 
continuous AU-rich motif has appeared, and a new sequence combination as 
AAUAAAAA. Based on the study by Foot et al 2014, AAAUAA sequence is the one of 
single stranded RNA sequences bound by T-STAR KH domain (Foot et al., 2014). The 
current new motif AAUAAAAA highly resembles the motif from the study above. Thus, 
deletion of repressor sequence might be creating a better T-STAR binding site.  
 
Chapter 3                    Dissecting the mechanism of Splicing of Nrxn2 cassette exon by T-STAR 
 
74 
 
3.4.3 Splicing repression of Nrxn2 can occur from upstream and downstream 
intronic locations 
The third aim of this Chapter was to investigate the importance of the upstream and 
downstream position of response element for splicing regulation. The position of protein-
RNA interactions relative to the target exon can play an important role in splicing 
regulation. The splicing activity of RBPs is linked to their binding site. For instance, TIA 
protein binding downstream of the target exons results in splicing activation (Wang et al., 
2010). Other RBPs are more flexible and show position-dependent splicing activity, i.e 
Nova, Fox, Mbnl and PTB RBPs (Dredge et al., 2005; Zhang et al., 2008a; Goers et al., 
2010; Llorian et al., 2010). For instance, Nova binding downstream of exons activates 
splicing, while binding within the exons causes splicing repression (Dredge et al., 2005). 
As the Neurexin genes are the first physiological splicing targets identified for T-STAR, 
it was so far unknown what the positional principles for T-STAR splicing regulation were 
(Ehrmann et al., 2013). To find out we moved T-STAR binding sites (that in a wild type 
are twelve nucleotides downstream the exon) further downstream from the exon as well 
as upstream from the exon. However, all five mutants produced, even with T-STAR 
binding sequences a distance of 250 bases downstream of the exon and 100 bases 
upstream of the exon (maximum distances tried), had Nrxn2 AS4 exon splicing repressed 
by T-STAR similarly to a wild type control. To summarize, here we show that, 
surprisingly, Nrxn2 splicing repression by T-STAR is position independent, and as 
efficient as on different distances from the exon both downstream and upstream.  
Commonly, RBPs binding downstream of the exons activate U1 snRNP and splicing 
(Förch et al., 2002; Xue et al., 2009; Wang et al., 2010; Witten and Ule, 2011). In the 
case of T-STAR, Nrxn2 splicing is repressed with regulation happening through a 
composite site twelve bases downstream of the exon. This site is very close to the 5' splice 
site where the spliceosome starts to assemble (Valadkhan, 2007). Thus, I hypothesised, 
that opposite to activation, splicing might be repressed by T-STAR directly blocking U1 
snRNP. In this case, splicing repression would fail to happen with T-STAR binding sites 
being at a greater distance from the exon. Hence, it is possible that my suggested model 
of splicing repression through blocking U1 snRNP was wrong and T-STAR may use a 
different mechanism to repress Nrxn2 splicing.  
T-STAR could also follow the mechanism suggested for hnRNP A1 and PTB proteins, 
which bind the target sites from both sides of the exon, and loop out the region containing 
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the target exon (Blanchette and Chabot, 1999; Black, 2003; Spellman and Smith, 2006). 
In published examples, U1 snRNP fails to interact with the 5' splice site on the looped 
part. This represses splicing. Here I have dissected the T-STAR target region downstream 
of Nrxn2 exon. To follow the hypothesis about the looping model, I have also checked 
the sequence upstream of Nrxn2 exon UCSC genome browser, to see if any T-STAR-like 
binding sites are present. Interestingly, within 150 bases upstream the exon I found two 
UAAA sites (10 and 63 nucleotides upstream) and one AAUU site (53 nucleotide 
upstream) (Figure 3.16). Thus, the proposed model might be functional for T-STAR. It 
would explain why repression is happening with T-STAR binding sites moved on a 
distance. The presence of RNA loops in Nrxn2 sequence could be tested by FRET and 
NMR spectroscopy, as in study by (Lamichhane et al., 2010). However, the simpler way 
to test the model would be to mutate the upstream and downstream target sequences 
together. 
 
Figure 3.16 – Nrxn2 target exon (in red font) with 150 bases of upstream and downstream 
flanking exon. Downstream target region is highlighted in grey; potential T-STAR binding sites 
upstream are highlighted in yellow.  
 
In the study by Hui et al 2005, a similar technique of moving the hnRNPL target motif 
on different distances was applied, to find out the positional effect of hnRNPL on splicing 
of target genes (Hui et al., 2005). In wild type genes, hnRNPL bound downstream of the 
target exon and activated splicing. When binding sites were moved further downstream 
of 5' splice site, for some of the tested genes splicing became repressed. However, for 
some genes, such as eNOS, even the binding sites at a distance still functioned as splicing 
enhancers. It was found that moving the binding sites further downstream in eNOS 
resulted in an activation of a cryptic 5’ splice site further downstream in the wild type 
sequence, and still enhanced splicing (Hui et al., 2005). However, cryptic downstream 
splice sites lead to changes in a final product size, as a part of an intronic region is spliced 
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together with exon. Assessing the T-STAR regulation of moving mutants, I did not see 
any difference in sizes of final product, thus a cryptic splice site version as a potential 
mechanism for T-STAR should be excluded, unless a cryptic splice site is activated very 
close to an original splice site, so that difference in product sizes cannot be detected on a 
gel.  
Witten and Ule et al 2011 described several possible mechanisms of how proteins regulate 
splicing by binding downstream of alternative exons (Witten and Ule, 2011). If not 
repressing U1 snRNP directly, T-STAR might interact with other proteins (like TIA 
proteins) and repress them from binding U1 snRNP, by these means destabilizing U1 and 
repressing the splicing.  
Another interesting explanation about how splicing can be regulated on a distance is by 
influencing the kinetics of the splicing reaction. For instance, some proteins (as TIA 
proteins) through binding to a preceding exon are thought to increase the speed of 
transition between different stages of splicing reaction, and hence to reduce the time for 
other RBPs to bind, what results in splicing repression (Witten and Ule, 2011).  
Splicing repression could also happen if T-STAR is interfering with enhancer elements 
of sequence, as it was suggested in study by Wu et al on splicing repression of MAG gene 
by Quaking protein (Wu et al., 2002). Splicing repression could also happen through 
some other means, including epigenetic modification of exons (Brown et al., 2012). 
All the mechanisms mentioned above are possible for Nrxn2 sites placed downstream the 
exon. For the sites placed upstream splicing repression could happen through blocking 
branch point sequence and inhibiting spliceosome assembly, as it happens for other RBPs 
as Nova, Fox and PTB, that bind upstream and repress the splicing (Ule et al., 2006; 
Zhang et al., 2008a; Xue et al., 2009).  
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3.5 Chapter Summary 
In this Chapter direct binding of T-STAR and Sam68 to Nrxn2 RNA was confirmed by 
EMSA analysis. The T-STAR target motif in Nrxn2 was dissected into separate binding 
sites, showing UAAAAA site as the one mostly used for T-STAR splicing regulation. 
Furthermore, the CUAACUAACUAA repeat region was identified as a general repressor 
site that regulates the availability of T-STAR sites and T-STAR involvement in Nrxn2 
repression. By the series of moving mutants it was found that Nrxn2 repression by T-
STAR is position independent. The exact mechanism by which T-STAR represses 
splicing in wild type Nrxn2 was not identified, but several mechanisms by which 
repression could happen, as looping model, or indirect repression model, or kinetics 
model, etc. were proposed. To conclude, Nrxn2 splicing regulation by T-STAR is having 
a multilevel control and thus might have a fundamental role for the cell. 
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Chapter 4: Dissecting the mechanism of splicing control of Tomosyn-2 
cassette exon by T-STAR and Sam68 
4.1 Introduction 
In the study by Ehrmann et al 2013, in addition to Neurexin targets, another physiological 
target of T-STAR was identified. This target exon is within a gene called Syntaxin-
binding protein 5-like (Stxbp5l, also called Tomosyn-2).  
Ehrmann et al 2013 showed the splicing of Neurexin targets to be region-specific in the 
mouse brain, with high levels of exon AS4 exclusion in the forebrain-derived regions. 
These regional splicing patterns were in agreement with T-STAR levels in these brain 
regions, and were totally abolished in the brains of T-STAR null mice (Ehrmann et al., 
2013). Figure 4.1 is reproduced from the paper by Ehrmann et al 2013. It shows the 
Western blot with the expression pattern of T-STAR and Sam68 in different brain regions 
(4.1 A). The Schematic in Figure 4.1 B shows where each area is situated in a mouse 
brain. In this Chapter I examine if Tomosyn-2 splicing repression by T-STAR is similarly 
differentially regulated in different mouse brain regions. 
Tomosyn-2 was shown to be a physiological target of T-STAR, however, it is not known 
if, in contrast to Nrxn2, Tomosyn-2 might be also regulated by Sam68. In this current 
Chapter I test this and find that Tomosyn-2 splicing repression is regulated by T-STAR 
and Sam68 in a minigene and the regulation sites are dissected.  
Based on results from Chapter 3, T-STAR splicing regulation of Nrxn2 appeared to be 
position independent, as with T-STAR binding sites being moved further downstream 
and upstream of the target exon, splicing was still highly repressed. In this current Chapter 
I similarly test if Tomosyn-2 splicing regulation depends on the position of protein-RNA 
binding sites relative to the regulated exon.  
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Figure 4.1 – T-STAR regulates region-specific splicing of Nrxn2 AS4 in the brain. Figures 
adopted from paper by Ehrmann et al 2013. A – The Western Blot performed earlier in the lab, 
showing the expression pattern of T-STAR and Sam68 proteins in different wild type and T-
STAR knockout mouse brain regions. B – Schematic representing the areas of mouse brain. C – 
Nrxn2 splicing pattern in different brain regions. Closed columns labelled by “+” show the 
Neurexin-2 splicing pattern in the wild type mouse brain. Opened columns labelled by “-” show 
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the Neurexin-2 splicing pattern in the T-STAR knockout mouse brain. Data represents the mean 
of minimum three biological replicates. D - Tomosyn-2 splicing pattern in wild type (WT), 
heterozygous (HET) and T-STAR knockout (KO) mouse brain. Graphs show the percentage of 
splicing exclusion. Data represents the mean of minimum three biological replicates. In each 
case, statistical significance was compared between wild type brain cells and heterozygous or T-
STAR knockout brain cells by means of independent two-sample t-test, where *p<0.05, 
**p<0.01, ***p<0.001. 
4.2 The aims of this Chapter are: 
1. To investigate if Tomosyn-2 splicing repression by T-STAR in the mouse brain is 
region-specific 
2. To investigate whether Tomosyn-2 is a direct splicing target for T-STAR using a 
minigene approach 
3. To dissect the target response elements and investigate their importance for Nrxn2 
splicing repression by T-STAR and Sam68 
4. To investigate the position dependence of response elements for Tomosyn-2  
splicing regulation  
 
4.3 Results 
4.3.1 T-STAR protein expression establishes regional splicing regulation of 
Tomosyn-2 exon in the mouse brain 
Tomosyn-2 splicing patterns were assessed in 11 brain regions of three wild type and three 
T-STAR knockout mice. For this purpose, whole RNAs, previously extracted from 
different mouse brain areas by Dr Ingrid Ehrmann, were converted by me to cDNAs and 
used as templates in RT-PCR reactions. The resulting samples were analysed using the 
capillary electrophoresis system. If T-STAR is a concentration-dependent splicing 
regulator as predicted, the more there is T-STAR is in each brain area the more exon 
exclusion (splicing repression) will happen. To test this, the percentages of exon 
exclusion were analysed for each brain region.  
In each brain region, the percentage of Tomosyn-2 exon exclusion was different (Figure 
4.2). Similar to Nrxn2 (Figure 4.1 C), Tomosyn-2 splicing was highly repressed in the 
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forebrain regions i.e. cortex and hippocampus. Splicing repression was also high in the 
thalamus and pons. Similar to Nrxn2, less exon repression was detected in the olfactory 
bulb and cerebellum. Intermediate splicing repression levels were detected in midbrain 
and medulla. As for Nrxn2, Tomosyn-2 splicing levels are correlated with T-STAR 
expression levels in the brain: i.e. T-STAR is highly expressed in cortex, hippocampus 
and thalamus, but low expression is seen in the cerebellum. Interestingly, in the pons, 
splicing repression appeared to be high (Figure 4.2), while T-STAR expression is 
moderate (Figure 4.1 A).  
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Figure 4.2 – T-STAR regulates region-specific splicing of Tomosyn-2 exon 23 in the brain.   
A and B - The graphs show percentages of exon exclusion of Tomosyn-2 in different areas of the 
wild type and T-STAR knockout mouse brain. Blue columns labelled by “+” show the Tomosyn-
2 splicing pattern in the wild type mouse brain. Red columns labelled by “-” show the Tomosyn-
2 splicing pattern in the T-STAR knockout mouse brain. Data represents the mean of minimum 
three biological replicates. In each case, statistical significance was compared between wild type 
brain cells and T-STAR knockout brain cells by means of independent two-sample t-test, where 
*p<0.05, **p<0.01, ***p<0.001. 
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In T-STAR knockout mice (Figure 4.2), regional splicing patterns of Tomosyn-2 were 
severely abolished, and splicing repression reduced. If for wild type brain parts splicing 
repression was in the order of 35%, for T-STAR knockout mice, it was not more than 
11%. Thus, it can be concluded, that T-STAR is regulating Tomosyn-2 splicing in 
different brain regions, with more repression happening in forebrain-derived regions. 
 
4.3.2 Tomosyn-2 splicing is repressed by T-STAR and Sam68  
As in Chapter 3, a minigene construct was made to test splicing regulation by T-STAR. 
The Tomosyn-2 exon controlled by T-STAR (171bp), together with 300bp of the flanking 
intron sequences was cloned into a minigene. This minigene was co-expressed in 
HEK293 cells with expression constructs encoding T-STAR and Sam68 proteins. The 
cells were harvested, RNA was extracted and reverse transcribed. Following capillary gel 
electrophoresis, splicing patterns were analysed. Two bands were observed on a gel, one 
for exon inclusion and one for exon exclusion. The concentration of each band was 
calculated by a multi-capillary QIAxcel gel electrophoresis device. Based on the 
concentration ratios between exon exclusion and exon inclusion, percentages were 
calculated and plotted on the graphs. 
Both T-STAR and Sam68 highly repressed exon inclusion of Tomosyn-2, compared to 
endogenous conditions (GFP lane) (Figure 4.3 A). The percentage of exon exclusion has 
significantly increased by 32% for T-STAR co-transfection and by 41% for Sam68 co-
transfection (compared to 22% for transfection with GFP-only). Interestingly, even 
though Tomosyn-2 was identified as a T-STAR target initially, Sam68 regulated its 
splicing in a minigene even more than T-STAR. Western blot confirmed similar levels of 
transfected fusion proteins (Figure 4.3 B). 
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Figure 4.3 – T-STAR and Sam68 repress the splicing of Tomosyn-2 exon 23 when expressed 
from a minigene. A – Graphs show the percentage of splicing exclusion in the wild type 
Tomosyn-2 minigene co-transfected with GFP-only control as well as GFP-coupled T-STAR and 
Sam68 fusion proteins. The data represents the mean of minimum three biological replicates. In 
each case, statistical significance was compared between HEK293 cells expressing GFP and 
HEK293 cells expressing the GFP fusion proteins by means of independent two-sample t-test, 
where *p<0.05, **p<0.01, ***p<0.001. B - Western blot analysis of HEK293 cells co-
transfected with GFP-coupled fusion proteins and wild type Nrxn2 minigene. The Western blot 
was probed for GFP and actin and shows equal expression levels of each fusion protein.  
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4.3.3 Tomosyn-2 sites are redundant for splicing regulation by T-STAR and Sam68 
The Tomosyn-2 sequence was analysed to identify potential T-STAR and Sam68 binding 
sites. Six potential regions were found in the upstream intron, two inside the exon, and 
seven in the downstream intron (Figure 4.4). Since Nrxn2 was repressed by T-STAR, 
with T-STAR binding sites being downstream the exon, I focused more on the 
downstream sites. One group of sites was located 38 bases downstream of the regulated 
exon and another group 106 bases downstream. One potential site was also detected very 
close to the exon (7 nucleotides downstream) and two potential sites further downstream 
(156 and 228 nucleotides).  
 
Figure 4.4 – Diagram of Tomosyn-2 cassette exon and flanking introns from the UCSC 
genome browser.  
The exon is highlighted in grey. The rest of the sequence are flanking introns. The target motifs 
are highlighted in yellow. The underlined sequences were subjected to mutagenesis.  
 
To test the involvement of the sites in splicing control, two groups of sites 38 and 106 
nucleotides downstream of the exon were chosen for site directed mutagenesis 
(underlined on Figure 4.4). TA motifs were replaced by CC sequences. Mutant 1 had 5 
potential single motifs mutated, while Mutant 2 had 2. (Figure 4.5). 
When co-transfected with T-STAR and Sam68 expression constructs, each mutant had 
significantly reduced splicing repression by both T-STAR and Sam68 proteins, compared 
to the wild type sequence (Figure 4.5). In Mutant 1, repression was reduced by 14% for 
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T-STAR, and by 18% for Sam68, in comparison to wild type. In Mutant 2 there was a 
reduction by 15% for both T-STAR and Sam68, in comparison to wild type. Thus, these 
data show the tested groups of sites are target sites for T-STAR and Sam68 splicing 
regulation. 
 
Figure 4.5 – Tomosyn-2 Mutants 1 and 2 show the reduced patterns of splicing exclusion 
by T-STAR and Sam68. Graphs show the percentage of exon exclusion for two Tomosyn-2 
sequence mutants and the wild type sequence. The data represents the mean of minimum three 
biological replicates. In each case, statistical significance was compared between HEK293 cells 
expressing GFP and HEK293 cells expressing the GFP fusion proteins by means of independent 
two-sample t-test, where *p<0.05, **p<0.01, ***p<0.001.   
 
To examine if mutation of all the sites tested above would abolish the splicing repression 
completely, a combined mutant was created, with both groups of T-STAR binding sites 
mutated. 
After co-transfection with T-STAR and Sam68 fusion proteins, the combined Tomosyn-
2 mutant had much less exon repression, suggesting that the two sequence elements 
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covered by Mutant 1 and Mutant 2 do cooperate in achieving normal levels of splicing 
repression (Figure 4.6). However, joint mutation did not completely abolish Tomosyn-2 
splicing repression by T-STAR and Sam68. Repression by Sam68 was higher, than by T-
STAR. This co-transfection was performed only single time, thus the result is 
preliminary, and needs replication.  
 
 
Figure 4.6 – The combined Tomosyn-2 mutant had much less exon repression than either 
single mutant, suggesting that the two motifs do cooperate. Graphs show the percentage of 
exon exclusion for Tomosyn-2 mRNAs encoded by a construct in which sites 1 and 2 were jointly 
mutated, compared to a wild type. Experiment for the joint mutant was performed once and needs 
replication. For the wild type, statistical significance was compared between HEK293 cells 
expressing GFP and HEK293 cells expressing the GFP fusion proteins by means of independent 
two-sample t-test, where *p<0.05, **p<0.01, ***p<0.001.   
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4.3.4 Tomosyn-2 splicing is repressed by T-STAR and Sam68 with binding sites 
being upstream of the exon 
In Chapter 3 it was found that splicing repression of Nrxn2 AS4 by T-STAR is position-
independent relative to the regulated exon. Hence, I tested if the same pattern of splicing 
regulation is observed for Tomosyn-2, for both T-STAR and Sam68. A version of the 
Tomosyn-2 minigene was cloned with the whole response element covered by site 1 
moved 54 nucleotides upstream of the target exon. The Combined Tomosyn-2 Mutant 
with both binding sites downstream the exon mutated (Section 4.3.3) was used as a 
template for mentioned cloning. Similar as in Chapter 3, a Sroogle (Splicing Regulation 
Online Graphical Engine) program (http://sroogle.tau.ac.il/) was used to locate the 
Branch Site sequence and Polypyrimidine tract in the sequence upstream (output is on 
Figure 4.7) of the regulated exon, so as not to interfere with these regions. A 54-nucleotide 
distance was chosen as an earliest point upstream the exon to prevent any interference 
with these important sequence elements.  
 
 
Figure 4.7 – A - Output of a wild type Tomosyn-2 sequence in a Sroogle program. Splice 
sites, Branch site and Polypirimidine tract are marked with coloured dash lines that match by 
colour with the names in a table below.  
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With the sites moved upstream and the downstream sites being blocked, splicing 
repression was reduced at endogenous protein levels. Comparing the ratios between GFP 
and T-STAR / GFP and Sam68, splicing repression of Tomosyn-2 exon by T-STAR and 
Sam68 in the mutant appeared to be even stronger than using a wild type minigene (Figure 
4.8). Thus, it can be suggested that T-STAR and Sam68 repress Tomosyn-2 splicing both 
upstream and downstream of the exon.  
 
Figure 4.8 – T-STAR and Sam68 response element can still potently repress splicing even 
when placed upstream of the regulated Tomosyn-2 exon. The percentage of splicing exclusion 
in mutant with target sites moved 54 bases upstream of the target Tomosyn-2 exon, comparing 
with the wild type minigene control. The data represents the mean of minimum three biological 
replicates. In each case, statistical significance was compared between HEK293 cells expressing 
GFP and HEK293 cells expressing the GFP fusion proteins by means of independent two-sample 
t-test, where *p<0.05, **p<0.01, ***p<0.001.   
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4.4 Discussion 
4.4.1 T-STAR splicing is regionally repressed in the mouse brain 
The first aim of this Chapter was to investigate if Tomosyn-2 splicing repression by T-
STAR in the mouse brain is region-specific. Splicing of different targets in the brain is 
coupled to different pathways in the brain. The study by Iijima et al 2011 has found that 
Nrxn1 splicing regulation by Sam68 is dependent on neuronal activity. Neuronal activity 
promotes a shift in Nrxn1 splice isoform choice by means of calcium/calmodulin-
dependent kinase IV signalling (Iijima et al 2011). The study by Ehrmann et al 2013 has 
suggested a model where T-STAR is providing a concentration-dependent switch to 
repress Nrxn2 splicing in different brain regions. According to this model, high 
concentrations of T-STAR in forebrain repress the splicing of Neurexin genes, while low 
T-STAR concentrations activate Neurexin splicing. The prediction of this model is that 
high T-STAR concentrations in forebrain-derived structures repress the splicing of 
Nrxn1, Nrxn2 and Nrxn3 AS4. Lower T-STAR concentrations in the brain regions like 
cerebellum result in splicing activation of Nrxn1, Nrxn2 and Nrxn3 AS4 (Ehrmann et al., 
2013).  
To test this model, in this Chapter I assessed the splicing of Tomosyn-2 exon 23 in 11 
brain regions of wild type and T-STAR knockout mice. The Tomosyn-2 repression pattern 
in the mouse brain by T-STAR was found to be similar to that of Nrxn2. Splicing was 
highly repressed by T-STAR in all forebrain regions tested (cerebral cortex, 
hippocampus, basal ganglia, thalamus and hypothalamus). The highest levels of splicing 
repression overlap with the highest T-STAR expression levels in these forebrain-derived 
regions. In the midbrain and hindbrain parts of the brain (cerebellum and medulla), the 
splicing repression level is less. This overlaps with lower T-STAR expression in these 
brain areas. In the T-STAR knockout mouse, splicing repression in all brain regions is 
reduced. These data are consistent with Tomosyn-2 splicing repression also being 
regulated by a T-STAR concentration-dependent switch model as suggested by Ehrmann 
et al 2013 for Nrxn2.  
  
Chapter 4 Dissecting the mechanism of splicing control of Tomosyn-2 cassette exon by T-STAR 
and Sam68 
 
91 
 
4.4.2 Tomosyn-2 is a direct target for T-STAR and Sam68 
The second aim of this Chapter was to investigate whether Tomosyn-2 is a direct splicing 
target for T-STAR using a minigene approach. Tomosyn-2 splicing is disrupted in the T-
STAR null mice, but Tomosyn-2 could be a direct or indirect target. To test between these 
possibilities I constructed a minigene and co-transfected it with T-STAR and Sam68 
expression constructs. The endogenous splicing repression of Tomosyn-2 by T-STAR in 
mouse brain was confirmed in a minigene. Furthermore, Tomosyn-2 splicing was shown 
to be highly repressed by Sam68. 
The third objective of this Chapter was to dissect the target response elements and 
investigate their importance for Nrxn2 splicing repression by T-STAR and Sam68. T-
STAR protein binds to A/U-rich sequences. By visually searching the sequence, I found 
seven sites downstream of regulated Tomosyn-2 exon, which appeared to respond to both 
T-STAR and Sam68. Seven identified motifs were mutated creating two mutants. Mutant 
1 covered a group of 5 potential single motifs, while Mutant 2 covered a group of 2 
potential single sites. Deletion of these motif groups individually impacted splicing 
repression by T-STAR and Sam68. When both groups were combined into one mutant, 
the effect of mutations was additive, showing that motifs cooperate in splicing repression. 
However, even with all seven downstream motifs mutated, Tomosyn-2 was still highly 
repressed by both T-STAR and Sam68. The motifs tested are not the only A/U-rich motifs 
in this sequence. Thus, I suggest that there is redundancy between T-STAR and Sam68 
regulatory motifs. When some sites are removed, others start to function. Alternatively, 
all of the sites can work all the time in a semi-redundant way. 
From Chapter 3 it was seen that Nrxn2 splicing was not repressed by Sam68. 
Interestingly, Sam68 repression of Tomosyn-2 is 9% stronger than repression by T-STAR. 
Comparing the target motifs in both genes, Tomosyn-2 mainly has 
UAAA/UAAAA/UAAAAA repeats, which are the best Sam68 sites based on SELEX 
(Lin et al., 1997; Galarneau and Richard, 2009b). The Nrxn2 splicing response region 
mainly consists of UUAA motifs and is repressed by T-STAR only. Thus, I speculate, 
that Nrxn2 target sites have higher affinity for T-STAR, while Tomosyn-2 motifs are 
better targets for Sam68. 
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4.4.3  Tomosyn-2 splicing is highly repressed by T-STAR from an upstream and 
downstream intronic locations 
As the last aim of this Chapter, I investigated the importance of the wild type downstream 
position of response elements for Tomosyn-2 splicing regulation. As shown in Chapter 3, 
Nrxn2 splicing repression by T-STAR appeared to be position-independent. Here I moved 
the Tomosyn-2 response sites from a downstream position to 54 nucleotides upstream of 
the regulated exon. This experiment showed that with response sites being upstream, 
Tomosyn-2 splicing was still significantly repressed. Thus, the splicing repression of 
Tomosyn-2 is position-independent. 
 
4.5 Chapter Summary 
In this Chapter T-STAR was shown to be a regional regulator of Tomosyn-2 splicing in 
mouse brain. Tomosyn-2 splicing was repressed by T-STAR and Sam68 when expressed 
from a minigene. Regulatory sites for both T-STAR and Sam68 were uncovered in the 
downstream intron of Tomosyn-2. However, the sites in Tomosyn-2 appeared to be 
redundant. With downstream motifs mutated, splicing was still repressed by T-STAR and 
Sam68, but at lower overall levels. Splicing regulation of Tomosyn-2 by T-STAR and 
Sam68 still occurred when the binding sites were both upstream and downstream of the 
exon.  
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Chapter 5: Why is there T-STAR specific regulation of Neurexin-2 
splicing? 
5.1    Introduction 
Based on our EMSA experiments described in a Chapter 3 both T-STAR and Sam68 
directly bind to the Nrxn2 target sequence. That means that the Nrxn2 sequence 
composition appears to be enough for Sam68 binding, but not for splicing regulation. This 
Chapter will investigate why Nrxn2 splicing is specifically regulated by T-STAR, but not 
by Sam68. I hypothesize that this regulation specificity is due to the Nrxn2 sequence 
composition, elements of which are specifically recognized and required for splicing 
repression by T-STAR, and not by Sam68.  
Based on SELEX experiments, high affinity sites for T-STAR are UAAA/UUAA motifs 
(Galarneau and Richard, 2009a). By NMR technique, Foot et al has identified an 
AAAUAA sequence as one single stranded RNA sequence bound by the T-STAR KH 
domain (Foot et al., 2014). Based on SELEX, Sam68 high affinity sites are comprised of 
UAAA/UUUA sequences (Galarneau and Richard, 2009a). As shown in Chapter 4, 
Tomosyn-2 splicing is regulated by both T-STAR and Sam68 through sequence motifs 
mainly comprising UAAA/UAAAA/UAAAAA. The UA-rich sequence downstream of 
the Nrxn2 exon (AAUUAAUUAAUUAAUUAACUAACUAACUAACUUUAAAA 
ACACGAUCUUAAA) consists of six UUAA repeats that resemble predicted T-STAR 
target motifs, and only one UAAAAA sequence that is a proposed target for Sam68 (as 
well as for T-STAR). Minigene analyses described in Chapter 3 have confirmed T-STAR 
splicing regulation using these Nrnx2 motifs. No effect of Sam68 on Nrxn2 splicing was 
observed. Neither was there an effect on Nrxn2 response to Sam68 after mutating the 
UAAAAA sequence that is a predicted Sam68 target, nor on any other motifs tested. 
Thus, based on previous data and on minigene analyses from previous Chapters, the 
Nrxn2 target region must be a better T-STAR response sequence, than a Sam68 one. In 
this current Chapter, I will replace this Nrxn2 target sequence with several AU-rich motif 
combinations, which are expected to be a better target for Sam68. I will also investigate 
whether the length of the potential Sam68-like motif affects the splicing regulation.  
In Chapter 4 it was shown that Tomosyn-2 splicing is repressed by T-STAR and Sam68. 
Regulatory sites for both T-STAR and Sam68 were uncovered in the downstream intron 
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of Tomosyn-2. In this Chapter I investigate whether it is possible to induce a Sam68 
response by moving a Tomosyn-2 regulatory element downstream of Nrxn2 AS4. 
Both T-STAR and Sam68 are members of STAR protein family that are very similar to 
each other. However, there are other proteins in these family as well, including Slm1 
(Synthetic Lethal with Mss4), SF1 (Splicing Factor 1) and QKI (Quaking). These also 
belong to the STAR family and share some similarity with T-STAR and Sam68. To 
further study Nrxn2 splicing regulation, I investigate if other STAR proteins regulate 
Nrxn2 splicing. I also examine through which sequences the splicing regulation is 
happening.  
 
5.2    The aims of this Chapter are: 
1. To test whether Nrxn2 is being regulated by Sam68 when the Nrxn2 sequence is 
changed to be a better Sam68 target 
2. To investigate, whether placing Sam68 responsive motifs from Tomosyn-2 into 
Nrxn2 can put Nrxn2 AS4 under Sam68 control 
3. To test if other STAR proteins also regulate Nrxn2 splicing and if so, through 
which sequences this regulation is happening 
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5.3    Results 
5.3.1    Sam68 regulates Nrxn2 splicing when Nrxn2 sequence is replaced by a 
different A/U-rich regulatory element 
Based on SELEX, UAAA/UUUA sequences are considered the best Sam68 targets 
(Galarneau and Richard, 2009a). The Nrxn2 target region already includes one UAAAAA 
sequence; however, it is not enough for splicing regulation by Sam68. To find out if 
Sam68 needs a different A/U-rich motif (i.e. longer, different base combination, etc.) to 
regulate Nrxn2 splicing, by means of site-directed mutagenesis, the wild type Nrxn2 
sequence was replaced by four copies of UAAA, with a final sequence being 
AAUAAAUAAAUAAAUAAA (Figure 5.1-1).  
 
Figure 5.1 – Sequence combinations that might respond to Sam68. A schematic representing 
five sequences (1-5) which were inserted into Nrxn2 mutant with a big mutation to test if these 
would enable a response to Sam68. The inserted sequence is highlighted in yellow and the other 
mutations are shown in red. 
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As previously, the Nrxn2 mutant with a big mutation where all target sites are blocked by 
mutagenesis was used as a cloning template. The new minigenes were co-expressed in 
HEK293 cells, with expression constructs encoding T-STAR and Sam68 fusion proteins, 
as well as a GFP-only control. As for previously described co-transfections, the cells were 
harvested, RNA was extracted and reverse transcribed. Capillary gel electrophoresis was 
performed and splicing patterns were analysed.  
Two bands were always observed on a gel, one for exon inclusion and one for exon 
exclusion. Concentrations for each band were calculated using a multi-capillary QIAxcel 
gel electrophoresis device. Based on the concentration ratio between exon exclusion and 
exon inclusion, percentages were calculated and plotted on the graphs. The full detail on 
how the calculation was performed are given in the section 2.5.4 of the Materials and 
Methods Chapter. T-STAR repressed the splicing of Mutant 4xUAAA up to similar 
extent as in the wild type minigene (Figure 5.2-A). However, even with four copies of the 
target sequence inserted, Sam68 still does not regulate Nrxn2 splicing (only 2% difference 
was observed after co-transfection of Sam68-GFP compared with the GFP-only control, 
which is not statistically significant).  
Chapter 5                                 Why is there T-STAR specific regulation of Neurexin-2 splicing? 
 
97 
 
 
Figure 5.2 – Sam68 starts regulating Nrxn2 splicing when Nrxn2 sequence is replaced by 
the string of eight UAAA motifs. Downstream binding sites were inserted comprising A) 
UAAA x 4 and B) UAAA x 8 that were designed to be potentially regulated by Sam68. Graphs 
show the percentage of splicing exclusion (PSE%) in different versions of the Nrxn2 minigene 
exon co-transfected with GFP-only, T-STAR and Sam68. Data represents the mean of minimum 
three biological replicates. In each case, statistical significance was compared between HEK293 
cells expressing GFP and HEK293 cells expressing the GFP fusion proteins by means of 
independent two-sample t-test, where *p<0.05, **p<0.01, ***p<0.001.  
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Following this experiment, it was decided to increase the length of the inserted potential 
Sam68 target sequence. The hypothesis was that a longer A/U-rich sequence could be a 
better target for Sam68. Hence, another mutant with 8xUAAAs was produced (with the 
final target sequence being AAUAAAUAAAUAAAUAAAAAUAAAUAAAUAAA 
UAAA) (Figure 5.1-2). Interestingly, when co-transfected into HEK293 cells, T-STAR 
repressed the Mutant 8xUAAA splicing at twice as high levels as the wild type Nrxn2 
minigene (Figure 5.2 - C). Importantly, when Mutant 8xUAAA was co-transfected with 
Sam68, a 9% higher splicing repression was observed compared to the GFP-only control. 
This PSE(%) difference was statistically significant (Figure 5.2 B). 
As UAAA x 8 did not reach strong repression levels by Sam68, another mutant with a 
potential Sam68 target sequence was cloned, where the sequence was converted into 
4xUAAAA (Figure 5.1-3). The hypothesis was, that the motif with more adenine 
nucleotides could be a better Sam68 target. When co-transfected with T-STAR and 
Sam68, a similar effect to that of mutant 8xUAAA was observed (Figure 5.3 – A): 
splicing was significantly repressed by T-STAR (18% significant difference comparing 
to GFP control) and to a lesser extent by Sam68 (7% significant difference comparing to 
GFP control) (Figure 5.3 – A). Thus, both 8xUAAA and 4xUAAAA sequences are 
apparently equally functional for Sam68 to repress Nrxn2 splicing.  
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Figure 5.3 – Sam68 starts regulating Nrxn2 splicing when Nrxn2 sequence is replaced by 
the string of four UAAAA motifs. Downstream binding sites were inserted comprising A) 
UAAAA, and B) UAAAA x 4 combined with the wild type Nrxn2 sequence. These were 
designed to be potentially regulated by Sam68. Graphs show the percentage of splicing exclusion 
(PSE%) in different versions of Nrxn2 minigene exon co-transfected with GFP-only, T-STAR 
and Sam68. Data represents the mean of minimum three biological replicates. In each case, 
statistical significance was compared between HEK293 cells expressing GFP and HEK293 cells 
expressing the GFP fusion proteins by means of independent two-sample t-test, where *p<0.05, 
**p<0.01, ***p<0.001.  
 
As long as T-STAR splicing repression of 4xUAAAA Nrxn2 mutant was not strong, I 
suggested, that the inserted 4xUAAAA sequence combined with UUAA repeats and a 
UAAAAA motif in the wild type Nrxn2 sequence could potentially result in stronger 
splicing repression levels by Sam68. Sam68 is known to bind to RNA as a dimer 
(Galarneau and Richard, 2009a). In this mutant, the inserted sequence was separated from 
the wild type Nrxn2 sequences by CUAACUAACUAA motif. The hypothesis was, that 
CUAACUAACUAA sequence will put A/U-rich sequences at a distance from each other, 
enabling Sam68 requirements for binding as a dimer. 
A mutant with 4xUAAAA sequence and the rest of the sequence wild type (containing 
original regulation sites) was cloned (Figure 5.1 – 4). As before, the new minigene was 
co-expressed in HEK293 cells, with expression constructs encoding T-STAR and Sam68 
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fusion proteins, as well as a GFP-only control. As for previously described co-
transfections, the cells were harvested, RNA was extracted and reverse transcribed. 
Capillary gel electrophoresis was performed and splicing patterns were analysed. For this 
mutant, splicing was highly repressed at endogenous protein levels (reached 81% for 
GFP-only control) (Figure 5.3 - B). When co-transfected with T-STAR and Sam68, the 
mutant still appeared to be highly repressed by T-STAR (14% difference between T-
STAR and GFP-only control; this difference is statistically significant) but not by Sam68 
(even though a 7% difference with GFP control was observed, this appeared to be not 
statistically significant) (Figure 5.3 - B).  
To further investigate sequence requirements, I also manipulated different AU-sequence 
combinations. According to SELEX, a string of adenine nucleotides (without uracil) is 
also a target of Sam68 (Galarneau and Richard, 2009a). Thus, a mutant in which the 
Nrxn2 sequence was replaced by string of twenty two adenine nucleotides was produced 
(Figure 5.1 – 5). The aim of this mutant was to test if for Nrxn2 this could be a better 
Sam68 target sequence, than those previously tried. However, when Mutant 22xA was 
analysed, only a small effect of T-STAR was observed (6% between T-STAR and GFP-
only control; statistically significant) and no regulation by Sam68 at all (Figure 5.4). 
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Figure 5.4 – Sam68 does not repress Nrxn2 through a string of 22 adenine nucleotides. A 
downstream binding site of 22 adenines was inserted as a potential Sam68 regulatory sequence. 
Graphs show the percentage of splicing exclusion (PSE%) in different versions of Nrxn2 A x 22 
mutant minigene co-transfected with GFP-only, T-STAR and Sam68. Data represents the mean 
of minimum three biological replicates. Statistical significance was compared between HEK293 
cells expressing GFP and HEK293 cells expressing the GFP fusion proteins by means of 
independent two-sample t-test, where *p<0.05, **p<0.01, ***p<0.001.  
 
5.3.2    Can the Tomosyn-2 downstream response element confer Sam68 regulation 
on T-STAR? 
In Chapter 4 I uncovered the elements in Tomosyn-2 sequence that respond to both T-
STAR and Sam68, from both downstream and upstream intronic locations (labelled 1 and 
2 on Figure 5.5). Here I test, if Nrxn2 responds to Sam68 when replacing the Nrxn2 
sequence by T-STAR and Sam68 regulatory elements from Tomosyn-2.  
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Figure 5.5 – A schematic to show how Nrxn2 sequence was replaced by Tomosyn-2 
sequences. T-STAR and Sam68 target sites in Tomosyn-2 (labelled 1 and 2) were inserted into 
Nrxn2 target region marked by red brackets. Nrxn2 mutant with a big mutation was used a 
template in cloning.  
 
The Nrxn2 sequence was converted so it contained Sam68 target sequences from 
Tomosyn-2. As known from Chapter 4, Tomosyn-2 contains two separate regions that 
were important for Sam68 regulation. Thus, two constructs were produced. Each 
contained one Sam68 target region from Tomosyn-2 (Figure 5.5). After co-transfection, 
T-STAR splicing repression was observed for each construct. Surprisingly, even though 
the Tomosyn-2 response regions were transferred into Nrxn2, Sam68 still does not 
regulate splicing of Nrxn2 (Figure 5.6). 
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Figure 5.6 – Nrxn2 does not significantly respond to Sam68 when replacing Nrxn2 sequence 
by T-STAR and Sam68 regulatory elements from Tomosyn-2. Graphs show the percentage 
of splicing exclusion in Nrxn2 wild type and two mutants with target sequences replaced by the 
Tomosyn-2 target A – region 1 and B - region 2. Data represents the mean of minimum three 
biological replicates. In each case, statistical significance was compared between HEK293 cells 
expressing GFP and HEK293 cells expressing the GFP fusion proteins by means of independent 
two-sample t-test, where *p<0.05, **p<0.01, ***p<0.001. C - Western blot analysis of HEK293 
cells co-transfected with GFP-coupled fusion proteins and Nrxn2 mutant with target region 
replaced by site 1 from Tomosyn-2. The Western blot was probed for GFP and actin and shows 
equal expression levels of each fusion protein. 
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5.3.3    Other STAR proteins also regulate Nrxn2 splicing 
To find out if other members of STAR protein family regulate Nrxn2 splicing, wild type 
Nrxn2 was co-transfected with a set of GFP-fusion proteins such as Slm1 (Sam68-like 
mammalian protein 1), SF1 (splicing factor 1)  and QKI (Quaking). GFP-fusion protein 
plasmids were given to us from our collaborator Prof. Chris Smith (Cambridge) and co-
transfected with wild type Nrxn2. The GFP-only plasmid was used as a control. 
Transfections were performed once only, thus the results are preliminary and need 
replication. SF1 expression did not regulate Nrxn2 splicing (Figure 5.7). Some splicing 
repression by Slm1 was detected. This corresponds with the results from a paper 
published about Nrxn2 splicing regulation by Slm1 by Iijima et al 2014 (Iijima et al., 
2014). The biggest effect was visible from Nrxn2 co-transfection with QKI protein 
(Figure 5.7). To test, if QKI represses Nrxn2 AS4 splicing through the same downstream 
sequence as T-STAR, QKI was co-transfected with the Nrxn2 mutant having the big 
mutation. As before, the big mutation showed half-reduced Nrxn2 splicing repression at 
endogenous protein levels. Furthermore, the splicing repression by QKI was completely 
abolished, suggesting that QKI regulatory motifs are situated within the sequence 12 
nucleotides downstream of Nrxn2 AS4, the same as T-STAR regulatory motifs.  
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Figure 5.7 – QKI represses the splicing of Nrxn2 AS4 from the downstream intronic 
location. Graphs show the percentage of splicing exclusion in wild type Nrxn2 co-transfections 
with Slm1, SF1 and QKI proteins, as well as in a co-transfection of Nrxn2 mutant with a big 
mutation with QKI. Data represents a single experiments, thus results are preliminary. More 
replicates is needed to calculate statistical significance.  
 
Thus, I further focused on studying splicing regulation by QKI protein. To start with, the 
Nrxn2 co-transfection with QKI was repeated in triplicate (Figure 5.8 - A) and Nrxn2 was 
confirmed to be highly repressed by QKI (39% difference compared to GFP-only 
control). Expression levels of transfected proteins were assessed by Western blot analysis 
(Figure 5.8 – B). Western blot confirmed the expression of the GFP-only and QKI fusion 
constructs. 
Subsequently, I decided to look for QKI regulation site in Nrxn2 minigene. Based on 
previous studies, the most common predicted binding motifs for QKI are 5’-NACUAAY-
N1–20-UAAY-3’, 5’-NA(A/C)UUA-3’ or 5’YAAY-3’ (where N is any base, and Y is  a 
pyrimidine) (Ryder and Williamson, 2004; Galarneau and Richard, 2005). These 
mentioned sequences exactly overlap with the already identified T-STAR responding 
sequence of Nrxn2 (Figure 5.8 - A, sequences marked in blue and purple).  
Using minigene analyses, I aimed to test if QKI regulates Nrxn2 splicing though the 
mentioned sequences. To test whether QKI binds to the sequence mutated previously in 
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Nrxn2 Mutant 7 (Chapter 3), this mutant was co-transfected with QKI. As before, a 
reduction of splicing repression of Mutant 7 was observed with endogenous protein levels 
in HEK293 cells.  
 
Figure 5.8 – QKI  regulation of individual motifs in Nrxn2 AS4 is similar to T-STAR 
regulation of these motifs. A - Graphs show the percentage of splicing exclusion (PSE%) in 
different versions of Nrxn2 minigene co-transfected with GFP-only and QKI. Data represents 
the mean of minimum three biological replicates. In each case, statistical significance was 
compared between HEK293 cells expressing GFP and HEK293 cells expressing the GFP fusion 
proteins by means of independent two-sample t-test, where *p<0.05, **p<0.01, ***p<0.001. B 
- Western blot analysis of HEK293 cells co-transfected with GFP-coupled QKI and wild type 
Nrxn2 minigene. The Western blot was probed for GFP and actin and shows equal expression 
levels of each fusion protein. 
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However, as seen from the graphs on Figure 5.8 - A, for Mutant 7 where the 
CUAACUAACUAA sequence mutated, QKI still represses Nrxn2 splicing. Thus, this 
sequence represents a Nrxn2 splicing repressor element, important for repression of AS4, 
but not responding to QKI. 
Nrxn2 Mutant 5 also destroys a possible QKI regulatory site (as it has UAAAAA motif 
mutated into ccAAAA). Thus, Mutant 5 was also co-transfected with QKI. However, it 
was still strongly repressed by QKI. Thus, there should be other sites in a downstream 
intronic sequence of Nrxn2 for Nrxn2 splicing repression by QKI. 
 
5.4    Discussion 
5.4.1    Can Sam68 regulate Nrxn2 splicing if the sequence is altered? 
The first aim of this chapter was to test whether Nrxn2 is regulated by Sam68 when the 
Nrxn2 sequence is changed to be a better Sam68 target. 
From the results in Chapter 3, Sam68 did not regulate Nrxn2 splicing through wild type 
UUAA motifs or the UAAAAA sequence downstream the exon. Based on the known data 
regarding the best sequence motifs for Sam68 binding and splicing regulation, I tested 
seven different sequence combinations, separately replacing wild type sequences by 
sequence versions that are expected to be Sam68 targets.  
Minigene analyses showed that all examined sequences were regulated by T-STAR much 
stronger, than by Sam68. Thus, all motifs tested in Nrxn2 minigene appeared to be better 
targets for T-STAR, rather than for Sam68. Nrxn2 was twice higher repressed by T-STAR 
when sequence was replaced by 8xUAAA, than through the wild type T-STAR response 
element in the Nrxn2 sequence.  
Interestingly, the motif that did not contain any uracil, but just a string of 22 adenines, 
provoked only a very small splicing repression by T-STAR (6% higher comparing to 
GFP-only control) in comparison with all AU-rich combinations tested. Thus, adenine 
motifs without uracil are very moderate targets for T-STAR. 
Although wild type Nrxn2 did not respond at all to Sam68, out of all sequences tested, 
8xUAAA (with UAAAAA inside) enabled some repression by Sam68. Some repression 
by Sam68 was also observed for the 4xUAAAA mutant. No significant effect of Sam68 
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was seen in the Mutants 4xUAAA, 22xA or 4xAAAA with the rest of sequence wild type, 
as well as in the Mutants where Nrxn2 sites were replaced by Tomosyn-2 sites.  
To make Nrxn2 sequence respond to Sam68 better, further sequence alterations could be 
performed in future. Currently, I have identified that Sam68 starts to regulate Nrxn2 
splicing through UAAA/UAAAA motifs. I suggest that for Sam68 regulation, motifs with 
three adenines need to be repeated more than motifs with four adenines. Possibly, the 
sequence with more adenines could provoke a stronger Nrxn2 regulation by Sam68. To 
find out an optimal number of adenines in each motif, by site-directed mutagenesis, a 
sequence with a single uracil and five adenines (the highest number tested in a current 
study) can be inserted into Nrxn2 downstream intron. In each new mutant, one adenine 
should be added to the mentioned sequence, and the effect of mutation on Nrxn2 splicing 
regulation by Sam68 should be assessed. The sequence with highest repression pattern 
might be considered as a Sam68 consensus motif with an optimal number of adenines.  
I found that Sam68 regulates Nrxn2 splicing through the continuous string of Sam68-like 
motif repeats. Currently, I tested combinations of four and eight repeats. It would be 
interesting to find out an optimal number of repeats in a motif, promoting the higher 
splicing repression pattern by Sam68, than currently observed. By site-directed 
mutagenesis, different numbers of repeats can be inserted, increasing the length by one 
motif per each mutant. The sequence with highest repression pattern might be considered 
as a Sam68 consensus sequence of an optimal length. 
 
5.4.2    Will Sam68 regulate Nrxn2 splicing if the Nrxn2 sequence is replaced by the 
downstream region of Tomosyn-2? 
The next aim of this chapter was to investigate whether placing Sam68 responsive motifs 
from Tomosyn-2 into Nrxn2 can put Nrxn2 AS4 under Sam68 control. To reach this aim, 
I replaced the Nrxn2 sequence by Sam68 regulatory motifs from Tomosyn-2. However, 
when Tomosyn-2 motifs together with flanking sequences were transferred into Nrxn2, 
Sam68 still did not regulate Nrxn2 splicing.  
One explanation can be, that Tomosyn-2 splicing repression is mediated by both groups 
of regulatory sites together. Thus, in future, two or more response regions can be inserted 
into Nrxn2 sequence together, what might give a stronger repression pattern by Sam68. 
Chapter 5                                 Why is there T-STAR specific regulation of Neurexin-2 splicing? 
 
109 
 
It is also possible, that Nrxn2 exon has strong splice sites, and thus needs T-STAR to 
regulate it. Tomosyn-2 exon might have weaker splice sites than in Nrxn2, thus it needs 
both T-STAR and Sam68 to regulate its splicing. That would explain, why even with 
Tomosyn-2 target sites inserted into Nrxn2, Nrxn2 splicing is still not regulated by Sam68. 
This hypothesis should be tested in a future study. 
 
5.4.3    Nrxn2 AS4 splicing is repressed by Quaking 
The last aim of this Chapter was to find out, if there are other proteins regulating Nrxn2 
splicing. Specifically, I was interested to see if any other proteins regulate splicing 
through the T-STAR and Sam68 binding sequence downstream of Nrxn2 AS4. That 
would give more information on which other factors could possibly interact with/control 
T-STAR and possibly suppress Sam68 from function. 
It is known that STAR proteins are highly related to each other by structure and by 
function (Ryder and Massi, 2010). It was found before that T-STAR and Sam68 proteins 
interact with each other (Venables et al., 1999). I supposed that other members of the 
STAR protein family might be also involved in Nrxn2 splicing regulation. Thus, Nrxn2 
was co-transfected with SLM1, SF1 and QKI GFP-fusion proteins. Some splicing 
repression was observed with SLM1. However, from my provisional data this effect of 
SLM1 on splicing was not high. Furthermore, during the time of my study, another group 
has published their research (Iijima et al., 2014) suggesting splicing regulation of Nrxn2 
by SLM1 in more detail. Based on my preliminary data, SF1 did not appear to regulate 
Nrxn2 splicing. However, I observed a strong repression of Nrxn2 by QKI fusion protein. 
Quaking is a STAR protein with its protein domains very similar to T-STAR and Sam68 
(Ryder and Massi, 2010). Interestingly, QKI is known to be involved in neural 
development and myelin formation. Thus, the splicing repression of Nrxn2 (that is also 
expressed in neurons) by QKI could have an important effect on the neural function. Mice 
lacking QKI fail to produce a compact myelin sheet and develop tremors in movement 
(Ebersole et al., 1996). QKI was also shown to be involved in cancers, including oral 
cancers (Lu et al., 2014). One of the few previously identified RNA targets for QKI is 
MAG (myelin-associated glycoprotein), where QKI acts as splicing repressor of MAG 
exon 12. Interestingly, similarly to T-STAR and Sam68, Quaking represses MAG splicing 
through regulatory sites in the downstream intron (Wu et al., 2002). 
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When QKI was co-transfected with the Nrxn2 mutant with a big mutation, splicing 
repression by QKI was abolished. Thus, QKI is repressing AS4 splicing through the same 
downstream intronic sequence region as T-STAR. When QKI was further co-transfected 
with other Nrxn2 mutants, a similar regulation pattern as for T-STAR was observed. 
Similarly to T-STAR, QKI still regulated Mutant 7, with the destroyed repetitive 
CUAACUAACUAA sequence. Thus, it is likely that QKI and T-STAR repress Nrxn2 
splicing through same motifs. Further study could continue dissecting the intronic 
sequence region downstream of AS4 to identify QKI regulatory sequences and to 
investigate the mechanism of splicing regulation by QKI. 
 
5.5    Chapter summary 
In this Chapter I show that Sam68 starts repressing Nrxn2 splicing when the Nrxn2 
sequence is replaced by a different A/U-rich regulatory element, however the repression 
is not strong, compared to the effect of T-STAR. I also found that all sequences designed 
to make Nrxn2 respond to Sam68 respond better to T-STAR than to Sam68. I also found 
out that single Sam68 target regions from Tomosyn-2 do not respond to Sam68 when 
inserted into Nrxn2. Presumably, Tomosyn-2 target sequences should be inserted together, 
to achieve the splicing repression by Sam68. I also showed in this Chapter, that Nrxn2 
splicing is highly repressed by Quaking protein. Quaking regulatory sites appeared to 
overlap with the T-STAR response element in Nrxn2.  
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Chapter 6: General discussion and future work 
 
6.1    General discussion 
Alternative splicing is an important mechanisms of pre-mRNA processing, regulated by 
many splicing factors. Aberrant splicing in just a single gene can lead to serious 
consequences in the cell and whole organism. Cancers, neurological conditions, muscular 
diseases, and infertility cases are linked to abnormal alternative splicing. To keep a strict 
control over splicing regulation, each gene has certain rules and mechanisms. To 
understand the principles behind splicing regulation, it is crucial to identify and study 
RNA-protein interactions on the resolution of the whole transcriptome. Using the data 
sets from several transcriptome-wide studies, RNA splicing maps have been built. These 
show position-dependent effects of protein-RNA interactions (Witten and Ule, 2011). For 
some RBPs, such as hnRNP proteins, existing splicing maps are already extensive and 
provide important information about the mechanism of splicing (Huelga et al., 2012). 
However, for some splicing factors even the general principles of splicing regulations are 
still unknown, as no splicing targets have yet been identified. 
In my PhD I studied the splicing regulation by T-STAR protein of two recently identified 
physiological targets, Nrxn2 and Tomosyn-2. These were the first physiological splicing 
targets identified for T-STAR protein. It gave me a unique opportunity to be first person 
to uncover the principles of T-STAR splicing regulation. 
By EMSA experiments I confirmed, that T-STAR is regulating Nrxn2 splicing through a 
direct binding. Once I knew that Nrxn2 is a direct target of T-STAR, I aimed to dissect a 
binding region for T-STAR on Nrxn2 RNA. A previous study by Ehrmann et al 2013 
uncovered a sequence element downstream of the Nrxn2 exon as a region involved in T-
STAR regulation. I performed sequence analysis of the element, and identified three 
groups of motifs: one UAAAAA motif, five UUAA repeats and one motif with three 
CUAA repeats. By site directed mutagenesis, I found that UAAAAA motif is the best T-
STAR target in Nrxn2. I also found that UUAA repeats together comprise a weaker T-
STAR target motif. Individually the UAAAAA sequence and UUAA repeat motif are 
redundant for splicing regulation. However, the loss of both elements together completely 
inhibits splicing repression by T-STAR. I also showed, that CUAA sequence repeats do 
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not respond to T-STAR directly, but comprise a more general element repressing the 
Nrxn2 exon.  
Studies of Nova, Fox, Mbnl and PTB RBPs splicing factors show, that splicing regulation 
is dependent on the position where protein binds on RNA (Dredge et al., 2005; Zhang et 
al., 2008a; Goers et al., 2010; Llorian et al., 2010). In my PhD I aimed to find out, if 
splicing regulation by T-STAR is dependent on its binding position. In wild type Nrxn2, 
T-STAR binds 12 nucleotides downstream of the exon. Moving the T-STAR binding 
region by site directed mutagenesis by 100, 150 and 250 nucleotides downstream of the 
target exon I found, that T-STAR still represses splicing efficiently, even with the binding 
sites being further downstream in the intron. By moving the T-STAR target region 42 and 
100 nucleotides upstream the target exon, I found that T-STAR is also efficiently 
repressing splicing with binding sites placed upstream the exon. Thus, by my research I 
found T-STAR splicing regulation of Nrxn2 is position-independent relative to the 
regulated exon.  
Typically, proteins that bind upstream of exons inhibit splicing through inhibiting the 
branch point sequence. Proteins that bind downstream activate splicing through activating 
U1 snRNP spliceosome component. Different from other factors, T-STAR is binding 
downstream of Nrxn2 exon and is repressing splicing. Thus, it was of interest to identify 
what the mechanism of regulation by T-STAR is. Our initial hypothesis was that T-STAR 
binding might directly inhibit U1 snRNP association with the pre-mRNA, thus de-
stabilizing spliceosome assembly. However, as T-STAR is repressing splicing even at a 
250 nucleotide distance downstream of the exon, splicing repression may be happening 
by another mechanism. By analysis of sequence upstream Nrxn2 gene, in addition to 
downstream target region, I found AU-rich sequences upstream Nrxn2 exon. Thus, I 
hypothesize that splicing could be repressed by T-STAR binding from both sides of the 
exon, and looping out the target exon, preventing spliceosome assembly. The following 
model has been already found functional for the PTB protein. It was shown by FRET 
experiments, that RNA binding domains of PTB protein RRM3 and RRM4 bind to 3' and 
5' PTB binding sites (polypyrimidine tracts), respectively, on several model RNAs tested. 
As a result, 3' and 5' end of the RNA come together, and the exon is looped out. U1 snRNP 
fails to interact with the 5' splice site on the looped part. This prevents the spliceosome 
assembly leading to splicing repression (Lamichhane et al., 2010). The study by 
Lamichhane et al 2010 is a good example of how to test the presence of RNA loops by 
FRET and NMR spectroscopy. My study could also be continued by testing formation of 
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RNA loops in Nrxn2 RNA as a result of T-STAR regulation by the techniques mentioned. 
However, the easier way would be to mutagenize the target Neurexin-2 binding sites both 
upstream and downstream of the target exon, what would inhibit that loop production. 
Hence, splicing will be no longer repressed. T-STAR could also inhibit U1 snRNP 
indirectly, or interfere with function of enhancers. All these hypotheses should be tested 
in a future study.  
In addition to Nrxn2 gene, the study by Ehrmann et al 2013 also identified another 
physiological target of T-STAR, called Tomosyn-2. In my PhD, I also focused on studying 
this T-STAR target, in order to compare the splicing regulation of T-STAR between 
Nrxn2 and Tomosyn2.  
I confirmed Tomosyn-2 splicing repression by T-STAR using a minigene. Interestingly, I 
also found Tomosyn-2 splicing to be highly repressed by another STAR protein, Sam68 
that is highly related to T-STAR. Thus, I aimed to dissect the regulatory sites on Tomosyn-
2 RNA needed for splicing regulation by both proteins. By sequence analysis, I found 
AU-rich motifs as potential binding sites for T-STAR and Sam68 in Tomosyn-2. By site 
directed mutagenesis, I confirmed two groups of UAAAA/UAAAAA motifs downstream 
Tomosyn-2 exon as targets for T-STAR and Sam68 splicing regulation. However, when 
I combined the identified target sites into one mutant, T-STAR and Sam68 were still 
highly repressing the splicing of Tomosyn-2. Thus, the other motifs in Tomosyn-2 
sequence might also regulate Tomosyn-2 splicing, what is a subject for further study.  
In my study I aimed to find, if Tomosyn-2 splicing repression by T-STAR and Sam68 is 
position-dependent. Tomosyn-2 splicing is repressed by T-STAR and Sam68 that regulate 
Tomosyn-2 target sites downstream of the exon (38 and 106 nucleotides downstream). 
When the target sites were moved 54 nucleotides upstream of the Tomosyn-2 exon, T-
STAR and Sam68 appeared to significantly repress splicing, similarly as with target 
motifs being downstream. Thus, I found that Tomosyn-2 splicing repression event is 
position-independent, however, splicing repression is stronger if binding is upstream of 
the exon. Therefore, one of the interesting findings in my PhD was that T-STAR and 
Sam68 proteins are unusual in that they repress splicing from either side of the exon. 
By Ehrmann et al 2013 it was found, that Nrxn2 splicing is regionally repressed in mouse 
brain. In my study, I have examined Tomosyn-2 splicing in different 11 mouse brain 
regions. I found out that Tomosyn-2 repression correlates with T-STAR expression in the 
brain and is abolished in the T-STAR knockout mouse. Splicing repression is highest in 
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the forebrain regions, and lower in midbrain and hindbrain. Thus, T-STAR is a regional 
splicing regulator of Tomosyn-2.  
Interestingly, previous studies have shown that the Tomosyn-2 alternative exon that is a 
current target for T-STAR and Sam68 regulation, codes for a hypervariable domain of 
Tomosyn-2 protein. This domain defines the fusogenic capacity in the synapse, through 
regulating Tomosyn-2 pairing with SNARE (soluble n-ethylmaleimide-sensitive-factor 
attachment receptor) complexes (McNew et al., 1999; Hatsuzawa et al., 2003). Thus, a 
functional consequence of Tomosyn-2 splicing repression by T-STAR and Sam68 might 
be the amount of neurotransmitter released in synapse, and hence, the overall function of 
synapse. Sam68 has been already shown before to be important for synaptic functioning 
(Klein et al., 2013). T-STAR has been associated with neurological conditions, as 
epilepsy (Sugimoto et al., 2001).  
If Tomosyn-2 splicing was shown to be regulated by both T-STAR and Sam68 proteins, 
the study by Ehrmann et al 2013 found that Nrxn2 splicing repression is T-STAR specific. 
This was a surprising finding, as T-STAR and Sam68 are both very similar proteins, 
sharing same protein domains and structure, as well as a similar AU-rich predicted target 
motif for RNA binding by both proteins. I investigated why T-STAR and Sam68 proteins 
have differences in terms of their function in Nrxn2 splicing. This would also help to 
explain why both proteins, even being so similar, were kept by evolution. By EMSA 
analysis I have confirmed that Sam68 is binding the Nrxn2 target region directly, but less 
efficiently than T-STAR.  
In my PhD I aimed to uncover why Nrxn2 splicing is not regulated by Sam68. Our 
hypothesis was that Sam68 fails to repress Nrxn2 splicing as the target sequence 
downstream of the exon is not efficiently bound by Sam68. Thus, in my study I converted 
the Nrxn2 downstream target region into four different AU-rich sequence combinations, 
attempting to make it more Sam68-like. Interestingly, I found that Sam68 did repress 
Nrxn2 splicing with continuous strings of four to eight UAAA/UAAAA motif repeats. I 
suggest that for Sam68 regulation, motifs with three adenines need to be repeated more 
than motifs with four adenines.  
Through converting the Nrxn2 sequence into the sequence that could be regulated by 
Sam68, I observed that splicing repression by Sam68 was much less than silencing by T-
STAR. It is known that Sam68 binds RNA sequence as a dimer (Galarneau and Richard, 
2009a). We hypothesized that to be more Sam68-like, AU-rich sequence might need to 
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be separated by unspecific sequence, to allow Sam68 to regulate splicing as a dimer. Thus, 
wild type Nrxn2 sequence was converted into Sam68-like sequence, leaving a gap 
between target sites. Also, Nrxn2 sequence was replaced by the Sam68 target motif 
(together with flanking sequence) from Tomosyn-2 sequence. However, no response of 
Sam68 was detected. I suggest that more Tomosyn-2 motifs might need to be inserted into 
Nrxn2 sequence together, to get the Sam68 response.  
It is important to note, that in addition to searching for ideal sequence combination for 
Sam68 binding, I also tested different AU-rich motifs with T-STAR. Interestingly, the 
strings of UAAA/UAAAA motifs appeared to be very strong T-STAR targets for Nrxn2 
splicing repression (stronger than wild type Nrxn2 target motif).  
To further compare and contrast splicing regulation of Nrxn2 by T-STAR and Sam68, it 
was decided to check if any other STAR family proteins regulate Nrxn2 splicing. 
Information about other Nrxn2 splicing regulators would tell more about the regulation 
of AS4 splicing in Nrxn2. The fusion-plasmids with Slm1, SF1 and QKI proteins were 
kindly received from our collaborator Professor Chris Smith. After a series of co-
transfections, I found the strong splicing repression of Nrxn2 by QKI (Quaking) protein. 
I also found some moderate repression by Slm1, and no effect by SF1. Thus, my further 
research was focused on QKI, as a strongest Nrxn2 splicing repressor out of three proteins 
tested. As the proposed target sequence for QKI comprised of similar motifs as those in 
Nrxn2 target region for T-STAR, it was decided to test some of the previously generated 
Nrxn2 mutants with QKI. When co-transfected with Nrxn2 mutant having a big mutation, 
Nrxn2 splicing repression by QKI got abolished. Hence, QKI represses Nrxn2 splicing 
through the mentioned downstream sequence region. Thus, QKI appeared to share some 
principles for splicing regulation with T-STAR.  
To conclude, research during my PhD enabled for the very first time to uncover the 
principles for splicing regulation by T-STAR protein. In Chapter three of my thesis I have 
dissected the T-STAR target site in Neurexin-2. Importantly, I also found Neurexin-2 
splicing regulation by T-STAR to be position-independent. As for Neurexin-2 in Chapter 
three, in Chapter four I have uncovered the regulatory sites for T-STAR and Sam68 in 
Tomosyn-2. Similarly as for Neurexin-2, splicing regulation of Tomosyn-2 appeared to be 
position-independent. I also observed the functional effect of splicing by T-STAR on a 
tissue level, in mouse brain. It was similar for both Neurexin-2 and Tomosyn-2. Thus, 
results in Chapters three and four show the similar pattern of splicing regulation for 
Neurexin-2 and Tomosyn-2, with the main difference that Tomosyn-2 is controlled by both 
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T-STAR and Sam68, while Neurexin-2 regulation is T-STAR specific. In Chapter five I 
showed that Neurexin-2 is a target for T-STAR but not for Sam68 due to sequence 
specificity. Sam68 starts repressing Neurexin-2 splicing when the Neurexin-2 sequence 
is replaced by a different A/U-rich regulatory element. In Chapter 5 I also showed that 
Neurexin-2 splicing is highly repressed by Quaking protein. Quaking regulatory sites 
appeared to overlap with the T-STAR response element in Neurexin-2.  Hence it is 
possible that the splicing regulation mechanism by Quaking is similar to that one by T-
STAR 
 
6.2    Future work 
Some future questions to be answered in future studies and possible experiments to be 
performed: 
 Which proteins regulate Nrxn2 splicing repression through CUAA repeat 
sequence? 
In a current study CUAA repeat region was detected as a general Nrxn2 splicing 
repressor, and sequence affecting splicing repression by T-STAR and Sam68. It 
would be interesting to find out which proteins regulate this sequence. 
Experimentally, this question could be answered by pull down assays.  
 Is Nrxn2 and Tomosyn-2 splicing position-independent at even further 
distances downstream and upstream of the target exons? 
T-STAR regulation of Nrxn2 splicing was currently found position-independent. 
However, it is interesting to follow until which downstream and upstream distance 
in the introns splicing repression will still be occurring normally. That would help 
us to further uncover positional principles of T-STAR regulation. This question 
could be answered by cloning new mutants with target sequence being moved by 
site directed mutagenesis. 
 Which splicing factors does T-STAR interact with? 
To find out more about the splicing mechanism of T-STAR, it would be 
interesting to find out which other splicing factors T-STAR might interact with. 
Interactions of T-STAR with other proteins can be studied in detail by pull-down 
assays or by protein immunoprecipitation assays.  
 Are Tomosyn-2 and Nrxn2 physiological targets for Sam68 and Quaking, 
respectively? 
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Some of the splicing regulation events in my PhD were only assessed in 
minigenes. It would be useful to know, if Tomosyn-2 is a real physiological target 
of Sam68 and Quaking, as well as if Nrxn2 is a target for QKI protein in a real 
tissue. To answer this, Sam68 and QKI should be knocked out in a mouse, or 
knocked down in cells, and splicing pattern of Nrxn2 and Tomosyn-2 should be 
assessed in a knockout, in comparison to wild type.  
 Does QKI repress Nrxn2 splicing directly? Do T-STAR and Sam68 repress 
Tomosyn-2 splicing directly? 
Is Nrxn2 splicing repression by QKI as well as Tomosyn-2 repression by T-STAR 
and Sam68 direct or indirect? To test this, Tomosyn-2 target regions should be 
cloned into a vector and EMSA essay with T-STAR and Sam68 (or Nrxn2 region 
with QKI) protein should be performed.  
 Does QKI regulate Tomosyn-2 splicing? 
It would be interesting to test if Tomosyn-2 splicing is also repressed by QKI. That 
would give us an idea if T-STAR, Sam68 and QKI are together involved in 
regulation of other targets apart from Nrxn2, and would help to better understand 
the interplay between these proteins.  
 What are the other target sites for T-STAR and Sam68 splicing regulation in 
Tomosyn-2? 
By site-directed mutagenesis I identified two groups of target motifs in Tomosyn-
2. Blocking them reduced the splicing repression by T-STAR and Sam68. 
However, it did not abolish the splicing repression by T-STAR and Sam68 
completely. It would be interesting to see through which other sites to T-STAR 
and Sam68 regulate Tomosyn-2 splicing. For this, other potential target sites 
should be mutagenized, and the effect of mutations on splicing regulation should 
be assessed.  
 Is Nrxn2 repression by T-STAR occurring through RNA looping 
mechanism? 
One of our hypotheses is that Nrxn2 splicing repression by T-STAR might occur 
through the formation of RNA loops, and hence, preventing the spliceosome 
assembly. To test this, binding sites from both downstream and upstream of the 
Neurexin-2 exon should be mutagenized together.  
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Appendix I 
Primer Sequence 
Template used for 
PCR in cloning 
Nrxn2 Mutant 1 F 
AATCCATTAATTAATTAACTAACTAACT
AACTTTAAAAACACGATCTTAAAAAGG
TGCAGAGCTCTCTC 
Wild type Nrxn2 
minigene 
Nrxn2 Mutant 1 R 
TTTAAGATCGTGTTTTTAAAGTTAGTTA
GTTAGTTAATTAATTAATGGATTCTGGT
TAATTACCTTTGTC 
Nrxn2 Mutant 2 F 
AATTAATCCATTAATTAACTAACTAACT
AACTTTAAAAACACGATCTTAAAAAGG
TGCAGAGCTCTCTC 
Wild type Nrxn2 
minigene 
Nrxn2 Mutant 2 R 
TTTAAGATCGTGTTTTTAAAGTTAGTTA
GTTAGTTAATTAATGGATTAATTCTGGT
TAATTACCTTTGTC 
Nrxn2 Mutant 3 F 
AATTAATTAATCCATTAACTAACTAACT
AACTTTAAAAACACGATCTTAAAAAGG
TGCAGAGCTCTCTC 
Wild type Nrxn2 
minigene 
Nrxn2 Mutant 3 R 
TTTAAGATCGTGTTTTTAAAGTTAGTTA
GTTAGTTAATGGATTAATTAATTCTGGT
TAATTACCTTTGTC 
Nrxn2 Mutant 4 F 
AATTAATTAATTAATCCACTAACTAACT
AACTTTAAAAACACGATCTTAAAAAGG
TGCAGAGCTCTCTC 
Wild type Nrxn2 
minigene 
Nrxn2 Mutant 4 R 
TTTAAGATCGTGTTTTTAAAGTTAGTTA
GTTAGTGGATTAATTAATTAATTCTGGT
TAATTACCTTTGTC 
Nrxn2 Mutant 5 F 
AATTAATTAATTAATTAACTAACTAACT
AACTTCCAAAACACGATCTTAAAAAGG
TGCAGAGCTCTCTC 
Wild type Nrxn2 
minigene 
Nrxn2 Mutant 5 R 
TTTAAGATCGTGTTTTGGAAGTTAGTTA
GTTAGTTAATTAATTAATTAATTCTGGT
TAATTACCTTTGTC 
Nrxn2 Mutant 6 F 
AATTAATTAATTAATTAACTAACTAACT
AACTTTAAAAACACGATCTCCAAGGTGC
AGAGCTCTCTC 
Wild type Nrxn2 
minigene 
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Nrxn2 Mutant 6 R 
CTTGGAGATCGTGTTTTTAAAGTTAGTT
AGTTAGTTAATTAATTAATTAATTCTGG
TTAATTACCTTTGTC 
Nrxn2 Mutant 7 F 
AATTAATTAATTAATTAACCCACCCACC
CACTTTAAAAACACGATCTTAAAGGTGC
AGAGCTCTCTC 
Wild type Nrxn2 
minigene 
Nrxn2 Mutant 7 R 
TTTAAGATCGTGTTTTTAAAGTGGGTGG
GTGGGTTAATTAATTAATTAATTCTGGT
TAATTACCTTTGTC 
Nrxn2 Mutant 1-4 F 
AATCCATCCATCCATCCACTAACTAACT
AACTT 
Wild type Nrxn2 
minigene 
Nrxn2 Mutant 1-4 R 
TGGATGGATGGATGGATTCTGGTTAATT
ACCTTTG 
Nrxn2 Mutant 57 F 
TAATTAATTAACCCACCCACCCACTTCC
AAAACACGATCTTAAAGGTGCAG 
Wild type Nrxn2 
minigene 
Nrxn2 Mutant 57 R 
GTTTTGGAAGTGGGTGGGTGGGTTAATT
AATTAATTAATTCTGGTTA 
Nrxn2 Mutant 145 F 
ACTAACTAACTAACTTCCAAAACACGAT
CTTAAAGGTG 
Nrxn2 Mutant 1-4 
minigene 
Nrxn2 Mutant 145 R 
CTTTAAGATCGTGTTTTGGAAGTTAGTT
AGTTAGT 
Nrxn2 Mutant with 
repressor sequence 
deleted F 
CCAGAATTAATTAATTAATTAATAAAAA
CACGATCTTAAAGGTG 
Nrxn2 minigene with 
big mutation  
Nrxn2 Mutant with 
repressor sequence 
deleted R 
CACCTTTAAGATCGTGTTTTTATTAATTA
ATTAATTAATTCTGG 
Nrxn2 Mutant with 
sequence moved 100bp 
downstream F 
AATTAATTAATTAATTAACTAACTAACT
AACTTTAAAAACACGATCTTAAACCCTG
CGTTCAGGCCGTTTG 
Nrxn2 minigene with 
big mutation 
Nrxn2 Mutant with 
sequence moved 100bp 
downstream R 
TTTAAGATCGTGTTTTTAAAGTTAGTTA
GTTAGTTAATTAATTAATTAATTGGGCA
GAAGGGAGCATCCTG 
Nrxn2 Mutant with 
sequence moved 150bp 
downstream 
AATTAATTAATTAATTAACTAACTAACT
AACTTTAAAAACACGATCTTAAAAAAG
TCTTCCTAGAGTG 
Nrxn2 minigene with 
big mutation 
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Nrxn2 Mutant with 
sequence moved 150bp 
downstream F 
TTTAAGATCGTGTTTTTAAAGTTAGTTA
GTTAGTTAATTAATTAATTAATTCTCTTC
CCTATTCCCAGC 
Nrxn2 Mutant with 
sequence moved 250bp 
downstream 
AATTAATTAATTAATTAACTAACTAACT
AACTTTAAAAACACGATCTTAAAGGAA
CACAGGCTAGAA 
Nrxn2 minigene with 
big mutation 
Nrxn2 Mutant with 
sequence moved 250bp 
downstream R 
TTTAAGATCGTGTTTTTAAAGTTAGTTA
GTTAGTTAATTAATTAATTAATTCCTCCT
ACTGCAGAATT 
Nrxn2 Mutant with 
sequence moved 42bp 
upstream F 
AATTAATTAATTAATTAACTAACTAACT
AACTTTAAAAACACGATCTTAAAGCGCT
GCCTGAGAAAC 
Nrxn2 minigene with 
big mutation 
Nrxn2 Mutant with 
sequence moved 42bp 
upstream R 
TTTAAGATCGTGTTTTTAAAGTTAGTTA
GTTAGTTAATTAATTAATTAATTAGTCC
ACAGGCTTTAGAAAG 
Nrxn2 Mutant with 
sequence moved 100bp 
upstream F 
CTTTCTGTTGAATGAATTAATTAATTAA
TTAACTAACTAACTAACTTTAAAAACAC
GATCTTAAATGGCTGCTTGCTGGG 
Nrxn2 minigene with 
big mutation 
Nrxn2 Mutant with 
sequence moved 100bp 
upstream R 
CCAGCAAGCAGCCATTTAAGATCGTGTT
TTTAAAGTTAGTTAGTTAGTTAATTAAT
TAATTAATTCATTCAACAGAAAGGAG 
Tomosyn-2 Mutant 1 F 
CAGTTCCAACCTTGACCAACCTTCGTTC
CTCATGGTAACAGGTGCTGGGAG 
Wild type Tomosyn-2 
minigene 
Tomosyn-2 Mutant 1 R 
TGAGGAACGAAGGTTGGTCAAGGTTGG
AACTGTACTCACAGAAATTGATAT 
Tomosyn-2 Mutant 2 F 
CATTCCAAAGATGATTCCAAAACAAAA
ACAAAAACAAAACTAC 
Wild type Tomosyn-2 
minigene 
Tomosyn-2 Mutant 2 R 
GTTTTGGAATCATCTTTGGAATGTAACT
TCCATTTCTTTGTCT 
Tomosyn-2 Combined 
Mutant F 
CAGTTCCAACCTTGACCAACCTTCGTTC
CTCATGGTAACAGGTGCTGGGAG 
Tomosyn-2 Mutant 2 
minigene 
Tomosyn-2 Combined 
Mutant R 
TGAGGAACGAAGGTTGGTCAAGGTTGG
AACTGTACTCACAGAAATTGATAT 
Tomosyn-2 Mutant with 
target sites moved 54bp 
upstream F 
GAATTGGAAGAACATATCAATTTCTGTG
AGTACAGTTTAAAATTTGATAAAATTTC
GTTTATCATGGTAACAGGTGCTGGGAGG
AATTCCTGTTCCTC 
Tomosyn-2 Combined 
Mutant minigene 
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Tomosyn-2 Mutant with 
target sites moved 54bp 
upstream R 
CAGGAATTCCTCCCAGCACCTGTTACCA
TGATAAACGAAATTTTATCAAATTTTAA
ACTGTACTCACAGAAATTGATATGTTCT
TCCAATTCATTTG 
Nrxn2 Mutant 
4xUAAA F 
AATAAATAAATAAATAAACCCACCCAC
CCACTTCCAAAAC 
Nrxn2 minigene with 
big mutation 
Nrxn2 Mutant 
4xUAAA R 
TTTATTTATTTATTTATTCTGGTTAATTA
CCTTTGTCG 
Nrxn2 Mutant 
8xUAAA F 
AATAAATAAATAAATAAAAATAAATAA
ATAAATAAACCCACCCACCCACTTCCAA
AAC Nrxn2 minigene with 
big mutation 
Nrxn2 Mutant 
8xUAAA R 
TTTATTTATTTATTTATTTTTATTTATTTA
TTTATTCTGGTTAATTACCTTTGTCG 
Nrxn2 Mutant 
4xUAAAA F 
AAGGTAATTAACCAGAATAAAATAAAA
TAAAATAAAACCCACCCACCCACTTC 
Nrxn2 minigene with 
big mutation 
Nrxn2 Mutant 
4xUAAAA R 
GTGGGTTTTATTTTATTTTATTTTATTCT
GGTTAATTACCTTTGTCG 
Nrxn2 Mutant 22xA F 
AAGGTAATTAACCAGAAAAAAAAAAAA
AAAAAAAAAACCCACCCACCCACTTC 
Nrxn2 Mutant with big 
mutation 
Nrxn2 Mutant 22xA R 
GTGGGTTTTTTTTTTTTTTTTTTTTTTCTG
GTTAATTACCTTTGTCG 
Nrxn2 Mutant with 
4xUAAAA and the rest 
wild type F 
CAAAGGTAATTAACCAGAATAAAATAA
AATAAAATAAAACTAACTAACTAACTTT
A 
Wild type Nrxn2 
minigene 
Nrxn2 Mutant with 
4xUAAAA and the rest 
wild type R 
TAAAGTTAGTTAGTTAGTTTTATTTTATT
TTATTTTATTCTGGTTAATTACCTTTG 
Nrxn2 with sequence 
replaced to Tomosyn-2 
(1) F 
AAGGTAATTAACCAGTACAGTTTAAAAT
TTGATAAAATTTCGCCCACCCACCCACT
TC 
Nrxn2 Mutant with big 
mutation 
Nrxn2 with sequence 
replaced to Tomosyn-2 
(1) R 
GTGGGCGAAATTTTATCAAATTTTAAAC
TGTACTGGTTAATTACCTTTGTCG 
Nrxn2 with sequence 
replaced to Tomosyn-2 
(2) F 
AAGGTAATTAACCAGTACATTTAAAAG
ATGATTTAAAAACCCCACCCACCCACTT
C 
Nrxn2 Mutant with big 
mutation 
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Nrxn2 with sequence 
replaced to Tomosyn-2 
(2) R 
GTGGGGTTTTTAAATCATCTTTTAAATG
TACTGGTTAATTACCTTTGTCG 
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